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Abstract 
 
Cellular therapy is emerging as a clinically viable strategy in the field of solid organ 
transplantation, where it is expected to reduce the dependency on conventional 
immunosuppression.  This has produced a demand for highly sensitive methods to 
monitor the persistence and tissue distribution of administered cells in vivo.    However, 
tracking cells presents significant challenges.  In many cases transplanted cells are 
autologous with the immune system of the transplant recipient, and hence are invisible 
to typical methods of detection.  To enable their differentiation, the cells must be 
labelled with a suitable, non-toxic and long lifetime label, prior to their administration to 
patients.  In addition, administered cells represent only a small fraction of the 
recipient’s endogenous cells, which necessitates the use of an extremely sensitive 
detection method.  Laser ablation – inductively coupled plasma – mass spectrometry 
(LA-ICP-MS) is an exquisitely sensitive analytical technique, capable of imaging trace 
elements in complex samples, at high spatial resolution. 
 
This thesis reports the use of commercially available labelling agents to tag therapeutic 
cells, permitting their subsequent detection on an individual cell basis using LA-ICP-
MS.  Label uptake rates in the order of 108 atoms per cell were achieved for T cells 
labelled with the Gd-based MRI contrast agent Omniscan, and Mregs and Tol-DC 
labelled with 50 nm gold nanoparticles.  Close to 100% labelling and detection 
efficiency was observed for all three cell types.  Importantly, the cells retained sufficient 
label to remain detectable for up to 14 days following administration to immunodeficient 
mice.  However, the lengthy analysis times associated with current LA-ICP-MS 
systems preclude its use for routine clinical monitoring.  Therefore, the final section of 
the thesis discusses a prototype fast-washout LA-ICP-MS interface, which provided a 
5-6 fold increase in detection efficiency and peak widths of less than 10 ms. 
 
 
Keywords: single cell analysis; cell tracking; laser ablation; ICP-MS; MRI contrast 
agents; gold nanoparticles; computational fluid dynamics; T cells; Mregs; Tol-DC. 
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1 Introduction 
 
 
1.1 Introduction to the ONE Study 
 
Cellular therapy is emerging as a clinically viable strategy in the fields of 
haematopoietic stem cell (HSC) transplantation, autoimmune disease and solid organ 
transplantation.  An international consortium, known as the ONE Study, is currently 
seeking regulatory approval for the use of several types of regulatory immune cells in 
living-donor kidney transplantation.  The ONE Study aims to provide a unified 
approach to the evaluation of cell based therapies, such as nTreg,1-3 Tr1 cells,4, 5 
dendritic cells,6 and macrophages.7, 8  It is expected that these tolerance promoting 
cells will reduce the dependence on existing pharmacological immunosuppression, 
providing a longer term solution to the rejection of transplanted organs, as well as 
lowering healthcare costs, toxicity concerns, and the problem of impaired general 
immunity associated with current immunosuppressant drugs. 
 
The ONE Study is broken down into eight different Work Packages, which cover the 
research, development, licensing, use, monitoring, and statistical analysis of the 
various cellular therapies.   Determining the survival and tissue distribution of 
administered cells is central to understanding their mechanism of action in vivo, which 
is likely to be a prerequisite for their progression beyond Phase I/II trials.  Therefore, 
the objective of Work Package 2 (WP2) is to develop a new methodology to track 
administered cells after their administration to patients.  This task is being undertaken 
by Loughborough University and will form the basis of this thesis. 
 
Tracking therapeutic cells presents a number of significant technical challenges.  In the 
majority of cases, cellular therapies are derived from either the transplant donor or 
from the transplant recipient.  Thus, the administered cells are indistinguishable from 
the patient’s own immune cells when using conventional detection methods, such as 
flow cytometry.  To enable their differentiation, the cells must be labelled with a 
clinically acceptable label prior to their administration to patients.  At minimum, this 
label should be non-toxic and remain detectable in the recipient’s blood for several 
weeks post-administration.9  At current planned doses, the administered cells will 
16 
 
represent only a small fraction of the recipient’s endogenous regulatory immune cells, 
perhaps less than 1 in 105 cells.  Therefore a highly sensitive detection method is 
required for their detection, capable of the detection of single cells at very high cell 
detection efficiency.  Laser ablation inductively coupled plasma mass spectrometry 
(LA-ICP-MS) is an ideal candidate for this application due to its potential to provide a 
combination of high sensitivity and high spatial resolution.  The technique has been 
widely used for the detection of trace elements in complex biological samples, and is 
applicable to both extracted cells and tissue sections.  A pictorial representation of the 
workflow required for the analysis is shown in Figure  1.1. 
 
 
 
Figure ‎1.1 A representation of the work flow required for tracking cells by LA-ICP-MS. 
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1.2 Introduction to Cell Labelling 
 
A wide variety of cellular labelling agents are currently in use for various medical 
applications.  For example, gadolinium contrast agents for magnetic resonance 
imaging (MRI), iodine and indium radiolabels for single photon emission computed 
tomography (SPECT), fluorescent dyes for fluorescence imaging, and various 
nanoparticles for imaging, bio-sensing and drug delivery.  Although initially developed 
for their respective applications, many of these agents contain elements detectable by 
ICP-MS.  However, in addition to compatibility with ICP-MS, there are three other key 
areas to consider when choosing a cell labelling agent.  Firstly, the amount of label 
taken up by the cells must be sufficient to enable their differentiation from non-labelled 
cells.  Secondly, the label must be retained by the cells at an adequate concentration 
to remain detectable at several weeks post-labelling.  Thirdly, the label must not induce 
toxic effects to either the cells themselves or the body as a whole.  These key issues 
will be discussed in the following sections. 
 
1.2.1 Label uptake 
Although there are examples of cell labelling in vivo, labelling cells in vitro prior to cell 
transplantation is the more common approach to cell tracking.  Following initial culture 
to expand the cell population, the label is added to the cell culture medium at the 
desired concentration.  The cells are then allowed to culture in the presence of the 
label for a further period, promoting uptake.  This incubation period varies considerably 
depending on the cell type, labelling agent and desired level of uptake, but is typically 
between 1 and 48 hours.  The cells must then be washed extensively to remove any 
unbound label, before administration to the subject of interest. 
 
As shown in Figure  1.2, some labels attach extra-cellularly to the cell membrane, 
whereas others are internalised and reside within the cytosol or intracellular vesicles.  
Extra-cellular labels are usually targeted towards specific features on the cell surface.  
This is often achieved through the use of antibody conjugated labels, which bind to 
their respective antigens on the cell surface (Figure  1.2 A).  An additional method 
involves the use of linkers that form covalent bonds to proteins on the cell surface.  For 
example, an approach reported by Digilio et al. used a 2-pyridyl-dithio group as a linker 
between the MRI contrast agent, Gd-DO3A, and exofacial protein thiols on human 
myeloid leukaemia cells.10  In general, internalisation of labels is preferable to extra-
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cellular attachment, as these labels tend to have a higher uptake and a longer lifetime 
attached to the cell.11   Additionally, internalised labels that are compartmentalised 
inside endosomes may exhibit reduced toxicity in comparison to their extracellular 
counterparts. 
 
 
Figure  1.2 A summary of the various mechanisms by which labels can attach to cells. 
 
 
Internalisation of labels usually occurs by an endocytic mechanism.  There are two 
main categories of endocytosis.  The first of these, phagocytosis (Figure  1.2 B), covers 
the internalisation of large solid particles.  Phagocytosis is carried out extensively by 
specific immune cells, such as macrophages and dendritic cells, whose function is to 
clear dead cells and remove pathogens.  The solid particles bind initially to the cell 
membrane, which triggers the extension of temporary projections, known as 
pseudopods, to engulf the particle and enclose it in a vesicle.12  Once enclosed, the 
vesicle separates from the membrane and passes into the intracellular fluid, where it 
may fuse with other cellular components.  In contrast, the second category, pinocytosis, 
concerns the internalisation of fluids and small particles in solution.  Pinocytosis is a 
broad term that covers many types of fluid uptake, the most common of which are 
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receptor/clathrin-mediated endocytosis (Figure  1.2 C), clathrin independent 
endocytosis (Figure  1.2 D) and micropinocytosis (Figure  1.2 E).13  These mechanisms 
differ slightly in terms of their pathway and scale.  However, as with phagocytosis, all 
involve initial contact with the plasma membrane, either through non-specific means or 
by specific interactions with receptors on the cell surface, followed by engulfment of the 
material into vesicles.  In contrast to phagocytosis, pinocytosis is performed to some 
extent by all eukaryotic cell lines. 
 
Optimisation of labelling agents to promote their uptake has been widely discussed.  
Characteristics such as the size and shape of the labelling agent, its concentration, the 
labelling method and the incubation time have a considerable impact on label uptake.  
Surface chemistry also plays a vital role.  Uptake can be increased, decreased, or 
made specific to a type of cell by the inclusion of surface modifiers on the labelling 
agent,14 or by their incorporation into liposomes.15  Cationic liposomal carriers are 
frequently used to increase label uptake, as their positive charge promotes adhesion to 
the cell surface, triggering endocytic uptake into the cell.15  
 
1.2.2 Label retention 
Section  1.2.1 covered the uptake of labels by cells.  Once within the cell, a mechanism 
exists to expel unwanted material.  When substances are not bound specifically to cell 
features, they may be removed over a period of time by a process known as 
exocytosis.  Exocytosis is the reverse process to endocytosis.  Vesicles form around 
material inside the cell and fuse with the plasma membrane, where they release the 
material into the extra-cellular environment.  As a result of this process, the cell loading 
of most labels is expected to decay over time. 
 
In addition to label leakage, the cell loading will also decrease during cell reproduction.  
It is important to know whether the labels are retained in one cell, split equally between 
daughter cells, or if they wholly or partially leak out to the surrounding tissue.  
Complete leakage of the label during cell division limits cell monitoring to only the 
original cells.  However, if the label is passed on to daughter cells, longer term 
monitoring can be achieved.  This was demonstrated by Guenoun et al., who 
performed tracking of Gd-DTPA labelled mesenchymal stem cells over several cell 
cycles.16  Interestingly, whilst the amount of Gd per cell clearly reduced after each 
division, the net amount of Gd in the cell population remained constant, indicating 
20 
 
excellent retention of the label by the cell population.  When labels are known to split 
equally between daughter cells, valuable information on the in vivo growth of the cell 
population can be obtained.  An example of this is the fluorescent label 
carboxyfluoresin diacetate succinimidyl ester (CFSE), which reacts with free amine 
groups on intracellular proteins.17  Since proteins are split equally between daughter 
cells during cell division, the quantity of the label, and hence the intensity of the 
fluorescence signal, is also halved.  This reduction in fluorescence can be easily 
quantified using flow cytometry,17 and consequently CFSE is widely used by 
immunologists as a marker of cell proliferation. 
 
It is also important to consider the fate of the label after cell death.  Cell death primarily 
occurs via one of two pathways: apoptosis or necrosis.18  Apoptosis is an example of 
programmed cell death, where the cell disassembles into small vesicles known as 
apoptotic bodies.18  Whereas, during necrosis, or accidental cell death, the cell falls 
apart and is digested by its own enzymes, spilling its contents out to the 
surroundings.18  In both instances the debris and apoptotic bodies are phagocytosed 
by neighbouring cells and macrophages.18  This is potentially problematic for cell 
tracking, as any label present in the cell will be passed on to other cells or 
macrophages, providing an erroneous signal.  This scenario was demonstrated by 
Winter et al., who were unable to distinguish living iron oxide labelled cells from those 
phagocytosed by macrophages when using MRI.19  The use of a dual labelling strategy 
is a suggested solution to the problem.  It is unlikely that two independent labels, with 
differing routes of excretion would be absorbed by the same non-implanted cell, so 
identification of a therapeutic cell can be confirmed by observation of both signals 
within the single cell. 
 
1.2.3 Indirect labelling 
As discussed above, most labelling strategies involve direct accumulation of the label 
by the cell, prior to administration of the cells to the subject.  However, in some 
instances, such as when using limited lifetime labels, it may be beneficial to introduce 
the label at a later time point, once the cells are in vivo.  An example of this is the 
reporter gene/reporter probe approach.20  A reporter gene, rather than a label, is 
transfected into the cells prior to transplantation.  The label, known as a reporter probe, 
is designed to bind to the reporter gene, and can be injected at analytically relevant 
intervals to label the cells.  The reporter gene/reporter probe approach has two main 
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advantages over direct labelling.  Firstly, as the label is not administered until shortly 
before detection, the problem of label leakage and decay is reduced.  Secondly, since 
the presence of the reporter probe is not reduced by cell division, the monitoring of 
daughter cells is also feasible.  However, the stable transfection of reporter genes into 
cell lines remains challenging, and extensive testing is subsequently required to 
determine the impact of the inserted genes on cell function and mortality.  
 
1.2.4 Toxicity 
Toxicity is a key concern when introducing exogenous substances into cells, 
particularly when these cells are intended for administration to patients.  The labels 
under consideration for this study were developed for medical applications, and 
accordingly their systemic toxicity has generally been assessed.21, 22  However, whilst a 
label may be licensed for a specific medical application, this license doesn’t 
necessarily cover their use for cell labelling and tracking.  Indeed, substances 
developed for intra-venous administration may have quite different effects when 
introduced directly into cells.  Even where cytotoxicity has been assessed,23, 24 the 
results may not prove applicable to all cell types.  Cell types can differ considerably in 
terms of their receptors and function, and this has been shown to produce differing 
levels of uptake and toxicity.25  Therefore, the toxicity of any proposed label and its 
effect on cell survival, proliferation and function will need to be separately evaluated for 
the ONE Study prior to the commencement of human clinical trials.    
 
Cytotoxicity is measured using a variety of toxicological assays.  These typically use 
changes in colour or fluorescence intensity to monitor various indicators of cell viability.  
Cell membrane integrity is assessed via the addition of dyes, such as propidium iodide 
or trypan blue, which easily diffuse through damaged cell membranes, but cannot 
penetrate intact cells.  The metabolic function of cells is tested by employing indicators, 
such as calcein AM and alamar blue, which produce fluorescent metabolites after 
reaction with intra-cellular esterases or reductases.26  Measurement of cellular 
autofluorescence is also an indicator of cell health, since the fluorescence of some 
cellular compounds is altered by the presence of toxic substances.  For instance, the 
fluorescence intensity of NAD(P)H is greatly reduced after reaction with reactive 
oxygen species during oxidative stress.27  As mentioned in section  1.2.2, cell 
reproduction may also be studied over a limited number of cell cycles by monitoring the 
reduction in the fluorescence emission from internalised fluorescent labels.    
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1.3 Introduction to Cell Analysis and Tracking 
 
The following section gives a brief introduction to the diverse range of techniques 
currently used for cell tracking and analysis.  The choice of technique is based on a 
balance of factors such as sensitivity, resolution, cost, safety, and the speed of data 
acquisition.  The choice is also heavily dependent on the cell type, test subject, and 
proposed application, with applications aimed towards human clinical use tending to 
favour non-invasive techniques over those requiring ex-vivo biopsies.  At present there 
is no single technique that is perfect for cell tracking.  Consequently the vast majority of 
research articles describe multi-modal imaging, using various combinations of the 
techniques outlined below. 
 
1.3.1 MRI 
Cells tracked by magnetic resonance imaging (MRI) are usually labelled with a contrast 
agent prior to implantation.  The presence of the contrast agent changes the relaxation 
rate of surrounding water protons, producing hypo- or hyper-intense regions in the 
image, and thus enabling differentiation of the cells from the surrounding material.  
Multiple articles report the use of MRI to visualise cells or cell clusters.  Examples 
include the in vitro visualisation of cells embedded in gelatine,28, 29 and the in vivo 
tracking of transplanted cells in rats or mice.16, 30-32  This tracking has even been 
performed at several weeks post-labelling.16, 30  
 
In some cases, MRI has sufficient sensitivity to detect signals from individual cells, and 
as a result many authors in this field classify their publications as single cell work.29, 32  
However, it should be noted that even with custom built modifications, the spatial 
resolution achieved for this analysis is typically around 100 x 100 x 200 µm3,29, 32 which 
is considerably larger than the average dimensions of a cell.  Co-registration with other 
techniques, such as fluorescence microscopy, is often required to differentiate the 
presence of a single cell from that of a cell cluster, or from other interfering artefacts, 
such as air pockets, haemorrhage, or non-cellular contrast agent.  This co-registration 
is often performed ex-vivo and may require co-labelling with other agents, such as 
fluorescent probes. 
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1.3.2 PET and SPECT 
Single photon emission computed tomography (SPECT),7, 33 and positron emission 
tomography (PET)34  have both been used to monitor the migration of cells for limited 
periods in vivo.  These techniques have higher sensitivity, but lower spatial resolution 
than MRI, and are typically used for bulk, rather than single cell tracking.  Both PET 
and SPECT rely on the detection of gamma rays emitted from radiolabels, and 
consequently exposure to radiation is an unavoidable product of these methods.  The 
labels are also prone to radioactive decay and biological clearance, rendering tracking 
beyond a few days or weeks extremely difficult.  Reporter gene/reporter probe labelling 
has the potential to permit longer-term tracking, as was noted by Sharif-Paghaleh et al. 
who used a transfected reporter gene to mediate uptake of a technetium radiolabel in 
vivo.35 
 
1.3.3 Fluorescence imaging 
Fluorescence based analysis relies on the detection of light emitted from a fluorophore, 
after its excitation by a light source.  Whilst many cells are self-fluorescent, a variety of 
organic dyes and quantum dots may serve as fluorescent labels to aid the 
differentiation of cell types.  In a technique known as flow cytometry, cells are treated 
with a range of fluorescently labelled antibodies, which bind to specific antigens within 
the cells.36  The cell suspension is then passed into the flow cytometer, where the cells 
are identified on the basis of their fluorescence emission.  Using this approach, cells 
may be identified in heterogeneous samples by the simultaneous detection of multiple 
biomarkers within individual cells.  The ease of use and high-throughput nature of flow 
cytometry has led to its widespread use for the analysis of cell populations in vitro.   
 
Whilst flow cytometry is the obvious choice for sorting cell suspensions, there are 
instances where information on the spatial distribution of cells within biological tissues 
is desirable.  For this reason, fluorescence imaging is also frequently performed on 
solid samples.  There are examples of in vivo imaging using fluorescent techniques,37 
however, the limited penetration depth of around 1 – 3 cm,38 has generally restricted its 
application to the analysis of small animals or ex-vivo sections.  With regards to cell 
tracking, the technique is predominately applied for the validation of other techniques,28, 
29 rather than as an independent imaging technique.  To facilitate this, bimodal and 
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even trimodal labels, containing combined fluorescent and paramagnetic modalities, 
have been developed.39-41 
 
1.3.4 Mass spectrometry 
1.3.4.1 Molecular mass spectrometry 
In 1998 Macallan et al. demonstrated the use of molecular mass spectrometry to 
monitor T cells in vivo, following labelling with deuterated glucose ([6,6-2H2]-Glc).
42  
The combination of mass spectrometry and stable isotope labelling has since been 
adopted by several groups to study T cell turnover in both human and animal 
models.43-47  During DNA synthesis the deoxyribose moiety of deoxyadenosine is 
synthesised from cellular pentose, which is derived from glucose.44  Therefore, 
intravenous (IV) administration of [6,6-2H2]-Glc leads to its incorporation into cellular 
DNA at a rate proportional to the ratio of labelled glucose molecules in the blood.44  
Upon cell division, the DNA in each daughter cell contains one newly synthesised 
strand and one strand of the original DNA, thus the amount of [6,6-2H2]-Glc per cell is 
halved, providing a marker of cell proliferation.44  
 
Stable isotope labelling in combination with mass spectrometry offers many 
advantages, particularly its lack of toxicity and applicability to clinical setting.  However, 
the method requires multiple sample preparation steps, including separation of 
extracted cells into cell subsets, extraction of the DNA from the cell line of interest, 
hydrolysis of the DNA to deoxynucleosides, and then purification of deoxyadenosine.  
When the analysis is performed by gas chromatography - mass spectrometry (GC-MS), 
a derivatisation step must also be performed prior to analysis.  The number of cells 
required for the analysis can vary between 2 x 104 and 5 x 105 cells,46, 47 depending on 
the label administration conditions, sample preparation mechanism, and the choice of 
the mass spectrometer.  This may pose a problem when the analysis of limited or 
infrequent cell populations is required, such as when monitoring cellular therapy. 
 
1.3.4.2 Atomic mass spectrometry 
Inductively coupled plasma - mass spectrometry (ICP-MS) is a highly sensitive 
analytical technique, which is a popular choice for trace analysis due to its ability to 
detect and quantify most elements down to ppt levels.  With regards to cell tracking, 
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ICP-MS is regularly used to determine the average cellular uptake of new labelling 
agents 48-51 and their distribution after passage through animals.52  This is commonly 
performed by bulk population analysis, after acid digestion of the cells.48, 51 
 
In addition its use for population analysis, ICP-MS has been attracting increasing 
attention for the analysis of single cells.  Indeed, this topic was the subject of a recent 
review in an issue of Analytical and Bioanalytical Chemistry focussed on single cell 
analysis.53  To perform single cell measurements, the cells must be introduced into the 
ICP in a manner which ensures that the signals from individual cells are well resolved.  
This is typically requires heavy dilution and optimisation of flow rates.  The introduction 
of single cells by pneumatic nebulisation was first reported by Li et al., who used a 
micro-concentric nebuliser to introduce cells into the ICP-MS.54  The authors observed 
occasional uranium signal spikes, which were thought to correspond to individual intact 
bacteria cells.  Ho and Chan also used pneumatic nebulisation when analysing the 
major elements in single algae cells.55  Magnesium, present at roughly 108 atoms per 
cell, and copper and manganese, both present at around 5 x 106 atoms per cell, were 
clearly detected.  Detection down to 1 x 106 atoms per cell was subsequently reported 
by Tsang et al., when analysing bismuth in Helicobacter pylori cells, following in vitro 
treatment with an anti-ulcer drug.56 
 
The drive to improve transport efficiency and reach lower detection limits has led to a 
recent increase in the use of piezoelectric micro droplet generators (µDG) as sample 
introduction systems.  The use of µDG was initially demonstrated by a variety of 
groups for the detection of single nanoparticles.57, 58  Subsequently, Shigeta et al. 
applied the technology to analyse single yeast cells, enabling the detection of 
femtogram levels of Na, Mg, Fe, Cu, Zn and Se, with signal durations of less than 500 
µs.59 
 
1.3.4.3 Mass cytometry 
Tanner and co-workers have developed a new ICP-based technique for detecting cells.  
The technique, known as mass cytometry, was inspired by flow cytometry.  As  
discussed in section  1.3.3, in traditional flow cytometry the cells are treated with a 
range of fluorescently labelled antibodies and subsequently identified by their 
simultaneous detection in individual cells.36  However, with fluorescent labels, spectral 
overlap limits the number of simultaneous measurements to around ten.36  For this 
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reason, Tanner and co-workers developed a new range of antibody labelling reagents, 
known as MAXPARTM reagents,60 which contain lanthanide rather than fluorescent tags.  
Lanthanides are particularly suitable for this purpose as they have a low natural 
abundance, resulting in a low background signal, and have similar chemical properties 
to each other, enabling their incorporation into the same tagged structure.  They are 
also detectable by ICP-MS.   
 
In 2009, a time-of-flight (TOF) based ICP-MS system was developed specifically for 
the simultaneous detection of multiple lanthanide labels in cells.61  Cells labelled with 
MAXPARTM bound antibodies were introduced into the ICP-TOF-MS through a syringe 
pump, connected to a nebuliser and a custom built, heated spray chamber.  This 
enabled the simultaneous detection of over 30 metal labelled antibodies in single cells, 
at a high-throughput sampling rate of around 1000 cells per second.36  The mass 
cytometer is now a commercially available instrument, which is marketed by Fluidigm 
as CyTOFTM.62  The CyTOF system has been applied to detect a variety of antibody 
labelled cell samples, including human leukaemia cell lines and bone marrow samples. 
36, 63 In addition to the detection of labelled antibodies, DNA intercalators have also 
been applied to simultaneously assess cell viability.36, 63, 64 
 
1.3.4.4 Laser ablation – ICP-MS 
Laser ablation (LA) is a sampling technique that uses a high power, short-pulsed laser 
to remove material from a sample surface.  The technique allows highly specific 
sampling of solid samples, at a resolution down to 1 micron.  Laser ablation is 
frequently used in combination with ICP-MS detection to map the distribution of 
elements in complex biological samples.  Examples include the imaging of copper, zinc 
and platinum in liver and kidney sections,65-67 the mapping of copper, zinc, iron and 
manganese in sections of brain tissue,68-72 and the detection of various elemental 
tagged antibodies directly from tissue sections or immunohistochemical membranes.73-
76  LA-ICP-MS has also been applied to image the distribution of iodine, silver and gold 
in single fibroblast cells, following labelling with KI3 and gold and silver nanoparticles 
respectively.77, 78   
 
The highly specific targeting achievable with LA combined with the exquisite sensitivity 
of ICP-MS makes LA-ICP-MS an excellent choice for cell tracking and analysis.  The 
capability for visualisation and specific selection of targets is particularly beneficial, 
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since it guarantees the detection of whole cells rather than cell clusters or partially 
degraded cells.  Furthermore, with the use of cell stains, such as trypan blue, sampling 
can be limited to those cells which are viable.  However, LA-ICP-MS does have 
limitations.  When compared the above techniques, the main drawback of LA-ICP-MS 
is the lengthy acquisition time, which can be in the order of several hours for the 
ablation of 1000 cells or the mapping of a 10 x 10 mm tissue biopsy.  Efforts to improve 
the speed of acquisition are on-going and will be discussed in chapter 4.  A description 
of the technological basis of laser ablation and ICP-MS can be found in the following 
sections. 
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1.4 Introduction to Laser Ablation 
 
In 1985, Gray introduced laser ablation as a method to directly introduce solid 
materials into the ICP-MS.79  Although traditionally used for geological analysis, LA has 
now been applied to a wide range of sample types, including biological tissue.66-68, 80-82  
The technique uses a high power, short-pulsed laser to remove material from the 
sample surface.  Ablation may occur by either a thermal or a non-thermal mechanism 
depending on the type of laser used.  In the thermal mechanism, electrons in the 
sample absorb the laser energy, which is distributed through the sample as heat, 
causing melting and vaporisation.  Conversely, in the non-thermal process the laser 
energy is sufficient to directly break the atomic lattice, without inducing heat dissipation 
through the sample.  The ablated material, which consists of atoms, ions, electrons 
and particulate,83 forms an aerosol above the sample surface, leaving behind a crater 
of around 0.02 to 5 µm depth.84  This aerosol is carried by a carrier gas down the inner 
tube of the ICP torch and into the plasma.  In some instances the aerosol may interact 
with the laser beam, resulting in reduced energy deliverance to the samples.  This 
effect is known as plasma shielding.  The LA technique has been reviewed extensively 
by a number of authors, including Russo,85, 86 Koch87 and Günther.88   
 
1.4.1 Challenges in the field of laser ablation 
Since the introduction of laser ablation, the technique has been plagued by two main 
problems; namely elemental fractionation and the limited availability of certified 
reference materials.  Elemental fractionation can be described as non-representative 
sampling, specifically when the relative elemental composition of the analysed material 
is not equivalent to that of the sample itself.  There are various theories about the 
mechanism of fractionation, which largely relate to the size and uniformity of the 
ablated particles.89  It has been shown that different sized particles may possess vastly 
different elemental compositions.90  This is particularly the case when the 
physicochemical properties of their constituent elements differ significantly.90  Large 
particles tend to become enriched in low volatility elements, whilst the smaller particles 
and the gas phase becomes enriched in the more volatile elements.90  Transport 
efficiency is largely size dependent, so large variations in particle size contribute to 
fractionation.  Very small particles and particles in the gas phase may impact or 
condense on the walls of the ablation chamber and the connective tubing,91, 92  
whereas large particles may succumb to gravitational settling.  Fractionation continues 
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inside the ICP itself, where large particles (>150 nm)93 are inefficiently ionised, 
resulting in preferential ionisation, and hence analysis, of the more volatile elements.   
 
Since the LA process is responsible for the initial particle distribution, careful 
consideration is required when choosing laser parameters, such as the wavelength 
and pulse duration.  These will be discussed briefly in section  1.4.2.1.  Optimisation of 
the ICP parameters is also important, particularly the RF forward power and the gas 
flows, as these control the temperature within the ICP, and therefore the proportion of 
particles that are completely vaporised, atomised and ionised.  National Institute of 
Standards and Technology (NIST) glass is often used for tuning the ICP parameters.   
 
For quantitative analysis, matrix-matching is essential because the amount of material 
ablated by each laser pulse is dependent on the composition and density of the sample.  
Many groups have attempted to create in-house calibration standards, for example by 
grinding and pressing powders.94  For biological analysis, calibration standards are 
often prepared by spiking animal tissue, blood or serum with elemental standards.70, 95  
However, the production of such standards can be expensive and it is difficult to 
guarantee homogeneity.96 
 
1.4.2 Instrumentation 
A typical LA system consists of a laser, a series of optics, a viewing system, an 
ablation cell, and a transport connection to the ICP-MS.  A schematic of a typical laser 
ablation system is shown in Figure  1.3. 
 
1.4.2.1 The laser source 
The laser source consists of an active medium, which undergoes excitation by an 
external stimulus to produce stimulated emission of radiation.97  A diverse range of 
laser sources are available.  A number of these, such as the ruby, excimer and 
neodymium-doped yttrium aluminium garnet (Nd:YAG), have been successfully used 
for laser ablation.  By far the most common of these is the Nd:YAG, which consists of a 
rod containing a single yttrium aluminium garnet (YAG) crystal doped with neodymium 
ions.97  The fundamental wavelength of this laser, 1064 nm, is poorly absorbed by 
many matrices.84   Therefore, harmonic generation is often employed, allowing the 
Nd:YAG laser to be operated at shorter wavelengths, such as 266 nm and 213 nm.84  
30 
 
In fact, Nd:YAG based lasers operating at 193nm have also been introduced,98 
however the excimer laser is perhaps the more successful of the 193 nm types.  
 
 
 
Figure ‎1.3   Schematic of a laser ablation system. 
 
 
In general, shorter wavelengths provide smaller particles and more uniform particle 
distributions, thereby reducing elemental fractionation.  Guillong et al. performed a 
comparison of the ablation characteristics of 266 nm, 213 nm and 193 nm Nd:YAG 
lasers on a series of NIST glass standards.98  They found that 193 nm laser had a 
lower penetration depth, producing particles with diameters smaller than 150 nm, and 
hence achieving the lowest level of elemental fractionation.98  However, the choice of 
wavelength is also dependent on the absorbance characteristics of the sample matrix, 
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as this affects the ablation yield.  Becker suggests that soft biological tissue is easy to 
ablate, and hence, the fourth harmonic, 266 nm, is sufficient for complete ablation of a 
tissue sample.99 
 
Early LA work utilised nanosecond pulsed lasers.100  However, at nanosecond pulse 
durations the interaction time between the laser and sample is sufficient for energy to 
dissipate into the sample matrix as heat.100  This heat causes melting and vaporisation 
of the sample, producing an aerosol in with an enriched composition of the volatile 
elements.  Consequently, there is now a trend towards shorter pulse durations, such 
as picosecond and femtosecond pulses, which reduce thermal heating of the sample 
and thereby reduce elemental fractionation.100  Additionally, the duration of a 
femtosecond pulse is shorter than the time taken for ablated material to leave the 
sample surface,100  so plasma shielding is not observed with this pulse width and the 
entire laser energy pulse is delivered to the sample surface. 
 
1.4.2.2 Beam delivery 
A range of mirrors and prisms direct the beam through the inner housing of the LA 
system, and an objective lens, positioned prior to the ablation cell, focusses the beam 
aperture onto the sample surface.  The size and shape of the ablation crater can 
usually be adjusted by the user, for example by passing the beam through a beam 
expander and an aperture wheel.  Ablation craters are generally either conical or 
cylindrical in shape and range between 4 micron and a few mm in diameter.  Some 
modern systems even enable the use of spot sizes down to 1 micron and below. 
 
1.4.2.3 The ablation cell 
Ablation takes place inside a laser ablation cell.  Various designs of LA cell exist.  
Typically they consist of a gas tight chamber, incorporating ports for gas entry and exit, 
and a fused silica window, to allow laser beam access.84  The cell is connected to the 
ICP via tubing, which can be over a metre in length and is typically 3-4 mm internal 
diameter.  The cell is mounted on a computer controlled adjustable platform for sample 
positioning, allowing highly precise selection of targets.  Imaging is achieved by moving 
the stage in a defined pattern (usually a set of parallel lines), whilst firing the laser in 
continuous mode.  If a mass spectrometer analyses the ablated material in a time 
resolved fashion, the acquired spectra can be converted into two-dimensional colour 
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maps, displaying signal intensity as a function of the image dimensions.  The speed of 
image acquisition is limited by the wash out time of the cell, which is largely controlled 
by its size and shape, along with the dimensions of the connective tubing.  Cell design 
is therefore a key area for laser ablation development and it is one that will be 
discussed in detail in Chapter 4.  
 
1.4.2.4 The carrier gas 
A carrier gas flows continuously through the cell to provide an inert atmosphere for 
ablation and to sweep the ablated material into the ICP.  Argon carrier gases were 
customary for early LA experiments, but due to its improved transport properties, many 
users have now switched to helium.  Around ten years ago, Horn and Günther 
performed a comparison of the effect of different carrier gases on the size distribution 
and transport efficiency of glass particles.101  They found that ablation in a helium 
atmosphere produces smaller particle size distributions than in argon, which leads to a 
gain in sensitivity.  The size of the laser induced plasma is smaller in He, which along 
with its higher thermal conductivity, leads to rapid removal of thermal energy from the 
ablation site, reducing the condensation and agglomeration of particles in the 
vapour.101   
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1.5 Introduction to Mass Spectrometry 
 
Mass spectrometry is frequently used to separate, detect and identify elements and 
molecular fragments on the basis of their relative molecular masses.102  A variety of 
mass spectrometers are currently in use, which can differ considerably in design.  
However, all involve five key steps; sample introduction, the generation of gaseous 
ions, separation of the ions on the basis of their mass-to-charge ratio, detection of the 
ions, and finally, communication of the results to a computer.   
 
The ionisation step has considerable impact on the format of the data generated by the 
mass spectrometer.  Soft ionisation techniques, such as electrospray ionisation (ESI) 
and matrix-assisted laser desorption ionisation (MALDI), are well established in bio-
molecular analysis, and provide information on the molecular structure of the 
sample.103  The application of hard-ionisation techniques, such as inductively coupled 
plasma (ICP), results in loss of all structural information, however offers many 
advantages, including high sensitivity and multi-element capability.  Since the 
technique is structure independent, the quantification of specific elements in complex 
samples can be more rapidly and reliably achieved.103  Due to the composition of many 
cellular labelling reagents, and the high sensitivity required to detect them, the use of 
an ICP ionisation source is the most obvious choice for this project.   
 
A selection of mass analysers are used in ICP-based instruments, including time-of-
flight (TOF), quadrupole, magnetic sector and electric field analysers.  High resolution 
instruments often employ two of these mass analysers in tandem.  An example of this 
is Thermo Scientific’s Element XR, which was the main mass spectrometer used in this 
project.  A schematic of the Element XR is shown in Figure  1.4 and will be described in 
more detail in the following sections.  For an introduction to alternative instruments the 
reader is pointed to reference 102. 
 
 
1.5.1 Sector Field Mass Spectrometry 
1.5.1.1 Solution-based sample introduction 
The introduction of solid samples into the ICP was covered in section 1.4.  However, 
the majority of current ICP-MS work is actually performed on liquid samples.   
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Figure ‎1.4 Schematic of a reverse Nier-Johnson double focussing sector-field ICP-MS. 
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Introduction of liquid samples is most commonly accomplished through pneumatic 
nebulisation.  Various types of nebuliser exist for this purpose, schematics of two of 
which are shown in Figure  1.5.  The function of the nebuliser is to convert a flowing 
liquid, received from a syringe pump or probe, into a stream of droplets.  Nebulisers 
typically operate at flow rates of around 1 l min-1, though micro and nano-flow 
nebulisers operating down to as low as 50 nl min-1 have been reported.104  The 
resulting aerosols tend to contain a wide particle size distribution of around 0.1 – 25 
µm.105  Since only small droplets (<10 µm in diameter)106, 107 are efficiently ionised by 
the plasma, spray chambers are often employed after nebulisation to remove the larger 
droplets and allow only those of the correct size to enter the plasma. 
 
 
 
(A) 
 
 
 
  (B) 
 
  
Figure ‎1.5 Schematic diagrams of two commercially available nebulisers. A) a 
concentric nebuliser, B) a cross-flow nebuliser. 
 
 
A notable alternative to the nebuliser – spray chamber approach is the use of 
piezoelectric micro droplet generators (µDG), which can reproducibly produce droplets 
of less than 40 µm in diameter.58  The droplets undergo desolvation before introduction 
into the plasma, usually with the aid of custom built desolvation apparatus.  This 
approach has been shown to achieve transport efficiencies of close to 100%,58 
compared to around 2-30% for nebuliser – spray chamber sample introduction.  
However, despite the improved transport efficiency, µDG are prone to clogging, 
particularly when used with solutions containing high suspended solids, such as 
cells.108  They are consequently not yet in use for routine work. 
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1.5.1.2 The inductively coupled plasma 
 
The ICP torch consists of three concentric quartz tubes through which an inert gas, 
usually argon, flows.  The main supply of argon is directed through the outer tube.  
This is generally termed the plasma or coolant gas, and flows at a rate of 
approximately 12 – 15 l min-1.  This flow is responsible for both shaping the plasma and 
shielding the outer torch from high temperatures, preventing melting.  An auxiliary gas 
flows through the second tube at a lower flow rate of 0.5 to 2 l min-1.  This directs the 
plasma away from the ends of the injector and auxiliary tubes.109  The final gas flow, 
often referred to as the sample gas, flows through the inner or injector tube at a rate of 
0.5 – 2 l min-1.  It is through this inner tube that sample is introduced.   
 
The top section of the outermost tube is surrounded by a copper coil, which provides a 
high frequency field of around 27-50 MHz.109  Free electrons are introduced into the 
plasma gas by a spark and are accelerated by the high frequency field to reach the 
ionisation potential of the gas.109  This results in an avalanche breakdown of the gas, 
leading to the formation of an inductively coupled plasma.109  The resulting plasma has 
an annular shape and contains zones of differing temperatures.  The sample passes 
through the central channel of the plasma, which has a temperature of around 6000 to 
8000 K, where it is desolvated, atomised and ionised. Most elements are fully ionised 
to singly charged atomic ions.  A schematic diagram showing the typical torch 
geometry is shown in Figure  1.6. 
 
 
 
Figure ‎1.6 Cut-through schematic of an inductively coupled plasma torch.  Figure not 
to scale. 
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1.5.1.3 The interface region 
Since the plasma operates at atmospheric pressure (760 Torr) and the mass 
spectrometer operates at high vacuum (10-6 Torr), an interface region is required to 
reduce the pressure and allow efficient extraction of ions from the plasma to the mass 
spectrometer.110  This interface consists of two water cooled metal cones, typically 
made from nickel or platinum.  The first of these cones, the sampler cone, is positioned 
at the end of the plasma and has an orifice of around 0.8 – 1.2 mm.  The second cone, 
called the skimmer cone, sits behind the sampler cone and has a smaller orifice of 
around 0.4 - 0.8 mm.  A mechanical roughing pump reduces the pressure between the 
two cones to around 2 Torr, forming a region of intermediate pressure between the 
atmospheric pressure of the plasma and the vacuum of the mass spectrometer.110  The 
gas reaches the speed of sound at the entrance to the sampler cone and becomes 
supersonic in the region between the two cones, which results in the formation of a 
shock wave, containing a region known as the zone of silence.109  The orifice of the 
skimmer cone is located within the zone of silence and samples ions from this region.  
 
1.5.1.4 The ion optics 
After passing through the interface region, a series of electrostatic lenses focus and 
accelerate the ions through the entrance slit towards the mass analyser.111 
 
1.5.1.5 Entrance and exit slits 
Resolution is controlled by two slits, known as the entrance and exit slits.    The first of 
these, the entrance slit, is positioned between the ion optics and the mass analyser, 
whilst the second, the exit slit, is positioned between the mass analyser and the 
detector.  Resolution (10% valley definition) is defined as m/Δm, where m is the mass 
at which the peak occurs and Δm is the mass difference between two resolved peaks, 
when the valley between the peaks is 10% of the peak height.112  The Element XR has 
three resolution settings; low resolution (R~300), medium resolution (R~4000) and high 
resolution (R~10000),112 which are controlled by adjusting the width of the slits.  
Decreasing the slit width produces an increase in resolution, but this improvement 
comes at the expense of sensitivity, which can drop to as low as 1-2% of the counts 
seen for low resolution when high resolution is selected.113  Peak shape also changes 
significantly depending on the resolution mode chosen.  Flat topped peaks, produced 
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in low resolution, are generally considered to yield higher measurement precision, 
compared to triangular shaped peaks, which are produced in medium and high 
resolutions.  This is because signal intensity is less variable with sampling position 
over a flat topped peak, as depicted in Figure  1.7. 
 
 
 
 
Figure ‎1.7 Diagram showing the typical peak shape seen for low, medium and high 
resolution peaks.  The instrument scans across the integration window (shown in 
yellow) measuring a pre-defined number of samples per peak (the areas between the 
blue lines).  Signal intensity is more variable between sampling positions for curved 
peaks compared to flat topped peaks, resulting in higher RSD’s. 
 
 
1.5.1.6 The mass analyser 
High resolution instruments often employ two mass analysers, which can be found in 
various geometries depending on the model of instrument purchased.  The Element 
XR uses a magnetic and an electrostatic (ESA) analyser, arranged in a configuration 
known as reverse Nier-Johnson geometry.   
 
In the magnetic sector, ions are dispersed by their energy and momentum, where 
momentum equals the mass of the ion multiplied by its velocity.102  A magnetic field 
operating perpendicular to the flight path deflects the ions, causing them to follow a 
curved trajectory.102  At a given magnetic field strength, the radius of the trajectory is 
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dependent on the momentum and charge of the ion.102  Hence, for single charged ions 
of a uniform velocity, the strength of the magnetic field can be adjusted to allow ions of 
the desired mass to pass through the magnetic sector.  Similarly, when the magnetic 
field is held constant, varying the acceleration voltage, and hence the velocity of the 
ions, also provides mass separation. 
 
The ions exiting the magnetic sector have differing energies, depending on their point 
of formation in the plasma.114  For single focussing instruments, this energy dispersion 
leads to peak broadening and loss of resolution.  As a result, an electrostatic analyser, 
which is dispersive with respect to ion energy only, is employed after the magnetic 
sector.  The ESA consists of two curved plates, which have opposing DC voltages 
applied to them.115  The negatively charged inner plate attracts the ions, whilst the 
positively charged outer plate repels them, hence focussing and deflecting the ions.  
The energy focussing of the magnet and ESA are of equal magnitude, but opposite in 
direction.  Combination of the magnetic and electric sectors provides both angular and 
energy focussing, whilst separating the ions according to their mass-to-charge ratio.  
Their combined usage is referred to as double focussing. 
 
As discussed above, the trajectory of ions through the magnetic sector can be 
controlled by adjusting the acceleration voltage and/or the magnetic field strength.  
This feature permits a choice of three different scan types: magnetic scan (B Scan), 
electric scan (E Scan) or SynchroScan.  E Scan is the default mode used by the 
Element XR.  In this mode, the magnetic field moves initially to the start mass and is 
then held constant whilst the acceleration voltage and corresponding ESA voltage is 
adjusted.112  This enables rapid scanning; however, the maximum scan range is limited 
from -6% to 30% of that of the magnet mass.112  As a result, B Scan is preferred for the 
analysis of large, continuous mass ranges, as is required for mass calibration.  During 
a B Scan, the accelerating and ESA voltages are kept constant, whilst the magnetic 
field strength is varied.112  B Scan mode is considerably slower than E scan, since it 
requires a settling time to allow the magnet to recover from the hysteresis of each 
cycle.112  The third mode, SynchroScan, is a combination of the B and E Scan modes.  
The magnet scans continuously in order of increasing mass, whilst the electric field 
scans each peak in in the opposite direction, freezing the measurement on the top of 
each mass peak.112  Thus, with SynchroScan a larger amount of time is spent 
measuring the peak tops compared to magnetic scan alone. 
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1.5.1.7 The detector 
After passing through the exit slit, the ions encounter a deflection plate.  This deflects 
pre-defined high mass peaks away from the detector, preserving its lifetime, whilst 
allowing the remaining ions to hit the conversion dynode.  As the ions hit the 
conversion dynode, secondary electrons are released from its surface, which are 
attracted into the secondary electron multiplier (SEM).  The SEM has 19 dynodes.  
Impaction with the first dynode produces secondary electrons, which hit the second 
electrode, producing even more electrons, and so on.  This cascade effect delivers an 
overall amplification of around 106 by the time the electrons reach the output electrode.  
The electrical pulses generated by each cascade are then counted and communicated 
to the computer in units of counts per second (cps). 
 
The SEM is arranged in two sections and can be operated in different modes 
depending on the signal intensity.  In counting mode, both sections of the detector are 
switched on.  This mode is useful for trace analysis where the signal is expected to be 
below 5 x 106 cps.  When signals of higher intensities than this are expected, analogue 
mode is used.  In analogue mode, the second section of the SEM is switched off.  This 
is to protect the dynodes from exposure to large signals, and thereby extend the 
lifetime of the SEM.  Analogue mode operates in the region of 104 to 1010 cps.   
 
The dynamic range of the instrument can be further increased to 1012 by the inclusion 
of a Faraday cup.  In contrast to the SEM, the ions entering the Faraday cup are not 
deflected by the deflection plate.  Instead they are directed straight into the hollow 
cylindrical shaped cup, where they are collected.  The Faraday signals (positive 
charges) are collected inside a capacitor, which is then discharged, with the discharges 
detected by the ion detection unit.  The Faraday cup is only used when triple mode is 
selected by the user.  In this mode the detector automatically switches between the 
SEM (analogue and counting) and the Faraday cup, depending on the signal intensity.  
This switch happens in under a millisecond. 
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1.6 Statement of Work 
 
This thesis is split into two main work streams.  The first focusses on identifying 
appropriate labels to mark the therapeutic cells, and on using these to perform short 
term LA-ICP-MS tracking in animal models (Chapters 2 and 3).  Loughborough 
University lacks facilities for producing, labelling and culturing mammalian cells.  Thus, 
following literature searching to identify suitable labels and labelling protocols, the 
biological preparation of the samples was kindly performed by our collaborative 
partners at the University of Oxford (T cell samples), Universität Regensburg (Mreg 
samples) and Université de Nantes (Tol-DC) samples).  The second stream of work 
(Chapter 4) involves development of a new laser ablation – ICP-MS interface, which 
will improve both the sensitivity and speed of detection, and thereby demonstrate the 
potential for LA-ICP-MS to rapidly and reliably track cells over extended periods. 
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2 Gadolinium Labelling of T cells 
 
 
2.1 Introduction 
 
T cells are a form of lymphocyte responsible for the regulation of the immune system.  
There are several types of T cell, each of which performs a discrete regulatory function.  
Regulatory functions include inducing apoptosis of infected cells, retaining memory of 
previous infections, and secreting cytokines that activate or deactivate other immune 
cells.116  A team at the University of Oxford are studying a subset of T cells known as 
naturally occurring regulatory T cells (nTreg).  These T cells, known previously as 
suppressor T cells, promote immunological tolerance by inhibiting the activation and 
expansion of donor-reactive cells.117  nTreg are non-phagocytic; thus any labelling 
approach must focus on substances that are likely to be taken up by pinocytosis or 
receptor mediated endocytosis. 
 
Contrast agents typically consist of a paramagnetic metal ion, such as Fe2+/Fe3+ or 
Gd3+, coordinated to a strong chelating ligand.118  They are widely used in conjunction 
with magnetic resonance imaging (MRI) because the metal ion shortens the relaxation 
times of surrounding bulk water protons, enhancing the quality of the image.  The 
presence of the paramagnetic core also permits the detection of contrast agents by 
ICP-MS.  Indeed, previous studies have demonstrated the use of LA-ICP-MS to detect 
gadolinium-based contrast agents in tumour and tissue samples.119-121  Two of these 
studies included a direct comparison between LA-ICP-MS and MRI, and highlighted 
the enhanced sensitivity and spatial resolution achievable when using LA-ICP-MS.120, 
121   In general, gadolinium contrast agents are a more suitable choice for ICP-MS than 
iron-based agents, on account of the low natural abundance of Gd in the human body 
and the absence of molecular ion interferences.  Additionally, their relatively low 
molecular weight and a short half-life, compared to some iron-based contrast agents, 
renders them less likely to undergo phagocytosis by neighbouring cells.122   
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Figure ‎2.1 The structures of nine commercially available gadolinium-based MRI 
contrast agents.  
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44 
 
Figure  2.1 shows the structures of nine commercially available MRI contrast agents.  
These are all octa-coordinated gadolinium chelates, with the addition of a water 
molecule resulting in a final coordination of nine.  The differing structure of the 
chelating ligands affects both the strength of their binding to Gd and the distribution of 
the complex in the body.123  Although the majority of these complexes were originally 
designed as blood pool or non-specific MRI agents, there are now a variety of 
publications that report the use of gadolinium chelates for cell labelling.  Some 
prominent examples of this are summarised in Table  2.1. 
 
 
Table ‎2.1 Published examples of cell labelling using gadolinium chelates. 
Ref. Cell type Gd chelate 
Uptake method / 
enhancement 
Gd uptake / 
atoms cell
-1
 
124 
3T3-NIH 
 
 
J774A.1 
 
Gd-DTPA  
Gd-HPDO3A  
Gd-DTPA-BMA 
Gd-DTPA  
Gd-HPDO3A  
Gd-DTPA-BMA 
Pinocytosis 
Pinocytosis 
Pinocytosis 
Pinocytosis 
Pinocytosis 
Pinocytosis 
~4 x 10
10 
~4 x 10
10 
~7 x 10
10 
~8 x 10
10 
~5 x 10
10 
~1 x 10
11 
125 Rat HTC Gd-HPDO3A 
Pinocytosis 
Electroporation 
~4 x 10
10  
~1.5 x 10
10
 
126 TBV2 Gd-DTPA 
Transfection (calcium 
phosphate, Lipofectin) 
Not reported 
30 Human MSC  Gd-DTPA 
Transfection 
(effectene) 
Not reported 
127 HeLa Gd-DOTA Liposome 3.4 x 10
9
 
16 Rat MSC  Gd-DTPA Cationic liposome 2.7 x 10
11
 
39 IGROV-I Gd-DOTA Cationic liposome 1.2 x 10
7
 
41 J774A.1 Gd-DTPA Lipid coat Not reported 
128 K562 Gd-DO3A 
Covalent binding to 
exofacial protein thiols 
1.2 x 10
10
 
129 T cells Gd-DTPA IL-2 Not reported 
40 Rat MSC Gd-DOTA Cyclodextrin scaffold 4.5 x 10
8
 
130 Pig MSC GdCl3 
Single walled carbon 
nanotubes 
~1 x 10
9
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Di Gregorio et al. achieved uptake rates in the order 1010 atoms of Gd per cell when 
labelling macrophages and fibroblast cells with three different Gd complexes.124  In this 
instance the cells were passively labelled, through doping of the commercial chelates 
into the cell culture medium.  However, publications involving other cell lines have 
reported modifications to this approach in an attempt to increase uptake.  Terreno et al. 
used electroporation, which induces reversible pores in the cell membrane to enable 
uptake of the material.125  Other approaches involved modification to the structure of 
Gd complexes, which facilitated initial binding to the cell surface to trigger endocytosis.  
Examples include the use of commercially available transfection agents, such as 
calcium phosphate 126 and effectene,30 or the inclusion of cationic lipids,16, 39, 127 a 2-
pyridyl-dithio group10, 128 or interleukin-2 (IL-2).129  The use of IL-2 is a good choice for 
assisting T cell labelling, since it binds to surface receptors on T cells, is essential for 
the growth and expansion of T effector cells, and is already utilised by the team at the 
University of Oxford as part of their T cell expansion protocol.  In principle IL-2-Gd-
DTPA could be used to label cells as part of the standard T cell expansion procedure.  
However, all reagents used in clinical trials must be produced in cGMP approved 
facilities.  Due to the difficulty in obtaining a cGMP version of modified complexes, only 
commercially available MRI contrast agents will be considered in this chapter. 
 
2.1.1 Aims for this thesis chapter 
This chapter reports the use of two clinically approved MRI contrast agents, 
Omniscan® (Gadolinium diethylenetriaminepentaacetic acid bismethylamide, Gd-
DTPA-BMA) and Dotarem® (Gadolinium 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetracarboxylic acid, Gd-DOTA), to label human CD4+ T cells.  Following labelling, the 
cells were tracked for short periods in animal models using LA-ICP-MS. The specific 
objectives of the work were as follows: 
1) To optimise the labelling method to achieve maximum uptake by the cell 
population, whilst minimising toxicity concerns. 
2) To determine cellular retention of the label after periods of in vitro culture. 
3) To develop an appropriate LA-ICP-MS sampling strategy capable of identifying 
labelled cells in mixed populations. 
4) To administer labelled cells to animal models and subsequently distinguish the 
labelled cells using LA-ICP-MS.  
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2.2 Experimental 
 
2.2.1 Instrumentation and operating parameters 
Analyses were performed on a sector-field ICP-MS instrument (Element 2XR, Thermo 
Scientific, Bremen, Germany).  For solution analyses, the instrument was fitted with a 
cyclonic spray chamber (Glass Expansion, Victoria, Australia), a conical glass 
concentric nebuliser (Glass Expansion, Victoria, Australia), and a 0.25 mm I.D. probe 
(Elemental Scientific, Omaha, USA).  For laser ablation, a UP-213 laser ablation 
system (Electro Scientific Industries, Cambridgeshire, UK) was coupled to the sector-
field ICP-MS instrument above.  The laser system was fitted with a low-volume, tear-
drop shaped cell, which has been described elsewhere.131   Helium was used as an 
ablation gas, at a typical flow rate of 0.6 l/min, with argon introduced through a Y-piece, 
at a flow rate of 0.8 l/min, downstream of the ablation cell.  The system was tuned daily 
for maximum 238U signal intensity, whilst keeping the Th/U ratio to approximately 1 and 
the ThO/Th ratio to below 1%, during the ablation of NIST 611 glass. 
 
2.2.2 Cell labelling 
Cell culture and labelling procedures were performed by Sheldon Edwards and Andrew 
Bushell at the University of Oxford.  Human peripheral blood mononuclear cells (PBMC) 
were isolated from an anonymised leukocyte cone, obtained from a local blood bank.  
Leukocytes were enriched by Ficoll density gradient centrifugation, and CD4+ cells 
isolated (~98% purity) by MACS positive selection (Miltenyi Biotec).  To isolate defined 
populations to greater than 98% purity, cells were labelled with anti-CD4 (Beckman-
Coulter clone SFCI2T4D11), anti-CD25 (BD Biosciences clone M-A251) and anti-
CD127 (BD Biosciences clone hIL-7R-M21) antibodies and flow-sorted on a BD 
FACSAria (BD Biosciences).  After isolation, cells were plated at a density of 1 x 106 
cells per well in 2 ml of RPMI 1640 medium, which was supplemented with 10% 
human albumin, penicillin, streptomycin and glutamine, plus 1 x 105 U/ml of human 
recombinant IL-2 (Proleukin, Novartis).  Each well also received a volume of either Gd-
DTPA-BMA (Omniscan®, GE Healthcare, UK) or Gd-DOTA (Dotarem®, Guerbet 
Laboratories, France).  The cells were incubated overnight (~16 hours) at 37oC in 95% 
air/5% CO2.  Following the incubation period, the cells were washed extensively in 
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phosphate buffered saline / 2% fetal calf serum (PBS/ 2% FCS) to remove any 
unbound label. 
 
Cell viability was determined using a trypan blue exclusion test.  An aliquot of the cell 
suspension was mixed with an equal volume of 0.4% trypan blue solution.  A 10 µl 
aliquot of the mixed solution was then introduced into a haemocytometer.  Viable cells 
were observed as bright and round in shape, whereas dead cells appeared blue in 
colour due to incorporation of the dye.  Cell viability was expressed as a percentage 
(the number of viable cells divided by the total number of cells x 100).   
 
2.2.3 Optimisation of the labelling process 
Optimisation experiments for Omniscan and Dotarem were performed in parallel using 
cells from the same donor.  Cell culture and sample preparation was performed in 
accordance with the procedure described previously in section  2.2.2.  For dose 
optimisation, doses of 5, 10, 20, 50, 100 and 200 µl of either Omniscan or Dotarem 
were added to each well prior to incubation overnight.  This corresponds to 0.19, 0.38, 
0.75, 1.86, 3.63 and 6.72 mg Gd/ ml, and 0.20, 0.39, 0.78, 1.92, 3.74 and 7.15 mg of 
Gd/ml, for the Omniscan and Dotarem wells respectively.  A total of three replicates 
were performed for each dose.  In addition, three control wells containing cells without 
contrast agent were prepared.  Following dose optimisation, the incubation time was 
varied using the optimum dose.  Incubation times of 0, 1, 2, 4, 8 and 16 hours were 
assessed in triplicate.  Assessment of Gd uptake by the cell population was 
determined by solution-based ICP-MS.  The optimum dose and incubation time were 
then carried forward to subsequent experiments.   
 
2.2.4 Sample preparation for solution-based ICP-MS  
For solution ICP-MS, cells were spun down into pellets and digested according to the 
method proposed by Yamada et al.132 and modified by Kerr.133  Briefly, this involved 
addition of 67% HNO3 (100 µl per 1x10
6 cells) and heating at 70oC for 1 hour, followed 
by addition of 30% H2O2 (100 µl per 1x10
6 cells) and heating at 70oC for a further 4 
hours.  The digested samples were evaporated to dryness under a stream of nitrogen, 
and reconstituted in 2% HNO3.  For quantification, a range of calibration standards 
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were produced by dilution of a 10 ppm elemental standard solution (SPEX Certiprep, 
Middlesex, UK). 
 
2.2.5 Sample preparation for LA-ICP-MS 
Slides for LA-ICP-MS were prepared by the group at the University of Oxford, 
immediately after labelling.  Four different slide preparation methods were tested.  
Each method aimed to deliver approximately 50,000 cells per slide at an adequate 
spacing to enable single cell targeting.  The first method involved simply dropping an 
aliquot of cells onto the slides and allowing the droplet to air dry.  For the second and 
third methods, the cells were fixed onto slides with acetone or paraformaldehyde 
respectively, followed by dehydration with a series of graded alcohols.  The final 
method used a Cytospin to position the cells.  This involved inserting a slide into a slot 
in the Cytospin, with a cardboard filter in place over the slide.  The filter had a hole of 
approximately 5 mm diameter through it, into which a 50 µl aliquot of the cell 
suspension was introduced.  The device was then allowed to spin for a few minutes, 
which removed the media and dispersed the cells.  Subsequently, the cells were 
allowed to air dry.  Each procedure was performed for both labelled CD4+ cells and a 
non-labelled CD4+ control. 
 
To simulate clinical samples, where labelled cells are present amongst a background 
of non-labelled cells, slides containing mixed populations of labelled and non-labelled 
cells were prepared.  For these, the relevant dilutions were made in solution before 
fixing the cells onto slides using the Cytospin method described above.  Ratios of 1:1, 
1:10 and 1:100 (labelled: non-labelled) were prepared as known samples, and a 
replicate of each was provided as a blind sample.  Blind samples were randomised and 
identified with a non-descriptive character.  The expected ratios of these were not 
communicated to the analyst until after the analysis was completed. 
 
2.2.6 Laser ablation of single cells 
Cells were examined on an individual basis by ablation of single 25 µm diameter shots 
at locations corresponding to cells.  This spot size was chosen to ensure sampling of 
the complete cell, whilst minimising the chance of overlap onto neighbouring cells.  A 
high laser energy (60%, 8.97 J cm-2 fluence) was chosen to ensure complete ablation 
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of each cell; and this was verified through visual observation of the resulting laser 
craters.  Only single cells were targeted; cells present in clusters or closer than 25 µm 
apart were disregarded.  The presence or absence of label was determined from the 
157Gd signal.   
 
2.2.7 In vivo mouse study 
Animal experimentation procedures were conducted by Andrew Bushell at the 
University of Oxford.  All experiments were performed in accordance with the UK 
Animals (Scientific Procedures) Act 1986.  Human peripheral blood mononuclear cells 
(PBMC) were isolated from a leukocyte cone.  The CD4+ component was isolated 
using the procedure described above, and these cells were labelled using the 
optimised labelling procedure.  Following labelling, the Gd-CD4+ cells were washed 
extensively and recombined with the non-CD4+ PBMC component.  Re-mixing with the 
unlabelled PMBC component was found to be necessary to ensure viability of the cells 
in the host.  The recombined cells were then injected intraperitoneally into BALB/C 
Rag-/- common-γ chain mice, at a level of 5 million cells per mouse.  At 3, 6, and 10 
days post infusion, the spleen and blood were harvested and a peritoneal lavage was 
performed.  The extracted cells were plated onto slides for LA-ICP-MS analysis.  Flow 
cytometry (BD FACSCanto, BD Biosciences) was used to determine the extent of 
human cell reconstitution. 
 
2.2.8 In vitro label retention 
To estimate the degree of signal loss caused by label leakage, an in vitro label 
retention study was performed in parallel to the in vivo study above.  For this, an 
aliquot of the labelled cells were washed using PBS/ 2% FCS, then cultured for a 
further period in gadolinium free media.  Samples were taken daily and plated onto 
slides for LA-ICP-MS analysis. 
 
2.2.9 Analysis of skin grafts 
An in vivo experiment was undertaken by the University of Oxford, as part of a 
separate project to determine the effect of gadolinium labelling on the regulatory ability 
of their nTreg.  Briefly, CBA Rag KO – (H-2k) mice were split into two groups.  At day 0, 
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all mice were given 1x105 Teff cells and 1x105 of either Gd labelled (group A) or 
unlabelled (group B) nTreg.  At day +1, the mice received a B6 (H2-b) skin graft.  The 
mice were then monitored for signs of rejection over a 100 day period, which is the cut-
off point defined by Oxford as long-term survival.134   
 
At the conclusion of the above study, the mice were sacrificed and their grafts were 
removed.  The extracted skin grafts were offered to Loughborough University for 
quantification of their Gd content.  Approximately half of each graft was digested in 
concentrated HNO3 and H2O2.  The Gd content of the digested samples was quantified 
using solution ICP-MS, as described previously.  The remaining half graft was frozen 
for future analysis.  
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2.3 Results and Discussion 
 
2.3.1 Optimisation of the labelling conditions 
Table  2.2 and Figure  2.2 show the impact of increasing the dose of contrast agent on 
the uptake of Gd by CD4+ T cells.  Uptake increased in a dose-dependent manner.  A 
quadratic fit with a low second order term fitted the data set; however, no plateau was 
observed within the range of doses examined.  Despite the increased uptake at the 
higher doses, a dose of 50 µl (corresponding to 1.86 and 1.96 mg Gd/mL of Omniscan 
and Dotarem, respectively) was chosen as the optimum.  Volumes higher than 50 µl 
occupy a significant proportion of a 2 ml well, which leads to nutrient dilution and could 
potentially produce osmotic effects; thus the decision to limit labelling volumes was 
taken on a precautionary basis.  However, cell viability was 96% or above for all doses 
tested and no obvious signs of toxicity were observed in any of the experiments 
performed.  
 
Gadolinium uptake increased strongly with increasing incubation time for both 
complexes, as shown in Table  2.3 and Figure  2.3.  The maximum uptake was 
observed at 16 hours, which was classified as the optimum incubation time for use in 
subsequent experiments.  Incubation times of longer than 16 hours were not tested on 
the grounds that they were impractical and may have a detrimental effect on cell 
viability.  A 0 hour time point was included in the study as a measure of the efficiency 
of the cell washing process.  For this, the Gd complexes were added to the well, and 
then the cells washed immediately, allowing insufficient time for label internalisation.  
Any Gd found in these samples was deemed to be from incomplete removal of the 
non-internalised complex, and thus represents the method blank for the assay.  The 
Gd content of the 0 hour samples ranged between 5 and 20 times larger than that in 
the non-labelled controls, but this represents only 0.7 and 3% of the final uptake at the 
optimised conditions for Omniscan and Dotarem respectively.  The cell washing 
procedure was therefore considered to be sufficient for quantification of the label 
uptake.  As seen for the dose experiments, Omniscan provided higher Gd loading than 
Dotarem, with an average of 1.43 x 108 atoms per cell compared to 9.36 x 107 atoms 
per cell at the optimum conditions.  By virtue of this higher Gd loading, Omniscan 
rather than Dotarem was used for all subsequent labelling experiments. 
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Figure ‎2.2 The relationship between the dose of Omniscan and Dotarem and the 
uptake of Gd atoms by CD4+ T cells.  Error bars show the standard error of the mean 
(n=3). 
 
 
 
Figure ‎2.3 The relationship between the incubation time with Omniscan or Dotarem 
and the uptake of Gd atoms by CD4+ T cells.  Error bars show the standard error of the 
mean (n=3). 
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Table ‎2.2 The uptake of Gd by human CD4+ T cells at varying doses of Gd contrast 
agent, when using an incubation time of 16 hours. 
Dose / µl 
Gd-DOTA (Dotarem) Gd-DTPA-BMA (Omniscan) 
Atoms per cell ± % RSD (n=3) Atoms per cell ± % RSD (n=3) 
0 8.17E+04 ± 31 1.49E+05 ± 136 
5 5.04E+06 ± 52 1.28E+07 ± 14 
10 1.59E+07 ± 3 2.51E+07 ± 15 
20 3.35E+07 ± 7 4.56E+07 ± 16 
50 8.37E+07 ± 3 9.35E+07 ± 1 
100 1.66E+08 ± 13 1.92E+08 ± 18 
200 2.52E+08 ± 16 3.37E+08 ± 5 
 
 
Table ‎2.3 The uptake of Gd by human CD4+ T cells when varying the incubation time, 
whilst keeping the dose of contrast agent at 50 µl per well. 
Incubation 
time / h 
Gd-DOTA (Dotarem) Gd-DTPA-BMA (Omniscan) 
Atoms per cell ± % RSD (n=3) Atoms per cell ± % RSD (n=3) 
0 2.83E+06 ± 28 9.47E+05 ± 50 
1 2.47E+07 ± 40 3.12E+07 ± 34 
2 3.85E+07 ± 24 3.97E+07 ± 22 
4 5.20E+07 ± 22 5.86E+07 ± 15 
8 5.55E+07 ± 28 6.95E+07 ± 6 
16 9.36E+07 ± 9 1.43E+08 ± 21 
 
 
2.3.2 Gadolinium uptake method 
It is likely that uptake of the Gd-complexes occurred predominantly by pinocytosis, as 
has been reported for other cell lines.124, 125  Gadolinium internalised via this route is 
known to localise to endosomes within the perinuclear region of the cell,125 where 
subsequent detachment of Gd3+ from its chelate may occur.124  Dechelation is 
expected to be more prevalent for Omniscan than Dotarem.  As shown in Figure  2.1, 
the DTPA-BMA chelate is non-ionic and has an open chain structure, hence providing 
less stable binding to Gd3+ than the macrocylic, ionic DOTA chelate.135  Dechelation is 
accelerated in the presence of phosphate or competing cations,136  both of which are 
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constituents of the cell culture media.  Thus it is likely that by the 16 hour time point, a 
proportion of the Gd in the culture media was present as free rather than complexed 
Gd.  Free Gd3+ ions may be subject to a different route of uptake than the complexed 
form.  Cheng et al. conducted a comprehensive study into the uptake of lanthanide 3+ 
ions by erythrocytes.137  Gd3+ was found to bind initially to membrane phospholipids, 
followed by a transfer to membrane proteins.  This process induced conformational 
changes in the membrane, which resulted in the formation of pores, facilitating the 
entry of Gd3+.  It is possible that this mechanism may have provided an additional route 
for Gd uptake.  Since Omniscan is known to be more unstable than Dotarem, this 
additional route may account for the differences in Gd uptake between the two 
chelates, particularly at the 16 hour time point. 
 
2.3.3 Biological variation 
Over the course of the project, 14 individual labelling experiments were performed 
under the optimum conditions, each with cells isolated from different individuals.  
Taking into account replicates, this involved a total of 48 different wells.  The collated 
data from these experiments is presented in Figure  2.4, which depicts the average Gd 
uptake from each of the 14 experiments.  The average uptake across the 14 
experiments was 1.09 x 108 Gd atoms per cell.  However, significant variation between 
individuals was visible, as demonstrated by the large inter-individual RSD of 81%.  This 
variation has implications for cell tracking, and highlights the importance of obtaining a 
sample of the labelled cells, prior to infusion, for every patient.  Intra-sample variances 
are also present and may partially relate to the cell counting process, which is based 
upon counting a small aliquot of the cells within the haemocytometer window, and is 
therefore a well-known source of random error. 
 
The data for the optimisation experiments was obtained using cells isolated from 
human PBMC by MACS positive selection of CD4+ cells.  The resultant populations 
were typically greater than 95% CD4+ cells, but contained 2-5% monocytes due to low 
level expression of CD4 by some monocytes.  It is difficult to remove these 
contaminating cells using MACS, since the technique separates populations by 
positive or negative selection, but does not account for high or low expressions of a 
molecule.  Monocytes are known to have very active phagocytic and pinocytic 
pathways; thus preferential uptake by these cells may have artificially inflated the 
average Gd uptake.  To assess this, human CD4+ T cells were purified to levels 
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exceeding 99% purity, but most importantly containing less than 0.2% monocytes.  
ICP-MS analysis of these highly purified cells showed a gadolinium uptake of 4.53 x107 
atoms per cell, which is roughly half of the average value presented above.   
 
It is clear that the presence of monocytes impacts upon the average uptake by the cell 
population.  This has a major impact on reproducibility, since different donors present 
different proportions of monocytes. Typically the leukocyte cones contained around 60% 
T cells and 20% monocytes prior to purification.  However, in one extreme case the 
leukocyte donor presented about 50% monocytes and less than 20% T cells.134  
Purification of these cells was then an issue, since reducing the contamination to below 
1% required complication of the CD4+ extraction process, as described above.  These 
extra steps resulted in cell losses and a produced a dramatic reduction in the final cell 
count.  High cell counts are necessary for multi-factor experiments and experiments 
involving replicates; so consequently flow sorting was not used for subsequent 
experiments.   
 
 
 
 
Figure ‎2.4 The Gd uptake by CD4+ T cells when labelling with Omniscan at the 
optimum conditions.  Each column represents the average data from an individual 
labelling experiment, each with cells taken from a different donor.  The number of 
replicates per experiment and the percentage CD4+ purity, where available, is given in 
the table below the graph.  Error bars show the standard error of the mean. 
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2.3.4 Sample preparation for laser ablation 
The nature of sampling by laser ablation requires cells to be fixed onto a solid surface, 
typically a slide, before ablation can take place.  This is in contrast to many biological 
imaging applications, where cells can simply be left in solution with a coverslip in place 
over the slide.  In the case of T cells, sample preparation is further complicated by their 
non-adherent nature, which prevents the direct growth of cells on slides, and hampers 
the removal of the culture media surrounding the cells.  This generates problems in 
terms of visualisation of the cells, preservation of their structure, and maintenance of 
their Gd burden.   
 
Four different slide preparation methods were employed in an attempt to find the most 
appropriate method.  Microscopic images obtained using these different methods are 
shown in Figure  2.5.  Initially samples were prepared through dropping an aliquot of 
the cell suspension onto the slide and allowing the droplet to air dry.  However, the 
samples were difficult to visualise under the laser microscope, because substances 
present in the cell culture media crystallised out upon drying, obscuring the cells from 
view.  This problem was not observed for slides fixed with either acetone or 
paraformaldehyde, since the washing and dehydration steps in these methods 
removed the cell culture media from the slide.  However, chemical fixation methods 
alter the structure of the cells and may lead to loss of antigen expression, which may 
be required for subsequent antibody post-labelling.  It is possible that these steps also 
caused the cells to perforate and release their label, as lower Gd signals were 
observed when analysing the chemically fixed samples.  Acetone fixation removes 
lipids and dehydrates the cells; thus any gadolinium bound to these lipids may be lost 
during this process. 
 
Preparation of samples using the Cytospin proved to be by far the most effective 
method.  Cells remained within a 5 mm area of the slide, aiding their location, whilst 
the rotation of the slide in the Cytospin ensured the cells were spread out adequately 
over this area, enabling single cell targeting.  The presence of the cardboard filter also 
helped to absorb the cell culture media, which was spun off during the rotation of the 
slide; thereby preventing the problem of crystallisation.  Accordingly, this method was 
utilised for all of the remaining experiments presented in this chapter. 
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Figure ‎2.5 Microscopic images of cells, obtained after using four different slide 
preparation methods.  Top left: T cells after air-drying only.  Top right: T cells prepared 
using a Cytospin, followed by air-drying.  Bottom left: Paraformaldehyde fixed T cells.  
Bottom right: Acetone fixed T cells.  All pictures were obtained using the built-in 
microscope on the UP-213 laser ablation system. 
 
 
2.3.5 Laser ablation of single cells 
To conclusively confirm uptake by CD4+ cells, and to quantify the percentage labelling 
efficiency, the labelled cells were analysed on an individual basis using laser ablation – 
ICP-MS.  The spot size and high fluence used in these experiments ensured complete 
ablation of the cells, so the integrated peak area is representative of the total amount 
of Gd per individual cell.  Figure  2.6 shows the 157Gd signal intensities for the ablation 
of 25 individual labelled cells (A) and 25 individual non-labelled cells (B).  Distinct 
signals were observed for the ablation of the labelled cells, compared to only 
background noise for their non-labelled counterparts.  Of the 1000 cells ablated, 998 
gave clear signals, confirming uptake of Gd by CD4+ cells at close to 100% labelling 
efficiency. 
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Figure ‎2.6 Signal intensities obtained when ablating 25 µm shots on A) 25 single Gd-
DTPA-BMA labelled CD4+ cells and B) 25 single non-labelled CD4+ cells. 
 
 
Figure  2.7 is a histogram showing the variation in label uptake observed when ablating 
1000 individual labelled cells.  For this, the 157Gd signal intensities were grouped into 
blocks, with the number of occurrences for each block plotted on the y-axis.  In the 
range of 0 - 15,000 counts, the distribution of signals was approximately Gaussian, 
with a RSD of 39%.  The large variance in uptake is likely to prevent the differentiation 
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of second or third generation cells from the original population.  A potential explanation 
for the variance is the laser fluence, which is known to be variable with the old laser 
system used for this study.  It is clear that temporary reductions in laser fluence may 
result in an unablated residue remaining for some cells.  This effect was not observed 
visually when inspecting the craters in this study.  However, it is possible that the 
variations in fluence altered the ablation mechanism between cells, which may have 
introduced diversity in particle transport or ionisation efficiency between each ablation 
event.  Heterogeneity of the cell population may also arise from differences in the 
individual micro-environment, stochasticity in gene expression and protein synthesis,138 
or differences in cell cycle phase between cells.139  A small percentage (1.6%) of 
signals occurred above the Gaussian region.  These higher signals are likely to 
correspond to the ablation of phagocytic monocytes.  Accordingly, the number of high 
signals observed matches closely with the 2.8% CD14+ monocyte impurity measured 
by FACS for this sample. 
 
 
 
 
Figure ‎2.7 Histogram showing the distribution of 157Gd signal intensities for the 
ablation of 1000 Gd labelled cells.  The inset shows an expanded view of the 
distribution within the first peak (0 – 15,000 counts). 
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Application of the technique to cell tracking requires discrimination of labelled cells 
from a background of non-labelled cells.  To simulate this scenario, labelled cells were 
mixed with non-labelled cells in various ratios, prior to analysis by LA-ICP-MS.  As 
shown previously in Figure  2.6, the signal-to-background ratio is large; hence 
differentiation between labelled and non-labelled cells is straightforward and can be 
performed visually.  The percentage of labelled cells determined by LA-ICP-MS 
matched approximately with the ratios prepared, see Table  2.4.  Differences can be 
accounted for by a combination of incomplete mixing and pipetting errors.  As shown, 
the ratios observed from the blind experiments corresponded remarkably closely to the 
expected ratios, adding further confirmation to the reliability of the technique. 
 
Table ‎2.4 The percentage of labelled cells found when ablating slides containing 
various ratios of labelled to non-labelled cells. 1000 cells were ablated per sample. 
 Labelled : Non-
labelled ratio 
% labelled cells 
identified 
% labelled cells 
expected 
K
n
o
w
n
 
1:0 99.8 100 
1:1 39.6 50 
1:10 5.5 9.1 
1:100 0.6 1 
0:1 0.1 0 
B
lin
d
 1:1 39.1 50 
1:10 5.2 9.1 
1:100 0.7 1 
 
 
A single gadolinium signal was observed in the non-labelled samples, setting a false-
positive rate of 0.1%.  It is possible that this signal was caused by carryover of material 
from a previous sample, which may have adhered to the walls of the cell or tubing and 
become dislodged during the run.  Similarly, a false negative rate of 0.2% was 
observed.  False negatives may be due to lack of label uptake by some cells, or 
alternatively laser misalignment may have prevented complete ablation of the cells in 
question.  In clinical samples, it is expected that administered T cells may represent 
between 5 and 25 cells per 1000, after isolation of the leukocytes from peripheral blood. 
Therefore, false positive and negative rates of the order reported here are not 
expected to obstruct detection of the presence of labelled cells. 
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2.3.6 In vitro label retention 
In addition to label uptake, the key second characteristic for cell tracking is label 
retention. To assess this, Gd labelled CD4+ T cells were cultured in vitro in gadolinium-
free growth medium, with samples taken daily for LA-ICP-MS analysis.  As shown in 
Table  2.5, the average signal intensities reduced with increasing follow-on time, 
reaching roughly 50% of the day 1 value after 10 days in culture.  A similar decreasing 
trend was recently reported for other Gd labelled cell lines.124  It is likely that this 
reduction represents a combination of cell division and exocytosis of the label.  
However, despite this, the label remained detectable at all of the time points examined, 
with 98.8% of cells retaining Gd after 10 days in culture.  In view of the low background 
signals observed for the non-labelled cells, it seems likely that Gd labelled cells should 
be detectable for periods well beyond the 10 days studied here. 
 
Table ‎2.5 The number of labelled cells observed after incubation in vitro for various 
intervals after labelling.  250 cells were ablated per sample. 
Day % labelled cells observed Average signal 
1 100 4118 
2 100 3296 
3 100 2901 
4 99.6 2959 
5 100 2744 
6 100 2473 
7 99.6 2220 
10 98.8 2014 
 
 
2.3.7 In vivo mouse study 
Although in vitro label retention was encouraging, the more important question with 
respect to cellular therapy is whether cells retain gadolinium in vivo.  A well 
characterised humanised mouse model, where immunodeficient mice lacking T cells, B 
cells, and functional NK cells are reconstituted with human immune cells, was utilised 
to demonstrate in vivo tracking.  Cells were injected intraperitoneally, with samples 
taken at 3, 6 and 10 days post-administration.  Previous studies have shown that 
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nTreg are enriched within the peripheral blood 140, 141 and spleen142 of tolerant 
transplant recipients, so demonstration tracking experiments aimed to identify cells 
extracted from these sites.  In addition, a peritoneal lavage was performed to recover 
any labelled cells remaining in the peritoneum (the site of administration). 
 
Slides for the in vivo experiments were visually different to those analysed in previous 
experiments.  While cells analysed after in vitro culture were relatively uniform in size, 
those examined from the in vivo experiments contained significant numbers of blasting 
cells, which were around twice the diameter of the cells ablated previously.  It is 
hypothesised that this effect was due to a reaction of the human regulatory cells to the 
immunodeficient mouse environment, which may have induced the cells to rapidly 
proliferate.  Accordingly, these cells produced lower 157Gd signal intensities than their 
in vitro counterparts, indicating increased division of the label in the mouse model.  To 
accommodate the larger cell diameters, the ablation spot size was increased from 25 
μm to 30 μm.  However, increasing the spot size made the selection of single cells 
more challenging; particularly considering that the larger nature of the cells produced 
less free space between cells on the slide.  Given these targeting difficulties, it is 
conceivable that overlap of the ablated region with the edges of neighbouring cells may 
have occurred in some cases.  To allow for this possibility, a threshold value was set at 
5% of the average signal intensity of the corresponding in vitro sample.  Signals below 
this threshold were not included in the percent labelled count. 
 
 
Table ‎2.6 The number of labelled cells identified in mouse peritoneal lavage 
samples following infusion of Gd labelled CD4+ cells.  250 cells were ablated per 
sample. 
Mouse Day 
% Gd positive cells  
(by LA-ICP-MS) 
Human cell reconstitution 
(by flow cytometry) 
1 3 13.2 negative 
2 3 66.4 positive 
3 3 14.0 negative 
4 6 2.0 negative 
5 6 35.6 positive 
6 6 48.4 positive 
7 10 20.4 positive 
8 10 49.2 positive 
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In agreement with previous experience of this model, which showed that reconstitution 
of spleen and blood lags behind that of the peritoneal lavage,134 human cells were not 
found in the spleen or blood up to day 10 using either LA-ICP-MS or FACS.  However, 
human cells were readily detected in the peritoneal lavage at all time points examined.  
Table  2.6 shows the percentage of labelled cells found in the lavage samples by LA-
ICP-MS, with the human cell reconstitution results provided as a reference.  
Reconstitution in this model is defined as greater than 1% human CD45+ cells in the 
leucocyte gate, as determined by flow cytometry.143  In each case, the detection of high 
numbers of Gd labelled cells by LA-ICP-MS correlated with the presence of human 
CD4+ T cells in the lavage.  Thus, both the in vitro and the in vivo data indicate that 
human CD4+ T cells retain a detectable gadolinium level for at least 10 days, when 
labelled with Omniscan.  Example FACS plots, showing the difference between 
reconstituted and non-reconstituted mice are provided in Appendix 1, whilst example 
LA-ICP-MS data for one of the mice is presented in Figure  2.8 below. 
 
 
 
 
Figure ‎2.8 Example data from the in vivo experiments (Day 3), showing the presence 
of 5 labelled cells.  Small peaks below the threshold value (red line), are indicated with 
arrows and were not included in the % labelled count.  
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2.3.8 Analysis of skin grafts 
The clinical application of any cell labelling technique is subject to an assessment of its 
toxicity and impact on cell function.  Cell viability was high for all of the experiments 
performed, as indicated above, and division history analysis following mitogenic 
stimulation of the cells revealed no effect of the label on proliferation.  A further in vivo 
experiment performed by the University of Oxford indicated that Gd labelling does not 
affect the ability of nTreg to regulate rejection.  In this experiment, two groups of mice 
received 1x105 Teff cells and 1x105 of either Gd labelled or non-labelled nTreg.  The 
mice were given a skin graft and monitored over the course of 100 days for signs of 
rejection.  No difference was noted between the labelled and unlabelled group in terms 
of their ability to tolerate the transplanted graft.134 
 
 
Previous studies demonstrated that following enrichment of T cells in the peripheral 
blood and lymphoid tissue, the cells eventually migrate towards the transplanted tissue 
itself.144  In some cases, accumulation within the graft can be sufficient to promote 
tolerance by a second recipient, following removal and re-transplantation of the graft.145  
With this in mind, the skin grafts from the above experiment were analysed for traces 
of Gd.  Solution analysis of the digested grafts showed significant accumulation of Gd 
in one of the tissue grafts compared to the unlabelled control, see Table  2.7.  However, 
the other 3 grafts showed no significant accumulation.  There are two possible reasons 
for this.  Firstly, in a tolerogenic environment, non-Treg may be recruited into the 
regulatory pool by a phenomenon known as ‘infectious’ tolerance.146  The labelled cells 
may therefore represent only a small proportion of the total regulatory cells at 100 days 
post-transplantation.  Secondly, the mice used in this experiment were profoundly 
lymphopenic.  It is known that transfer of T cells into immunodeficient hosts induces 
homeostatic proliferation, where the cells replicate rapidly to populate the host.147  
Thus, it is possible that this rapid division diluted out the Gd label within the infused 
CD4+ cells.  Such an effect could have also contributed to the lower signals seen in the 
in vivo versus in vitro 10 day tracking studies, as reported in sections  2.3.6 and  2.3.7. 
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Table ‎2.7 Gd concentration in transplanted skin graft samples at 100 days post-
administration, as determined using solution based ICP-MS. 
Mouse no. +/- Gd pg Gd / mg tissue 
1 + Gd 10.96 
2 + Gd 0.12 
3 + Gd 0.18 
4 + Gd 1.29 
5 No Gd 0.72 
6 No Gd 0.93 
7 No Gd 0.65 
8 No Gd 0.27 
 
 
 
2.3.9 Nephrogenic systemic fibrosis 
Whilst gadolinium chelates are routinely administered during MRI imaging, their use in 
some patients is restricted due to reports of nephrogenic systemic fibrosis (NSF).  
Although rare, this condition is potentially fatal and is characterised by “extensive 
thickening and hardening of the skin”.148  Studies on patients with renal impairment 
have found a link between the intra-venous administration of gadolinium chelates and 
the onset of NSF.149, 150  Consequently, the administration of gadolinium contrast 
agents is contra-indicated for MRI imaging in patients with impaired renal function.  
Any proposed use of gadolinium labelling should be treated with caution, particularly 
since regulatory approval is being sought for cellular therapy in renal transplant 
patients.  However, it is important to note that at the anticipated doses for the ONE 
Study (3 ×106 cells/kg patient body weight), the Gd exposure from the proposed 
labelling method is dramatically lower than that received from a typical MRI scan.  
Taking in account the average cell uptake of ~27 fg, and the proposed administration 
levels of 3 million cells per kg, the Gd exposure from cell labelling is ~81 ng/kg.  This is 
over 100,000 times lower than the 15.2 mg/kg dose employed for MRI imaging 
(Omniscan is typically administered at a level of 0.2 ml per kg patient weight; the 
formulation contains 287 mg/ml Gd-DTPA-BMA, which equates to 76.1 mg/ml Gd).  
The risk is further minimised due to the route of administration, since with cell labelling 
the gadolinium chelates are compartmentalised inside the cells rather than being 
introduced into the systemic circulation.  
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2.4 Conclusion 
 
This chapter represents the first application of LA-ICP-MS to perform individual 
tracking of therapeutically relevant cells.  The technique was demonstrated in an 
immunodeficient mouse model, where the Gd chelate enabled identification of CD4+ T 
cells for up to 10 days post-administration.  A dose of 50 µl Omniscan was used for cell 
labelling, which enabled passive loading of around 108 Gd atoms per cell, with close to 
100% labelling efficiency.  This dose was based upon sufficiency for short-term 
tracking.  However, since the Gd content will decrease with each cell division, it may 
be beneficial to increase the dose when longer term tracking is required.  Detailed 
analysis of the effect of cell division on label conservation was not undertaken in the 
course of the work presented here.  However, future studies to quantify this effect are 
feasible.  This could include co-labelling with CFSE dye, as a marker of cell 
proliferation, stimulation with mitogenic beads to induce cell division, followed by FACS 
sorting of the cells according to division history, prior to ICP-MS analysis.  A similar 
demonstration experiment to estimate label transfer would also be beneficial, which 
could involve incubation of the labelled cells with other cell lines prior to FACS sorting. 
 
The experiments reported here indicate a favourable toxicity profile for the Gd chelates, 
with no obvious effects on cell viability or proliferation noted.  A further immunological 
investigation, carried out by partners at the University of Oxford, confirmed that 
labelling with Gd chelates does not alter the ability of nTreg to promote tolerance of 
transplanted skin grafts.  ICP-MS analysis of the digested grafts established that the 
label was still detectable in one of the four grafts analysed at 100 days post-
transplantation.  There is scope for future investigation of the localisation of Gd within 
this graft, for instance through high resolution LA-ICP-MS mapping of Gd within thin 
cryostat sections of the graft. 
 
The LA-ICP-MS detection method described here provides several advantages over 
other techniques for detecting Gd chelates within cells.  Firstly, elemental detection 
does not rely on stable binding of Gd3+ to the chelate; thus, the label can be detected 
at periods when its enhancement on MRI relaxation would be lost.  Secondly, the use 
of laser ablation allows single cell targeting, removing interferences from other artifacts, 
such as air pockets or hemorrhage, which may hamper MRI detection.  Thirdly, the 
exquisite detection capability of sector field ICP-MS allows detection at levels of 107 
atoms per cell and below, which compares favourably to the value of 108 atoms per cell 
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recently reported for molecular mass spectrometry.124  Thus, it can be concluded that 
gadolinium labelling followed by LA-ICP-MS detection offers a safe and feasible 
method for assessing the persistence of nTreg therapies. 
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3 Gold Labelling of Regulatory 
Macrophages and Dendritic Cells 
 
 
3.1 Introduction 
 
The previous chapter focussed on labelling and tracking naturally occurring regulatory 
T cells (nTreg).  Instead, this chapter presents the tracking of two monocyte-derived 
antigen presenting cell types, the regulatory macrophage (Mreg) and the tolerogenic 
dendritic cell (Tol-DC), which are the subject of immunological studies at the 
Universitӓt Regensburg and Université de Nantes, respectively.  These cells induce 
tolerance of transplanted organs through a variety of mechanisms, which have been 
reviewed extensively elsewhere.151, 152   Both Mregs and Tol-DCs are phagocytic; thus 
a wider range of cell labelling options are available for these cells compared to the 
nTreg reported in Chapter 2. 
 
Nanomaterials are attracting increasing attention for their potential therapeutic uses, 
most notably for targeted drug delivery 153 and photodynamic therapy 154 in cancer 
treatment.  Their ability to infiltrate cells and tumours is considered a key advantage in 
cancer treatment, and hence there is a wealth of literature concerning their uptake by 
HeLa and other cancerous cell lines.14, 24, 155, 156  The nanomaterials themselves exist in 
a range of shapes and sizes, including spherical nanoparticles,157 nanotubes,130 
nanorods,158 nanoshells159 and nanocages.160  They also vary in their composition, 
comprising a range of metallic, semi-conductor, and even carbon cores, often with the 
addition of a surface coating to impart stability and prevent aggregation.24, 157  However, 
not all of these materials are suitable for detection by ICP-MS, since low mass 
elements in particular can prove challenging.161  Iron and zinc oxide nanoparticles 
represent a large proportion of the available nanomaterials, but due to the high natural 
abundance of these elements,162 they are a poor choice for cell tracking. 
 
Chithrani et al. studied the effect of nanoparticle size and shape on the uptake of 
citrate stabilised gold nanoparticles by HeLa cells.155  Spherical nanoparticles, with 
diameters of 14, 30, 50, 74 and 100 nm, and rod shaped nanoparticles, with 
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dimensions of 40 x 14 nm and 74 x 14 nm, were studied.  The uptake rate of spherical 
nanoparticles was reported to be significantly higher than for rod shaped nanoparticles, 
with the 14 and 74 nm spherical particles achieving a 375 and 500% higher uptake rate 
than the 14 x 74 nm rods.155  Of the spherical particles, 50 nm particles achieved the 
highest uptake rate, with around 6 x 103 nanoparticles internalised per cell.155   
 
Liposomal carriers can be used to increase the uptake of gold nanoparticles of non-
optimal size.  In a study using HeLa cells, phospholipids conjugated with 1.4 nm gold 
nanoparticles were exchanged into pre-formed liposomes.156  When formed at a ratio 
of 2000 nanoparticles per liposome, 8.5 x 105 Au nanoparticles were internalised per 
HeLa cell, which was a thousand-fold enhancement on the uptake achieved without 
the use of a carrier.156  Connor et al. took a slightly different approach, using surface 
coatings rather than liposomes to enhance cellular uptake of 4, 12 and 18 nm spherical 
gold nanoparticles.24  The 4 and 12 nm particles were coated with cysteine and 
glucose coatings respectively, whilst the 18 nm particles had either a citrate, biotin or 
cetyltrimethylaluminium bromide (CTAB) surface coat.  The exact levels of nanoparticle 
internalised in this study were not reported, however it was clear from TEM images of 
the cells and spectroscopic measurements of the culture media that high levels of 
these nanoparticles were internalised by K562 cells. 
 
3.1.1 Aims of this thesis chapter 
The previous chapter focussed primarily on the analysis of isolated cells.  However, the 
ONE Study protocol also includes a routine biopsy of the transplanted organ, which is 
expected to take place at 12 weeks post-transplantation.  Therefore, this chapter aims 
to demonstrate the potential of LA-ICP-MS to provide high-resolution imaging of Mregs 
and Tol-DC in biopsy samples.  The specific objectives of the work were as follows: 
 
1) To optimise a gold nanoparticle labelling method for Mregs and Tol-DC, in order 
to achieve maximum label uptake by the cell population, whilst minimising 
toxicity concerns. 
2) To administer the labelled cells in animal models and to subsequently determine 
their general location through ICP-MS analysis of digested organ samples. 
3) To demonstrate that LA-ICP-MS can be used to identify labelled cells at high 
specificity within thin tissue sections. 
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4) To evaluate the feasibility of using antibody based post-labelling to correlate 
gold signals with the presence of defined cell subsets.  
 
It is recognised that there are differences in generation, culture, nature and function of 
the two cell types used in this chapter.  There is further contrast in the administration 
method between groups, since Regensburg intend to administer their Mregs one week 
pre-transplant, whereas Nantes favour post-transplant administration of Tol-DC.151  It is 
therefore accepted that there will be differences in the cell tracking methodology used 
for the two cell types.  The primary objective of this chapter is to demonstrate that both 
Mregs and Tol-DC can be tracked using LA-ICP-MS; however it is not the intention to 
provide a comparison of their mechanism of action in vivo or their relative clinical 
suitability. 
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3.2 Experimental 
 
Mreg culture and labelling procedures were performed by James Hutchinson and co-
workers at the Universität Regensburg, Germany.  Culture and labelling of Tol-DC was 
performed by Aurélie Moreau and colleagues at the Université de Nantes, France.  All 
animal experimentation, dissection and staining procedures were performed at these 
sites, in accordance with the applicable ethical guidelines. 
 
3.2.1 Culture and labelling of Mregs 
Human Mregs were generated from purified CD14+ peripheral blood monocytes, 
according to a previously published protocol.163  The harvested Mregs were washed 
twice in Dulbecco’s phosphate buffered saline (DPBS) and resuspended at a density of 
106 cells/ml in pre-warmed X-Vivo 10 medium (Lonza, Cologne, Germany).  A PBS 
stabilised 50 nm gold nanoparticle suspension (Sigma-Aldrich, Munich, Germany), 
known to contain ~3.5 x 1010 Au nanoparticles/ml, was used to dope the above 
medium.  The cells were then incubated at 37oC in a closed 15ml tube, with end over 
rotation.  A range of doses and incubation times were initially tested (see Table  3.2), 
however, the final conditions used 1 ml of the nanoparticle suspension per tube and an 
incubation time of 1 hour.  Following labelling, the cells were washed three times in 
DPBS, to remove any unbound label, before further processing.   
 
For experiments involving solution ICP-MS analysis, the cells were spun down into 
pellets and the supernatant removed, before shipping to Loughborough at room 
temperature.  For laser ablation experiments, the cells were resuspended in Mreg 
generation medium, before replating into chamber slides (BD Falcon, Heidelberg, 
Germany) at a density of 106 viable Mregs/ml.  The cells were allowed to adhere to the 
glass slide over a 24 hour period.  The adherent cells were then washed with ice cold 
DPBS, air dried and stained with Diff-Quik Giemsa staining reagents (Medion 
Diagnostics, Munich, Germany). 
 
3.2.2 Culture and labelling of Tol-DC 
Tol-DC were generated from bone marrow precursors according to previously 
published protocols.164   The cells were plated at a density of 0.5 million cells/ml in 5 ml 
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of AIM V medium (Gibco BRL, Paisley, UK), supplemented with 100 U/ml recombinant 
murine GM-CSF (Novartis, Basel, Switzerland).  At day 6, both adherent and non-
adherent cells were harvested, counted, and re-incubated at a density of 0.5 million 
cells per well in 1 ml AIM V medium.  A 50 nm gold nanoparticle suspension (Sigma-
Aldrich, Lyon, France) was added to each well (see Table  3.3) and the cells allowed to 
incubate at 37oC for 1 hour.  Following labelling, the cells were washed extensively (5 x 
PBS).  Samples for solution ICP-MS were transferred into tubes and spun down into 
pellets, whilst samples for laser ablation were plated onto slides using a Cytospin. 
 
3.2.3 In vivo tracking of Mregs in NSG mice 
Mouse experiments were conducted in accordance with permission Nr. 54-2532.1-
10/12 granted by the Regierung von Oberbayern.  NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) mice were bred in-house.  Animals were kept in individually ventilated 
cages and fed on a conventional diet.  Immediately prior to injection, the concentration 
of gold-labelled Mregs was adjusted to 5 x 106 viable cells/ml in Ca2+ and Mg2+ free 
Dulbecco’s PBS, supplemented with 60 IU/ml of heparin. Cell suspensions were 
injected through a 27-gauge needle into the tail vein of recipient NSG mice, over 30–
180 s.   Organs were harvested at either 24 hours or 7 days post-infusion by post-
mortem dissection.  Each organ was weighed prior to separation into sections.  Three 
sections from each organ were individually weighed and placed into tubes for ICP-MS 
analysis, with the remainder retained for LA-ICP-MS analysis.  Tissues for analysis by 
LA-ICP-MS were fixed in paraformaldehyde and embedded in paraffin wax, before 
sectioning to a thickness of 6 μm.  Sections were mounted on SuperFrost slides 
(Thermo Fisher Scientific, Schwerte, Germany) and stored in a dry environment at 
37°C for several days.  Sections were dewaxed with Roti-Histol (Carl Roth, Karlsruhe, 
Germany), then progressively rehydrated with increasingly dilute ethanol before 
analysis.  
 
3.2.4 In vivo tracking of Tol-DC in NSG mice 
Animal experimentation was conducted in accordance with the institutional and 
national ethical guidelines at the Université de Nantes.  At day 0, NSG mice were 
irradiated and injected intravenously (i.v.) with 5 x 106 labelled Tol-DC and 
intraperitoneally (i.p.) with 5 x 106 non-labelled PBMC.  The mice were sacrificed at 
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days 3, 6 and 10, post-administration and the organs harvested.  Three mice were 
used for each time point, with a further three mice given non-labelled cells as a 
negative control.  Each organ was weighed and separated into sections, with 3 
individually weighed sections (~20-200 mg each) per organ provided for solution ICP-
MS, and the remaining organ frozen for subsequent experiments.  These frozen 
organs sections were stored at -80oC for approximately one month, then sectioned to a 
thickness of approximately 5μm using a cryostat.  Sections were mounted on 
SuperFrost slides (Thermo Fisher Scientific, Schwerte, Germany) and sent to 
Loughborough on dry ice. 
 
3.2.5 MAXPAR antibody labelling 
Following conventional immunohistochemical techniques, tissues were blocked with 5% 
normal mouse serum in Tris buffered saline (TBS) for 1 h.  Tissues were stained 
overnight at 4°C using primary metal-tagged MAXPAR antibodies (Fluidigm Sciences, 
Sunnyvale, CA) diluted in TBS + 5% normal mouse serum, according to the 
manufacturer’s recommendations.  Specifically, tissues were stained with 154Sm-
tagged anti-CD45 (clone HI30), 159Tb-tagged anti-CD11c (clone Bu15) or 174Yb-tagged 
anti–HLA-DR (clone L243). Sections were counterstained with H&E before progressive 
dehydration in alcohol and air drying. 
 
3.2.6 Solution-based ICP-MS  
Digestion of the cell and organ samples was performed prior to ICP-MS analysis, 
according to a procedure proposed by Yamada et al.132 and modified by Kerr.133  This 
involved addition of 67% HNO3 (100 µl per 1x10
6 cells, or 0.5 ml per organ), heating at 
70oC for 1 hour, followed by addition of 30% H2O2 (100 µl per 1x10
6 cells, or 0.5 ml per 
organ) and heating at 70oC for a further 4 hours.  The samples were evaporated to 
dryness under a stream of nitrogen, and then reconstituted in 5% aqua regia.  For 
quantification, a range of standards were produced by dilution of a 10 ppm elemental 
standard solution (SPEX Certiprep, Middlesex, UK).   
 
Analyses were performed on a sector-field ICP-MS instrument (Element 2XR, Thermo 
Scientific, Bremen, Germany).  The instrument was fitted with a cyclonic spray 
chamber (Glass Expansion, Victoria, Australia), a conical glass concentric nebuliser 
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(Glass Expansion, Victoria, Australia), and a 0.25 mm I.D. probe (Elemental Scientific, 
Omaha, USA).  Gold is known to have an affinity for the surfaces of the sample 
introduction system,133 so to minimise memory effects, solutions of 5% aqua regia and 
10mM cysteine were aspirated between samples. 
 
3.2.7 LA-ICP-MS 
A UP-213 laser ablation system (Electro Scientific Industries, Cambridgeshire, UK) 
was coupled to the sector-field ICP-MS instrument above, in external trigger mode.  
The laser was fitted with a low-volume, tear-drop shaped cell, which has been 
described in detail elsewhere.131   Helium was used as an ablation gas, at a typical flow 
rate of 0.6 l/min, with argon introduced through a Y-piece, at a flow rate of 0.8 l/min, 
downstream of the ablation cell.  The system was tuned daily for maximum 238U signal 
intensity, whilst keeping the Th/U ratio to approximately 1 and the ThO/Th ratio to 
below 1%, during the ablation of NIST 611 glass. 
 
Cells were examined on an individual basis by ablating single 55 µm diameter shots at 
locations corresponding to single Au labelled cells, single non-labelled cells, and areas 
of the media containing no cells.  The spot size was chosen to ensure complete 
sampling of each cell, whilst minimising the chance of overlap onto neighbouring cells.  
However, Mreg morphology dictated that in a few cases a small portion of the cell 
extended beyond this region and was not ablated.  A high laser energy, producing ~ 9 
J cm-2 fluence, was chosen to ensure complete ablation of cellular material within the 
sampled region.  Only single cells were targeted; cells present in clusters or closer 
than 55 µm apart were disregarded.  The integrated 197Au counts per peak were taken 
to be representative of the total Au content per cell.  
   
Imaging of cells and tissue sections was accomplished by performing adjacent line 
scans across a section of the slide, whilst measuring 197Au and 154Sm, 159Tb or 174Yb in 
time resolved mode.  The ICP measurement parameters for this analysis are shown in 
Table  3.1.  A ~2 J/cm2 laser fluence, 5 Hz repetition frequency, 8 μm spot size and 8 
μm/s scan speed were used, with zero spacing between ablated lines.  Images were 
constructed from the data using Iolite version 2.15 (Melbourne Isotope Group, Victoria, 
Australia), which is a freeware data deconvolution package that runs on the IGOR Pro 
6.22A platform (WaveMetrics, Oregon, USA).  The software converts each raw data 
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point into a colour coded pixel; thus the colour profile of the resulting image depicts the 
distribution of the respective elements across the sampled region. 
 
 
Table ‎3.1 The ICP-MS measurement parameters for the co-detection of Au 
nanoparticles and MAXPAR antibody labels. 
Parameter First isotope Second isotope 
Isotope Sm154, Tb159 or Yb174 Au197 
Mass window 20 % 20 % 
Integration window 20 % 20 % 
Settling time 0.001 s 0.001 s 
Sample time 0.001 s 0.001 s 
Samples per peak 50 50 
Segment duration 0.01 s 0.01 s 
Scan type EScan EScan 
Detection mode Triple Triple 
Integration type Average Average 
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3.3 Results and Discussion 
 
3.3.1 Optimisation of the labelling conditions 
Both cell types are known to have very rapid phagocytic ability; thus only a narrow 
range of incubation times were tested for Mregs and only one time point was tested for 
Tol-DC.  The label concentration is perhaps the more defining parameter for uptake, as 
can be seen in Table  3.2 and Table  3.3, which show the average number of Au atoms 
internalised by Mregs and Tol-DC at each condition.  Problems generating and 
expanding the cells in vitro produced insufficient cell numbers for an adequate number 
of replicates per dose, hence, where replicates were performed, the observed %RSD 
were large.  Despite this, the general trend was clearly identifiable.  Label uptake was 
heavily concentration dependent and did not reach saturation within the range of 
concentrations examined. 
 
Table ‎3.2 The effect of the Au labelling dose and the incubation time on the uptake 
of Au nanoparticles by Mregs.  Data is presented as the average number of Au atoms 
internalised per cell for each labelling condition. 
 Incubation time 
10 s 1 h 2 h 
D
o
s
a
g
e
 /
 µ
l 
0 Not detected Not detected Not detected 
1 Not detected 1.79E+06 1.75E+06 
5 Not detected 1.06E+07 9.52E+06 
10 1.54E+06 3.09E+07 3.76E+07 
50 1.05E+07 1.71E+08 3.64E+08 
100 1.51E+07 3.39E+08 4.36E+08 
 
 
Table ‎3.3 The effect of the Au labelling dose on the uptake of Au nanoparticles by 
Tol-DC, when using an incubation time of 1 hour. %RSD’s are given as n=2, unless 
specified by an asterisk, where n=3. 
 
Au atoms per cell ± % RSD (n=2) 
D
o
s
a
g
e
 /
 µ
l 0 5.81E+05 ± 81 
10 5.06E+07 ± 32 * 
100 3.94E+08 ± 44 * 
200 6.42E+08 ± 66 
500 6.81E+08 ± 50 
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To ascertain whether gold labelling affects the viability, phenotype or function of the 
cells, flow cytometry studies was performed at the Universität Regensburg and 
Université de Nantes.  This involved analysis of common surface markers that are 
expressed by each cell type, as well as an assessment of their ability to suppress 
proliferation of allogeneic T cells in vitro.  No difference was observed between labelled 
and non-labelled Mregs in terms of their surface marker expression or suppressor 
activity, when using 100 µl of the nanoparticle suspension (~3.5 x 109 Au 
nanoparticles).  Toxicity tests with Tol-DC examined a higher range of concentrations, 
up to 500 µl (~1.75 x 1010 Au nanoparticles).  No difference in the suppressive ability of 
Tol-DC was noted.  However, Tol-DC incubated with nanoparticles exhibited a slight 
increase in CD83 and CD86 expression, which increased with increasing nanoparticle 
concentration.  For this reason, the labelling dose was limited to 100 µl nanoparticle 
suspension per 1 ml of media for all subsequent experiments. 
 
3.3.2 Laser ablation of single cells 
To assess the variance in nanoparticle uptake, the cells were analysed on an individual 
basis using LA-ICP-MS.  High labelling and detection efficiencies of 100% and 97.8% 
were obtained for Mregs and Tol-DC respectively.  LA-ICP-MS of the labelled cells 
yielded an average signal of 1.9 x 105 counts/cell (77% RSD, n=100) for Mregs and 2.1 
x 105 counts/cell (148% RSD, n=978) for Tol-DC.  As mentioned in Chapter 2, variation 
in label uptake across the population is expected due to intrinsic biological 
heterogeneity, as well as sampling constraints regarding the laser fluence and 
morphology of the cells.  With nanoparticle labelling, a further source of variation may 
arise from the formation of nanoparticle aggregates in the regions surrounding cells, 
which may be non-uniform in size and shape and may interact with cell receptors in 
different ways.165  The extent of variance in uptake is accordance with published LA-
ICP-MS data on Au nanoparticle uptake,166 which was acquired using a different laser 
system than the one used here.  Despite the variation in uptake, each signal was 
clearly distinguishable from the low background of approximately 0 to 20 counts, 
(Figure  3.1).  No signals above background were observed for the ablation of non-
labelled cells (Figure  3.1).  This demonstrated that the labelled cells can be rapidly and 
reliably distinguished from their non-labelled counterparts, which was subsequently 
confirmed during the analysis of mixed populations of labelled/non-labelled Mregs (see 
Table  3.4). 
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Figure ‎3.1 Example LA-ICP-MS signals for the ablation of 10 individual Mregs (A) 
and 10 individual Tol-DC (B) following incubation with 3.5 x109 gold nanoparticles for 1 
hour.  Background noise was observed during the ablation of unlabelled Mregs (C) and 
Tol-DC (D). 
 
 
 
 
Table ‎3.4 LA-ICP-MS analysis of mixed populations of labelled/non-labelled Mregs. 
Ratio of Labelled/ 
Non-labelled Cells 
Culture time after 
labelling / h 
No. of cells 
ablated 
No. of labelled 
cells detected 
1:0 1 100 100 
0:1 1 100 0 
1:1 1 100 45 
1:0 36 100 100 
0:1 36 100 0 
1:1 36 100 43 
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3.3.3 Co-labelling with metal-conjugated antibodies 
Release of gold nanoparticles from decaying cells and their subsequent reuptake by 
phagocytes could lead to false positive detection.  One solution to this problem is to 
establish that cells bearing the tracer label express the anticipated marker phenotype, 
through immunohistochemical “post-labelling” with metal-conjugated antibodies.  This 
form of phenotypical analysis may also prove useful in determining the functional 
status of infused Tol-DC.  It is thought that immature dendritic cells are responsible for 
inducing tolerance, whilst mature cells play a role in establishing immunity.6  Maturation 
can be monitored by measurement of changes in characteristic surface markers.  For 
example, HLA-DR molecules are upregulated following maturation of Tol-DC.167   
 
A feasibility study was conducted to assess whether Au nanoparticles and metal-
conjugated antibodies can be co-detected in cells using LA-ICP-MS.  Following Au 
labelling, cells were counter-labelled by incubation with either 154Sm tagged anti-CD45, 
159Tb tagged anti-CD11c or 174Yb tagged anti-HLA-DR.  Co-detection of transient 
signals from different elements is challenging when using sector-field ICP-MS, due to 
the sequential scanning mode.  Scanning using the magnetic sector requires a long 
settling time between measurements of each mass, but faster electrostatic scanning is 
possible between elements of similar mass.  The metal-tagged antibodies selected for 
this study were therefore chosen to be close enough in mass to 197Au to avoid a 
magnet jump.   
 
LA-ICP-MS line scans were performed across a cluster of the labelled cells to simulate 
tissue imaging.  Figure  3.2 and Figure  3.3 show a selection of the resulting LA-ICP-MS 
images.  Although relatively low, the count rate was sufficient to enable detection of the 
cells and importantly the spot size and scan speed were sufficient to discriminate 
between the signals from individual cells. Co-existing signals were obtained for the 
antibody and nanoparticle labels, demonstrating that the method could, in principle, be 
applied to detect dual labelling of cells in tissues.  In this study, where the cells were 
Au labelled for 1 hour with no follow-on culture, both labels appeared to be 
homogeneously distributed across the cells.  However, a recent study of 14 nm Au 
nanoparticle uptake in fibroblast cells indicated that nanoparticles may begin to 
aggregate and locate to the perinuclear region in cells that are cultured for 1 to 3 hours 
after labelling.168  As long as labels are internalised, their cellular location is not critical 
to cell tracking.  However, it is notable that perinuclear localisation of nanoparticles 
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would produce Au signals of shorter duration for in vivo studies, where there is further 
opportunity for aggregation, than for the images shown in Figure  3.2 and Figure  3.3. 
 
 
 
 
Figure ‎3.2 A: Microscopic image of a section of slide-mounted Au and anti-HLA-DR-
174Yb labelled Tol-DC (top).  LA-ICP-MS image of the same section, showing the Yb 
(middle) and Au (bottom) distribution.   
B: Microscopic image of a section of slide-mounted Au and anti-CD11c-159Tb labelled 
Tol-DC (top).  LA-ICP-MS image of the same section, showing the Tb (middle) and Au 
(bottom) distribution.  
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Figure ‎3.3 A: Microscopic image of a section of slide-mounted Au and anti-HLA-DR-
174Yb labelled Mregs (top).  LA-ICP-MS image of the same section, showing the Yb 
(middle) and Au (bottom) distribution.   
B: Microscopic image of a section of slide-mounted Au and anti-CD45-154Sm labelled 
Mregs (top).  LA-ICP-MS image of the same section, showing the Sm (middle) and Au 
(bottom) distribution.  
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3.3.4 In vivo mouse study 
The distribution of cells after intravenous infusion reflects their active and passive 
migration and engraftment into tissues, as well as their death and elimination.  In a 
previous tracking study, Hutchinson et al. used single photon emission computed 
tomography (SPECT) to analyse 111In-oxine labelled Mregs in a transplanted human 
patient.7  In this study, the 111In-oxine label was predominately detected within the 
lungs during the first 2.5 hours after administration, but by 4.5 hours had begun spread 
to the liver and spleen via the blood.7  However, due to radioisotope stability, the 
survival and fate of the Mregs could not be characterised beyond 30 hours using this 
method.  In contrast, the use of Au nanoparticle labelling and LA-ICP-MS detection 
could provide valuable information on the trafficking of cells beyond this limit.   
 
Gold labelled Mregs and Tol-DC were injected into NSG mice in two separate 
experiments.  The presence of label in the major organs was assessed at day 1 and 7 
post administration for Mregs and at days 3, 6 and 10 post-administration for Tol-DC. 
Figure  3.4 shows the amount of Au detected per organ for mice given labelled Mregs, 
compared to a non-labelled control.  Gold was principally detected in the lungs, liver 
and spleen, with minor accumulation also observed in the kidney, heart, brain and 
intestine. 
 
The distribution of label shown in Figure  3.4 is unsurprising, considering the route of 
cell administration used.  High accumulation within the lungs is expected in the initial 
period after injection, since cells given intravenously are carried through the lungs by 
the blood and may become trapped in the pulmonary vasculature.  Similarly, highly 
perfused organs, such as the liver, are expected to attract and accumulate cells.  
Interestingly, a SPECT study by Eggert et al. indicated that cells administered 
intravenously may show different migration patterns to those given subcutaneously or 
intraperitoneally.169  Eggert observed that up to 55% of the cells injected into the 
peritoneum remained at the site of injection at 48 hours post-administration, which 
correlates with the findings of the Gd-labelled cell study, reported in Chapter 2, which 
used the intraperitoneal route. 
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Figure ‎3.4 Tracking of Mregs and Tol-DC in immunodeficient mice using solution based ICP-MS analysis of digested organ samples.  The 
proportion of gold detected within each organ, for samples taken at various time points after administration of Au labelled cells. Control animals 
given non-labelled cells are included for comparison.  Graphs on the left hand side show the experiments involving Mregs (n=1), whilst the 
graphs on the right hand side show the average uptake for experiments involving Tol-DC (n=3).  The lower panels show an expanded view of 
the scale between 0 and 1 ng Au per organ, to enable visualisation of the lower intensity data. 
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3.3.5 Laser ablation of tissue sections 
Although the above ICP-MS study provided valuable information on the general 
localisation of administered cells, it offers very limited insight into the precise 
distribution of the cells within the tissues studied.  To demonstrate the applicability of 
laser ablation sampling to provide spatially resolved information, paraffin embedded 
tissue sections from the above experiments were sectioned to a thickness of 6 µm.  
Investigations focussed on the liver, lung and spleen, which previously identified as the 
major sites of Au accumulation.  Sampled areas were 320 x 245 µm in size, with two 
areas selected per tissue section.  The results of this analysis are presented in 
Figure  3.5.  As predicted by solution ICP-MS, label was detected in all three tissues.  
However, no pattern of signal distribution was perceived within the relatively small 
areas of tissue examined. 
 
From Figure  3.5 it is difficult to verify whether the observed signals are from intact cells 
or from individual nanoparticles that may have been released through exocytosis or 
cell death.  Concurrent detection of signals from cells pre-labelled with gold and post-
labelled with metal-bound antibodies to HLA-DR would imply the presence of intact 
cells in mouse tissues.   Unfortunately, sections of spleen that were counterstained 
with 174Yb-conjugated anti-HLA-DR gave rise to high 174Yb background signals, as 
shown in Figure  3.6.  Therefore, no correlation between the distribution of 174Yb and 
197Au signals could be established.  It is possible that these metal-tagged antibodies 
are unsuitable for use on tissue sections, possibly owing to destruction of antigens 
during tissue fixation, or perhaps due to subsequent detachment of the label during 
storage, shipping or handling of the samples.  It is equally possible that MAXPAR 
reagents have a greater propensity for non-specific binding to tissues than antibodies 
tagged with alternative labels.  A previous publication by Waentig et al. noted high 
backgrounds for MAXPAR reagents in Western blot immunoassays, when compared to 
other reagents.170  As the authors of this work pointed out, the MAXPAR reagents and 
their recommended protocols were optimised for single-cell analysis by mass 
cytometry.  Post-labelling tissues with metal-labelled antibodies may require 
development of more suitable metal-conjugated antibodies, possibly labelled using 
different chemistries, as well as better histological methods to block non-specific 
binding of antibodies. 
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Figure ‎3.5 High resolution imaging of Au in small sections of mouse tissue. Optical 
images of mouse liver, lung and spleen tissue and the corresponding LA-ICP-MS 
images, showing the distribution of gold within each section.  Regions of high gold 
intensity appear as coloured spots in the LA-ICP-MS images.  It is likely that the 
broader spots correspond to cells, whilst the narrower streaks may indicate the 
presence of individual nanoparticles.  Tissues were harvested at 24 hours (upper 
panels) and 7 days (lower panels) after administration of gold labelled Mregs, and were 
subsequently counterstained with H&E.   
 
86 
 
 
Figure ‎3.6 High resolution imaging of a section of mouse spleen tissue, which was 
counter-labelled with 174Yb-tagged anti-HLA-DR. Top: Microscopic image of the 450 
μm x 632 μm section of NSG mouse spleen tissue.  Bottom: corresponding LA-ICP-MS 
image showing the 174Yb distribution across the section. 
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3.4 Conclusion 
 
This chapter reports the use of 50 nm sized gold nanoparticles to label regulatory 
macrophages and tolerogenic dendritic cells, which facilitated their detection by ICP-
MS in ex-vivo mouse samples.  Solution-based ICP-MS of the major organs identified 
the lungs, liver and spleen as the major sites of Au accumulation, at periods of up to 10 
days after administration of the labelled cells.  LA-ICP-MS of these tissues offered a 
unique combination of high sensitivity and spatial resolution and permitted longer 
tracking periods than were possible in previous experiments using SPECT detection.  
In addition, the use of non-radioisotopic tracers may be safer and more convenient 
than the 111In-oxine labels, when manufacturing and administering cell based therapies.  
The only notable disadvantage of LA-ICP-MS compared to SPECT is its ex-vivo nature, 
which demands invasive sampling and precludes repeated measurements within a 
short timeframe. 
 
Antibody-metal labels were successfully used to co-label isolated Tol-DC and Mregs 
with high specificity.  LA-ICP-MS imaging revealed strong correlation of the antibody 
tags with gold signals, which has potential applications for the validation of Au tracking 
data.  Unfortunately, the method could not be translated to the analysis of tissue 
sections, owing to high background levels of the rare earth metal in the tissue.  This 
may be an indication of non-specific binding of the antibody labels used.  The inability 
to identify co-labelled cells in tissue samples does not derive from the effectiveness of 
the LA-ICP-MS technique, but points instead to the limitations of current metal-tagged 
antibodies and histological methods.  With the development of a new mass cytometry 
imaging platform expected in 2015,171 there is likely to be considerable interest in 
developing new protocols and improved reagents for staining tissues with rare earth 
labels. 
 
For phenotypic analysis of cells, it would be beneficial to measure many more 
parameters than studied here.  The principal restriction on analysing a greater number 
of metal labels was the rate at which sector-field instruments detect each element, 
which they must do sequentially.  Simultaneously detecting mass spectrometers, such 
as time-of-flight mass spectrometers, would enable concurrent, multi-channel 
measurements of a vast array of metals.  However, TOF systems provide considerably 
lower sensitivity compared to sector-field mass spectrometers, or in the case of the 
CyTOF system,61 have a limited mass range.  Given the signal intensities observed for 
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metal-tagged antibody labels, it appears that performing this analysis with 
commercially available LA and TOF systems may prove challenging.  However, Wang 
et al. recently reported the development of a custom designed, high speed and high 
sensitivity laser ablation cell,172 which was successfully coupled to a CyTOF to image 
an array of lanthanide-tagged antibodies.173  Improvements of this nature to the core 
LA technology are of paramount importance to multi-parametric single cell analysis and 
hence will be discussed in more detail in Chapter 4.  
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4 Development of a High-speed LA-
ICP-MS Interface for Bio-imaging 
 
 
4.1 Introduction 
 
Since the development of LA-ICP-MS imaging, there has been focus on improving the 
speed and sensitivity of the technique.  Convolution of signals from consecutive laser 
pulses reduces the effective spatial resolution of images, so the degree of signal 
dispersion is considered the limiting factor for sampling speed.  Commercially available 
systems have aerosol residence times of approximately a second; thus to image a  1 x 
1 mm tissue biopsy at 10 μm resolution would take approximately 2.8 hours.  Whilst 
this may be acceptable in the research setting, such lengthy analysis times preclude 
the application of LA-ICP-MS for routine clinical monitoring.  Numerous groups have 
attempted to solve this problem by designing custom modifications to the existing 
systems.172, 174-184  The interface between the laser and the mass spectrometer has 
attracted considerable interest here, particularly the dimensions of ablation 
cell/chamber, the position of the gas ports within it, and the transport conduit 
connecting the cell to the ICP. 
 
4.1.1 The ablation cell/chamber 
In order to accommodate a variety of sample formats, commercial LA cells typically 
have large inner volumes, which results in high aerosol dispersion.  Consequently, 
there has been a drive to create low-volume, fast-washout cells for small samples,131  
whilst “open” cells, placed on top of the sample surface, are sometimes used for larger 
samples.176, 177  An example of an open cell is the non-contact cell, which is suspended 
200 µm above the sample surface and uses a curtain gas to exclude atmospheric 
gases from the site of ablation.177  However, due to the complexity required to maintain 
an inert ablation atmosphere, the concept of open cells has not gained popularity.   
 
More recently the focus has shifted to two-volume or cell-in-cell configurations.  These 
typically include a low-volume inner sampling device, positioned above the ablation site, 
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within a closed external cell.  This enables the analysis of large format samples, such 
as gels or membranes, whilst maintaining a low effective volume within the ablated 
region.  Furthermore, in systems where the inner cell maintains a consistent sampling 
position within the outer chamber, signal reproducibility is improved.  Various inner 
sampling devices have been reported.178-180  The laminar flow reactor (LFR) used a 
simple tube above the ablation site, and achieved washout times of 45 ms (to 10% 
peak maximum).178  The volume-optional low-memory (VOLM) chamber used a 0.4 
cm3 cylindrical inner cell, producing washouts of 0.45 s (to 10% peak maximum).179  
Whilst the Laurin cell employed a ~1-2 cm3 funnel shaped inner cell, yielding washouts 
of 1.5 s (to 1% peak maximum).180   
 
4.1.2 Gas inlet/outlet ports 
Expansion of the carrier gas as it enters the cell, and contraction as it exits, generates 
turbulent gas flows that can entrain ablated particles and increase their residence 
time.181  Consequently, it is beneficial to arrange the gas ports in a geometry that will 
produce a laminar flow in the ablation region.  This concept was integral to the single-
volume designs reported by Gurvevich et al. and Monticelli et al., who achieved 
washouts of 30-40 ms (to 37% peak maximum) and 30 ms (to 10% peak maximum), 
respectively.181, 182  In contrast to this, Bleiner and Altorfer’s rotating nozzle inlet 
increased turbulent mixing, but this was beneficial as it reduced the dead volume within 
their large (30 cm3) cell.183  The rotating nozzle produced a  two-fold higher 
“improvement factor” compared to their standard inlet, which was defined as signal 
intensity divided by point-to-point repeatability.183 
 
4.1.3 The transport conduit 
Another key area is the conduit connecting the ablation cell to the ICP torch.  Many 
systems employ flexible polymer tubing, which is usually around 3-4 mm internal 
diameter and can be several metres in length.  The flow path is usually intersected by 
a T- or Y-piece, for argon introduction, and may pass through a series of valves and 
other flow impedances.  Flow modelling suggests that minimising these disruptions and 
maintaining a constant diameter conduit is beneficial to reduce signal dispersion.185  
This was confirmed experimentally in the aforementioned LFR cell, which used a 
tubing diameter equal to that of the injector tube, and included a custom, laminar flow 
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connector for argon addition.178  Wang et al. also developed a “tube cell” using this 
concept.172  The ablation cell was adjoined below the tubing, such that the plume was 
lifted upwards by the helium flow, directly into the laminar argon flow, through an 
opening in the tubing.  This removed the requirement for a conventional dispersive T-
piece, producing signal widths of 30 ms at 1% peak maximum. 
 
4.1.4 In torch ablation 
Liu et al. designed an in situ laser ablation system for inductively coupled plasma - 
optical emission spectroscopy (ICP-OES), whereby ablation took place inside the ICP 
torch itself, removing the need for the LA cell or connecting tubing.186  The sample was 
placed a millimetre below the plasma discharge, and the laser beam was directed 
through the plasma onto it.  The resulting aerosol was transported into the plasma by 
the sample gas flow.  Signals with a full width at half maximum (FWHM) of 0.7 ms were 
reported.186  However, this arrangement was unsuitable for use with ICP-MS, as the 
MS interface, placed after the plasma, would have obstructed the laser beam.   
 
Tanner et al. modified Liu’s in torch arrangement for use with mass spectrometry.184  
Instead of directing the laser beam through the plasma, it was focussed through a 10 x 
10 mm hole in the top of the torch.  The system produced signal durations with a 
FWHM of 4 ms when using a quadrupole mass analyser.  However, the in torch 
system was impractical to implement, since it was limited to small samples and precise 
sample movement was impossible.  Due to the high temperature of the sampling 
position, the system was also restricted to high melting point samples.  Despite this, 
the speed of the in torch system can be regarded as the ultimate benchmark for the 
development and characterisation of new LA-ICP-MS interfaces. 
 
4.1.5 The Loughborough system 
Douglas et al. developed a new LA-ICP-MS interface that encompassed the key 
design areas outlined in sections  4.1.1 to  4.1.3.187  The ablation cell used a two-volume 
arrangement, containing a 0.005 cm3 internal volume “Sniffer” cell, sealed inside the lid 
of a standard UP-213 cell.  This inner device, shown in Figure  4.1, sat approximately 
100 μm above the sample surface and used a pressure gradient to efficiently capture 
the ablated plume, preventing its expansion into the outer cell.   
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Figure ‎4.1 A) Semi-transparent rendered image and, B) cross-sectional view of the 
Sniffer.  Image B reproduced with permission of David Douglas. 
 
 
The Sniffer was integrated with a 250 m i.d. fused silica capillary, which formed the 
central injector in a Dual Concentric Injector (DCI) ICP torch, shown in Figure  4.2 and 
Figure  4.3.  The fused silica provided a short, constant diameter transport conduit, free 
from valves, T-pieces and other flow disruptions.  The fused silica was held 
approximately concentric inside the outer injector by a Macor centring piece; thereby 
maintaining the sample flow on-axis with the orifice in the sampler and skimmer cones.  
Holes in the Macor allowed passage of the argon make-up gas; thus a stable central 
channel was formed through the plasma, independently of the helium flow.  Moreover, 
the fused silica could be extended beyond the tip of the injector, past the turbulent 
recirculation region188, 189 at the base of the plasma. 
A 
B 
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Figure ‎4.2 Cross sectional view of the Direct Concentric Injector (DCI) showing the 
extension of the fused silica tubing beyond the tip of the injector. Image reproduced 
with permission of David Douglas. 
 
 
 
Figure ‎4.3 Rendered image of the Direct Concentric Injector.  Image reproduced with 
permission of David Douglas.  
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When using the Sniffer with the DCI and standard UP213 cell, sub-100 ms single shot 
widths were achieved, leading to order of magnitude improvements in image analysis 
speed, and around a 10 fold improvement in peak area, compared to the standard 
system.187 
 
The speed and sensitivity delivered by the DCI/Sniffer are key requirements for the 
acceptance of LA-ICP-MS as routine clinical monitoring technique.  However, the 
Sniffer is a static device, so when used with a standard cell it is only capable of 
sampling at a single location per analysis.  A modified arrangement is necessary to 
enable targeted imaging of tissue biopsies, blood smears or individual cells. 
 
4.1.6 Aims for this thesis chapter 
This section describes the development of a new outer cell, known as the Enterprise 
cell, for use with the Sniffer and DCI.  Since the Sniffer is a stationary device, scanning 
across the sample surface must be accomplished using movement of the sample 
beneath the Sniffer.  Two sample movement configurations are described.  The first 
involved movement of the sample stage via a magnetic coupling between the sample 
holder and the existing UP213 2-axis movement stage.  The second option involved 
direct contact between the sample holder and movement stage, through a hole in the 
base of the cell.  These designs aimed to fulfil the following criteria: 
 
1. Exclude atmospheric gases and maintain a pressurised inert ablation 
atmosphere. 
2. Direct the gas flows in a way that is conducive to the capture and complete 
transport of ablated material by the Sniffer. 
3. Retain a constant angular orientation of the sample in the cell. 
4. Maintain a consistent distance between the base of the Sniffer and the sample 
surface. 
5. Enable precision in sample movement, such that the sample can be reliably 
and consistently moved in 1 µm steps, with minimal lag. 
 
Computational fluid dynamics (CFD) is a useful tool when designing and implementing 
any new fluid-based technology.  It enables the user to optimise experimental designs 
prior to construction of a prototype, and offers insights into experimental results.  
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Numerical simulations have already been used in the field of ICP-MS for modelling gas 
flows within laser ablation cells, the transport tubing, spray chambers, and even the 
plasma itself.185, 188-191  Here CFD was used to guide development of Enterprise cell, to 
examine the gas flows around the Sniffer region, and to monitor the trajectory of 
simulated particles through it.  
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4.2 Experimental 
 
4.2.1 Materials 
The Enterprise cell was designed to fit the UP-213 laser ablation system (Electro 
Scientific Industries, Cambridgeshire, UK).  All custom delrin and aluminium parts were 
fabricated by Creative Machine, Washington, USA.  The fused silica window was 
purchased from CVI Melles Griot, UK.  All Macor parts were fabricated by Ceramic 
Substrates, Isle of Man, UK.  The 3-axis manual movement stage was purchased from 
Edmund Optics, Yorkshire, UK.  Dynamic seals were made from graphite filled PTFA 
and were purchased from Parker, USA.  All static o-ring seals were made from Viton® 
material and were purchased from RS Components, Northamptonshire, UK.  The ball 
race used for the magnetic coupling was also purchased from RS components.  
Compression fittings were purchased from Swagelok, Manchester, UK. 
 
4.2.2 Design and construction of the basic Enterprise Cell 
The design, shown in Figure  4.4 and Figure  4.5, was extensively refined within Solid 
Works before fabrication of the Enterprise Cell.  The cell was constructed in a modular 
fashion, to allow cost effective modification and replacement of parts, as optimisation 
of the physical prototype progressed.  The basic cell consisted of a delrin base, middle 
section, lid, optical window holder and positioning bar, with a 30 x 3 mm fused silica 
optical window.  When assembled, the cylindrical cell had an internal volume of 118 
cm3.  The Sniffer was glued into the bottom of the positioning bar, which was 
positioned above the sample holder, perpendicular to the sample gas inlet.  At the 
default position, the Sniffer sat 100 µm above the sample surface.  The use of 
removable washer shaped spacers below the positioning bar, or beneath the sample 
itself, allowed this distance to be adjusted as necessary.  The cell incorporated four 
gas ports accessed through 1/8-27 NPT compression fittings.  One of these gas ports 
was required for carrier gas entry, and another for exit of the fused silica tubing.  The 
remaining two ports could be used for attachment of a pressure relief valve or for 
addition of a second ablation gas; although these were easily blanked off when these 
options were not required.  The cell was attached to the UP213 system via a bracket, 
which incorporated a 3-axis manual micrometer movement stage, to enable alignment 
of the laser firing position with the 800 µm laser access hole in the Sniffer. 
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Figure ‎4.4 Rendered image of the closed Enterprise cell, showing the attachment 
bracket, incorporating a 3-axis manual micrometer movement stage. 
 
 
 
Figure  4.5 Rendered image of the open Enterprise cell. 
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4.2.3 Magnetic coupling 
In this configuration, a set of magnets inside the sample holder were magnetically 
aligned to magnets in a positioning plate below the cell.  This plate was connected to 
the existing UP213 2-axis movement stage, which is computer controlled.  Two sets of 
magnets were required to ensure consistent alignment: the first positioned the sample 
holder, and the second prevented it from twisting during movement.  The sample 
holder accommodated slides of up to 25 x 25 mm in size, and was mounted on a ball 
race, which ran along a Macor insert in the base of the cell.  This insert had a 0.4-0.8 
µm Ra surface finish, providing a smooth running surface for the ball race.  A cross 
section of the magnetic coupling configuration is shown in Figure  4.6. 
 
Figure ‎4.6 Cross section of the Enterprise cell, with the magnetic coupling, 
showing a) 25 x 3 mm optical window, b) sample position, c) Sniffer, d) positioning bar 
for the Sniffer, e) fused silica tube, f) acetal thrust race bearing, g) Macor insert, h) set 
of positioning magnets, i) set of aligning magnets, j) spare inlet/outlet ports, k) 
Swagelok 1/8 NPT connector.  Dimensions are in mm. O-rings are shown in black. 
 
4.2.4 Dynamic o-ring seal 
As with the magnetic coupling, this configuration used a positioning plate attached to 
the 2-axis computer controlled movement stage.  In this case the positioning plate was 
directly attached to the sample holder by means of a M4 screw, which fitted through a 
25 mm hole in the base of the cell.  To ensure the cell remained airtight, the gap was 
sealed with two dynamic seals, which were located between the sample holder and the 
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inner base of the cell, and between the outer base of the cell and the movement plate.  
The movement plate incorporated a grease well, to reduce friction between the cell and 
movement plate, as necessary. A cross section of the o-ring seal configuration is 
shown in Figure  4.7. 
 
 
Figure ‎4.7 Cross section of Enterprise cell with dynamic o-ring seal movement, 
showing a) 25 x 3 mm optical window, b) sample position, c) Sniffer, d) positioning bar 
for the Sniffer, e) fused silica tube, f) spare inlet/outlet ports, g) Swagelok 1/8 NPT 
connector, h) M3 screw, i) metal support for the screw, j) grease well.  Dimensions are 
in mm. O-rings are shown in black. 
 
 
4.2.5 Flow simulation 
Solid Works Flow Simulation 2011 SP5.0 (Dassault Systems, Massachusetts, USA) 
was used to model the gas flows within the Enterprise cell.  Firstly, a three dimensional 
CAD model of the Enterprise cell was constructed within the Solid Works software.  
This model was set as the computational domain.  The components were automatically 
selected by the software as the solid region and the volume within them was selected 
as the fluid region.  The computational domain was then divided by a set of intersecting 
planes, forming a grid of control volumes, known as the initial mesh.  This was set so 
that the lines of the mesh were spaced at 100 µm intervals.  A higher level of 
refinement was required to accurately predict the flows around sharp edges and 
narrow channels, such as Sniffer and the gap between Sniffer and the sample surface, 
where the flow experiences a significant change in pressure and direction.  Therefore, 
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a finer refinement level, of 50 μm was set in these regions.  This resulted in the 
formation of 1,410,611 sub-volumes within the fluid region, which are known as fluid 
cells, along with 1,591,687 volumes that cross both the solid and fluid region, known as 
partial cells. 
 
The initial conditions were set so that the calculation began under atmospheric 
pressure at 298 K.  Atmospheric pressure was also specified at the 250 μm i.d. fused 
silica outlet; although it is acknowledged that under experimental conditions the 
pressure in this region might not be exactly atmospheric.  Helium was introduced into 
the cell through the main inlet port, at a flow rate of 125 ml/min.  In dual flow 
simulations, argon was used as the major flow, at a flow rate of 100 ml/min, with He 
directed into a modified Sniffer through the second inlet port, at a flow rate of 25 ml/min.  
Following set-up, the software calculated the gas flows through the model using an 
iterative solver, which operates by calculating the Navier-Stokes equations for each 
fluid cell at the specified conditions.192  Upon completion of the calculation, flow 
trajectories emanating from the inlet ports, and cut plots showing the gas velocity 
through the cell, were produced.  Particle tracking studies were performed for an 
injection of 100 nm glass particles, originating from a sketch point 200 µm beneath the 
sniffer, concentric with the laser access hole.  The average transit times for 100 
particles to reach the outlet was taken as the computed wash-out time for the cell. 
 
4.2.6 Demonstration for bio-analysis 
The performance of the system was evaluated for single cell analysis of Gd labelled 
CD4+CD25+CD127lo nTreg.  Cell labelling and preparation procedures were described 
previously in Chapter 2.  The Enterprise was fitted to the UP-213 laser ablation system 
(Electro Scientific Industries, Cambridgeshire, UK) as outlined in section  4.2.2.  The 
Sniffer was fabricated from Macor, a brilliant white material, which reflects illuminating 
light and impairs sample visualisation.  Thus, cochineal food colouring (Dr Oetker, 
West Yorkshire, UK) was used to dye the Sniffer pink, prior to assembly.  The Sniffer 
was then positioned 100 – 200 µm above the sample surface with the aid of feeler 
gauges.  A 685 mm length of fused silica (250 µm i.d, 360 µm o.d.) was used to 
connect the Sniffer to the DCI.  The DCI was then inserted into the semi-demountable 
torch on the Element XR (Thermo Scientific, Bremen, Germany).  The fused silica was 
initially positioned within the DCI, such that the outlet was flush with the end of the 
injector tip.  This was then extended towards the plasma at 1mm intervals.  A pressure 
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monitor was attached to the cell to monitor the pressure throughout the experiment.  
Typical operating parameters are given in Table  4.1. 
 
Table ‎4.1 Laser and ICP-MS operating parameters when using the Enterprise cell. 
Laser operating parameters  
Spot size 30 µm, round 
Repetition frequency 1 Hz (single shot) 
Laser power / fluence 42% / 6.40 J cm-2 
Helium flow rate 120 ml min-1 
Cell back pressure 11.62 psig 
Sample to Sniffer distance 100 – 200 µm (approx.) 
Fused silica length 685 mm 
ICP-MS operating parameters  
Radio frequency (RF) power 1250 W 
Cool gas flow rate 15.80 l min-1 Ar 
Auxiliary gas flow rate 0.95 l min-1 Ar 
Sample gas flow rate 1.45 l min-1 Ar 
Torch x position 4.9 mm 
Torch y position 2.9 mm 
Torch z position -2.0 mm 
 
 
4.2.7 Peak characterisation 
Instruments developed by different manufacturers employ unique software, and thus 
the terminology used to define the acquisition parameters varies considerably between 
systems.  For clarity, a brief description of the key acquisition terminology used by the 
Element XR is outlined here.  All data in this thesis was acquired using E Scan mode.  
When measuring one isotope using this mode, the magnetic field is set to a fixed value 
and the accelerating voltage and electric field are adjusted to repeatedly scan across a 
proportion of the mass peak, referred to as the mass window.  The mass peak is split 
into a series of “samples” or measurement channels, which are described as the 
number of samples per peak.  The user may define the time duration of each sample 
and the number of samples measured per peak.  Conventionally, time resolved data is 
extracted from the ICP-MS in “FIN2” format, where the samples within each peak are 
averaged and the data is presented as the average signal acquired per time bin or 
“segment”.  The duration of these segments is a function of the mass window, the 
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sample time and the number of samples per peak, plus the ~3 ms blind time of the duty 
cycle. 
 
To determine the sensitivity improvement of the new ablation interface, an ICP method 
using 50 samples per peak, a sample time of 5 ms, and a mass window of 20% was 
used, which resulted in a segment duration of 50 ms.  The data was extracted from the 
ICP in the conventional FIN2 format, such that the data points were spaced at 53 ms 
intervals.  This method was chosen to maintain compatibility with the data presented 
previously in Chapters 2 and 3, which is typical for most single element LA applications.  
Processing of these signals was performed by summing the total signal corresponding 
to each ablation event, as described in previous chapters. 
 
Since the peaks from the new interface were in the order of 10 ms, a finer time 
resolution was required for peak profiling.  Thus, a second method using counting 
mode, a sample time of 0.1 ms, 1000 samples per peak and a mass window of 20% 
was used.  For this, the individual ‘samples per peak’ (I.e. the raw data points), rather 
than the averaged data for each segment, were extracted directly from the inf file.  This 
file format displays the data in a series of columns, with each column showing an 
individual scan across the mass window, and the rows in each column depicting the 
signals from each 0.1 ms measurement.  Each sweep was then successively stitched 
together using an Excel macro, to provide 0.1 ms spaced, time resolved signal. 
 
The time resolved data was transferred to IGOR Pro 6.22A (WaveMetrics Inc., Lake 
Oswego, USA) for calculation of the peak characteristics.  A linear rise, plotted from 
the first data point to the peak top, was used to obtain the time at which the rising 
signal reached 50% of the peak maximum.  An exponential decay curve was fitted from 
the peak top to the baseline using Equation 4.1. This was rearranged to Equation 4.2, 
to calculate the point at which the signal decayed to 50% of the peak maximum.  The 
values were then subtracted to give the full width at half peak maximum (FWHM) in 
seconds.  This process was repeated to calculate the full width at 10% peak maximum 
(FW0.1M) and full width at 1% peak maximum (FW0.01M) respectively. 
 
 
𝑦 =  𝑦0 + 𝐴. 𝑒
(
−(𝑥−𝑥0)
𝜏 ) Equation 4.1 
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𝑥 =  − [𝑙𝑛 (
𝑦 − 𝑦0
𝐴
) . 𝜏] Equation 4.2 
 
Where 𝑦 and 𝑥 are the signal and time variables 𝑦0 and 𝑥0 are constants, 𝐴 is the fitted 
peak maximum and 𝜏 is the exponential decay constant. 
 
4.2.8 Use of a fast data acquisition board 
In later experiments, a P7882 dual-input photon counter board (FAST ComTec GmbH, 
Oberhaching, Germany) was connected to the ion detection board on the ICP-MS to 
improve the time resolution.  To prevent data losses, the trip cable was disconnected 
from the ion detection board and ion beam deflection during ESA flyback was disabled.  
Signals were captured using the MCDWIN software supplied with the board, which 
displayed the signals as two dimensional arrays.  The results were exported to IGOR 
Pro 6.22A in tab-delimited format, for further processing. 
 
The above electrical connections were made after consultation with Thermo Fisher 
Scientific.  To minimise the risk of instrument damage, or exposure to high voltages, 
users are strongly advised to obtain advice from the relevant instrument manufacturer 
before attempting to replicate these procedures. 
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4.3 Results and Discussion 
 
4.3.1 Flow simulation 
Flow simulations revealed that positioning the sample gas inlet collinear to the sample 
provided the most favourable gas flow dynamics.  Examination of the individual flow 
trajectories revealed that the sample gas flowed around the outer chamber and 
converged upon the Sniffer region.  The contour plot in Figure  4.8 displays the velocity 
profile across a horizontal cross section of the cell.  It was shown that the computed 
gas flow accelerated considerably upon entering the Sniffer, from less than 0.5 m/s 
prior to the Sniffer entrance, to speeds of 70 m/s by the end of the fused silica tube.  In 
dual-flow simulations the directed second flow entered the Sniffer at a higher speed 
than the main flow, and produced a gas velocity of nearly 80 m/s by the end of the exit 
tube.   
 
 
 
 
Figure ‎4.8 Cut plot showing the gas flows within the Enterprise cell as isolines and 
contours, with blue representing low velocity and red representing high velocity. 
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A detailed view of the flow pattern within the Sniffer region is shown in Figure  4.9.  The 
bulk of the carrier gas flow entered through the cut out section at the front of the Sniffer, 
then swept across the sample surface, before entering the fused silica exit tube.  A 
second gas flow entered the sniffer through the laser access hole.  This flow may 
restrict the ablation plume and prevent escape of the ablated material into the outer 
cell.  Minor gas pressure from behind the Sniffer was also present.  This may help to lift 
the ablated material from the sample surface, assisting its entry into the fused silica 
exit tube.  These flows are in accordance with flow modelling reported by Douglas for 
the modified UP-213 lid,187 indicating that the use of a large volume outer chamber 
does not impact negatively on the gas flow dynamics within the Sniffer region. 
 
 
Figure ‎4.9 Simulation of the gas flows through the standard Sniffer (top) and Dual-
flow Sniffer (bottom).  Coloured bands represent the flow velocity, with blue signifying 
low speed and red signifying high speed (> 0.5 m/s).  Black arrows have been inserted 
to indicate the flow direction. 
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Particle studies, using 100 nm glass particles, which originated from a location 200 µm 
beneath the Sniffer, concentric to the laser access hole, predicted that material ablated 
within the Sniffer cavity is efficiently captured by the Sniffer, and is conducted through 
the fused silica tubing towards the plasma.  Residence times within the cell of 4 ms 
and 3.9 ms were calculated when using the Sniffer and Dual-flow Sniffer respectively.  
These results are indicative of a very fast washout system.  However, it should be 
noted that the modelling did not account for the laser interaction, the spread of 
particulate within the ablation plume, or the plasma characteristics downstream of the 
ablation cell.  Furthermore, the constructed model was based on an idealised setup, 
whereby the cell was perfectly sealed, the Sniffer was exactly parallel to the sample, 
and the fused silica connections provided an exact fit, with zero dead volume.  These 
conditions can be difficult to achieve experimentally due to tolerance issues during 
manufacture, plus operator variation when constructing the cell.  In addition, it is likely 
that edge effects will be introduced by the inclusion of variable sample shapes and 
sizes.  For instance, sharp edges, such as those created during the cutting down of 
slides, will produce changes in flow direction and may introduce turbulence.  
Nevertheless, the flow modelling provided a positive indication of the flow 
characteristics within Enterprise cell, which supported construction of the prototype. 
 
4.3.2 Evaluation of the two movement configurations 
Pressure testing was initially performed off-line from the ICP-MS.  A pressure monitor, 
placed prior to the cell, measured the back pressure at various sample gas flow rates.  
The magnetic coupling used an entirely enclosed outer cell; thus stable pressures were 
reached within a few minutes using this design, and were maintained stably for several 
hours, without adjustment of the gas flow.  Cell pressure increased linearly with 
increasing increments of the sample gas flow in the range of 50 to 125 ml/ min, see 
Figure  4.10.  Flow rates producing pressures above 12 psig were not investigated in 
this study due to safety concerns. 
 
The magnetic coupling was capable of repositioning the sample beneath the Sniffer, 
but a significant amount of lag was observed between adjustments of the computer 
controlled stage and movement of the sample holder.  Movements of the computer 
controlled stage of less than 100 µm were not registered by the sample holder, and 
larger movements at high speed were required to produce a response.  Such 
movement is sufficient for single shot analysis, particularly on homogenous materials, 
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where the aim is simply to shift to a different location on the sample surface.  However, 
the ablation of lines or rasters, was not possible using the magnetic coupling.   
 
 
 
Figure ‎4.10 Back-pressure from the Enterprise cell at various He flow rates, when 
using the magnetic coupling. 
 
 
The dynamic o-ring design used a hole in the cell base to enable direct contact and 
positioning of the sample tray.  Atmospheric gases were excluded using two graphite 
c-seals, which were designed to operate with moving parts.  Cell pressure was heavily 
dependent on the amount of compression applied to these seals, which was adjusted 
manually using the positioning stage on the cell bracket.  Internal pressures of up to 8 
psig were reached with this design.  However, pressure was variable with the location 
of the sample tray.  Adjustments to the sample position, for example when performing 
line scans, led to rapid decreases in the internal pressure, which was particularly 
evident when scanning at high speed.   
 
The high level of c-seal compression required to maintain a consistent pressure within 
the cell compromised the sample movement capability.  With high c-seal compression, 
friction between the moving components and the base of the cell caused drag of the 
sample holder.  It is likely that an optimum degree of compression exists, which 
provides effective sample movement, whilst maintaining favourable gas flow dynamics.  
However, this optimum compression was difficult to reproducibly achieve using the 
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prototype design developed here.  Moreover, it is possible that friction observed during 
testing contributed to the overheating and subsequent failure of an electronics board 
on the UP-213 platform.  The dynamic o-ring design was therefore abandoned at an 
early stage and the magnetic coupling was used for the demonstration experiments 
presented in section  4.3.3. 
 
4.3.3 Demonstration for bio-analysis 
The performance of the system was evaluated for single cell analysis of 98.5% pure 
CD4+CD25+CD127lo nTreg, which were previously determined to contain an average 
Gd content of 5.08 x 107 atoms per cell, using solution-based ICP-MS.  The peak 
characteristics for the Enterprise at various DCI extensions are shown in Table  4.2 and 
Figure  4.11.  Peak widths were in the order of 3.5, 6 and 10 ms at full width 50%, 10% 
and 1% of the peak maximum respectively.  However, slight signals above background 
were noted up to 20 ms after the peak had reached 1% maximum.  These secondary 
signals were also observed by Van Malderen et al. when using a fast washout cell,193 
and thus may be a reflection of aerosol formation and transport processes previously 
masked at lower speeds. 
 
 
Figure ‎4.11 Average peak data for the ablation of 5 Gd labelled cells at each DCI 
extension.  Note, peak maximum data is shown on the second axis. 
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Table ‎4.2 Average peak data for the ablation of 5 Gd labelled cells at each DCI 
extension. 
Extension / mm FW 0.01M / ms FW 0.1M / ms FWHM / ms Ypeak max / cps 
0 10.47 6.56 3.91 1.77E+06 
1 12.48 7.72 5.03 1.55E+06 
2 6.72 4.31 2.57 3.00E+06 
3 7.34 4.79 2.80 2.02E+06 
4 10.93 6.17 3.31 1.22E+06 
6 9.46 5.79 3.14 2.71E+06 
8 10.87 7.21 4.80 1.90E+06 
10 7.01 4.18 2.22 2.66E+06 
12 11.11 7.04 4.28 1.64E+06 
 
 
 
Figure  4.12 shows the peak profiles from five individual cells analysed at the 2 mm 
extension, which provided the narrowest signals at 1% peak maximum.  These five 
individual peaks were then averaged to produce a typical peak profile, as shown in 
Figure  4.13.  Peak profiles for the other DCI extensions are presented in Appendix 2.  
All peaks included a sharp linear rise, occurring over less than 10 data points, with an 
approximately exponential decay.  However, the peak shape between these regions 
was variable, with a range of flat topped, sharp and split peaks occurring.   
 
Split peaks were previously reported for in-torch ablation,194 where the splitting was 
attributed to two overlapping Gaussian functions caused by particle separation during 
aerosol formation and expansion.  It is likely that similar processes occurred within this 
system.  For instance, the compressed nature of the plume within the Sniffer, when 
combined with the relatively small exit orifice, may have induced aggregational 
processes within the aerosol.  A periodic ‘chocking’ effect is possible, in the sense that 
there may be insufficient pressure to maintain the velocity in the tube at very high mass 
flows.  Differential transport within the plasma may also have contributed, since in 
practice it was difficult to implement a perfectly concentric dual injector.  The fused 
silica is transported on a coil; thus even with the aid of a centring piece, it had the 
tendency to bend at the end.  This may have led to some material entering the ICP off-
axis, which was recently demonstrated to produce temporal shifts in signals.195  The 
angle of the bend became more pronounced as the fused silica was extended further 
into the plasma, which may have contributed to the changing peak shape towards the 
longer extensions. 
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Figure ‎4.12 Peak profiles from of five individual Gd labelled cells when using the 
Enterprise cell, with the fused silica extended 2 mm past the tip of the injector.  Signals 
are offset by 200 ms in the x direction and 2.5 x 105 cps in the y direction to aid 
comparison. 
 
 
 
 
 
Figure ‎4.13 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 2 mm past the tip of the injector. 
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It was hypothesised that, in addition to speed, the prototype technology would provide 
an increase in absolute sensitivity (integrated counts per unit mass) compared to 
conventional instrumentation.  There are two potential factors that may contribute to 
this effect.  The compression of the plume within the Sniffer region may reduce losses 
on the walls of the ablation chamber, whilst the use of an axial inner injector ensures 
more efficient ion sampling, through reduced deposition on the cones.  To evaluate this 
hypothesis, the absolute sensitivity of the Enterprise system was compared to that of 
the tear-drop cell and standard injector used in Chapters 2 and 3.  The tear drop cell, 
which has also been described as the Zircon cell, is a low, single-volume ablation cell, 
which was developed by Horstwood et al.131 in response to aerosol transport 
experiments performed by Bleiner and Günther.196  The cell provides sub 0.5 second 
peak widths for single shot work and produces greater sampling reproducibility than 
possible with the standard UP-213 cell.   
 
The Enterprise was demonstrated to provide a significantly higher absolute sensitivity 
than the teardrop cell (one-tailed t-test, n=50, d.f. = 98, P <0.05) at all DCI extensions 
tested.  The effect was greatest at 6 mm extension, where the peak area was almost 6 
times higher than obtained using the teardrop cell.  Taking into account the average 
Gd loading of 5.08 x 108 atoms per cell, this corresponds to an increase in detection 
efficiency from 4.24 x 10-5 to 2.35 x 10-4, where detection efficiency is defined as the 
ratio of the ions reaching the detector to the number of atoms sampled by LA. 
 
Robust statistics were used to evaluate the differences between each DCI extension.  
Robust statistics, such as Huber’s H15 method, provide a more reliable estimation of 
the mean for data sets that include a small proportion of outliers.197  Their use is 
particularly appropriate for this data set, which is normally distributed, but suffers from 
occasional high intensity outliers due to the 1.5% phagocytic monocyte contamination.  
Figure  4.12 shows the average signals at each extension, represented by the H15 
mean.  Error bars representing the H15 standard deviation indicate that there is no 
statistical difference between the various extensions, and this hypothesis was 
supported analysis of variance (F8,441 = 1.43, P = 0.183).  However, it is likely that 
biological variation between samples and variability in laser fluence, along with 
concentricity problems of the inner injector, obscured any potential differences 
between these extensions. 
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Figure ‎4.14 The H15 mean 157Gd signal intensities for the ablation of 50 labelled T 
cells at various DCI extensions, compared to those obtained for the tear drop cell 
(TDC).  Error bars depict the H15 standard deviation (n=50). 
 
 
The current Enterprise cell does not include any provision for rapid sample exchange.  
Sample changeover required detaching the cell from the bracket via two screws, and 
removal of the cell lid via a further five screws.  The narrow diameter of the fused silica 
outlet tube was beneficial during this process, since the cell lid could be opened with 
minimal air entrainment by the plasma.  However, subsequent re-pressurisation of the 
cell was required before analysis.  The total sample changeover process was 
accomplished in slightly under 10 minutes.  This is considerably longer than for most 
commercial cells, but in the context of a 2 hour tissue biopsy analysis this time is not 
significant. 
 
4.3.4 Limitations with ICP-MS data acquisition 
ICP-MS was originally designed for the analysis of homogeneous solutions, where a 
continuous flow of analyte is nebulised, to produce a signal of constant average 
intensity.  This form of analysis still represents the major proportion of all ICP-MS 
applications.  However, the field has since expanded to include coupling to separation 
techniques and/or the use of alternative sample introduction strategies, which produce 
a time resolved transient signal profile.  In many cases the software developed by ICP-
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MS manufacturers has not sufficiently evolved to meet the new data acquisition 
requirements.  This is most apparent when working with high speed sample 
introduction systems, such as the one developed here, where the capture of very short 
duration, temporally resolved signals is required.  It is essential that the improved 
temporal resolution provided by high speed interfaces is not compromised by 
subsequent data grouping or averaging occurring within the software.  Thus, when 
characterising the peaks in this chapter, it was necessary to extract the raw data points 
from the ICP-MS, rather than using the conventional data files.  Significant time and 
computer processing power was required to convert the large number of raw data 
points into a 0.1 ms spaced, time resolved signal. 
 
 
 
Figure ‎4.15 Signals from five individual peaks, showing detector trips and the 
associated data losses occurring when count rates exceed 5 x 106 cps. 
 
Examination of the raw data highlighted further limitations with the data acquisition 
system on the Element XR.  Methods using short sample durations suffer from high 
data losses, due to the electrostatic analyser (ESA) operation cycle.  At the end of 
each sweep of the mass range the ion beam is deflected onto the wall of the electrical 
sector, whilst the ESA returns to the start mass to begin the next scan.  This leads to 
loss of approximately 3 ms of data per sweep, which for the method used here 
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amounted to approximately 15% of the duty cycle.  Clearly, a 10 ms peak falling across 
the 3 ms gap cannot be accurately measured; thus nearly half of the data captured in 
the experiments above was unusable.  Furthermore, working with small sample 
durations requires the detector to operate in counting mode.  This mode is typically 
used for trace analysis, and accordingly the detector trips when the count rate exceeds 
5 x 106 cps in two consecutive integrations.  With such short, compressed signals it is 
easy to exceed this threshold with relatively low concentration samples, as 
demonstrated by the single cell data shown in Figure  4.15. 
 
4.3.5 Use of a fast data acquisition board 
To achieve faster data acquisition, some users have connected external devices to 
read out signals directly from the electron multiplier of quadrupole mass spectrometers.  
Examples include a digital oscilloscope connected to a Perkin Elmer ELAN 600,194 
which provided 20 μs time resolution, and an ion pulse counting unit connected to the 
Agilent 7500a via a function generator,198 which produced 50 μs spaced data.  An 
alternative approach combined a time-of-flight (TOF) mass analyser with the ICP and 
vacuum interface of a commercially available quadrupole instrument, enabling multi-
element detection at 30 μs time resolution.199, 200   
 
In this study, a multi-channel scaler board was used to read the TTL pulse output from 
the ion detection board on the Element XR.  The board is similar to the type employed 
on TOF instrumentation and has a programmable time resolution, with a minimum bin 
width of 100 ns.  Disabling ion deflection during the ESA flyback prevented the 3 ms 
data losses described above.  In addition, disconnecting the detector trip cable enabled 
the analysis of the higher intensity signals associated with gold nanoparticle labelled 
macrophages.  The signals produced from this analysis were of wider duration than 
reported previously, typically ranging between 20 and 50 ms (to 10% peak maximum), 
which could be a feature of the much higher count rate for the gold labelled cells. 
 
Figure  4.16 shows signals from individual gold labelled macrophages, captured using 
bin widths of 10 and 100 µs, with magnified views of satellite signals occurring after the 
main peaks.  It is assumed that these satellites correspond to free nanoparticles on the 
slide, which may have been ejected by the laser induced shockwave, possibly from 
locations outside of the Sniffer region.  The 10 μs resolution appeared excessive for 
single cell analysis; however, it was shown to significantly enhance the profile of the 
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nanoparticle signals.  Indeed, the shape and duration of these signals is consistent 
with a recent paper, which reported peaks of 100-200 μs (FWHM) for Au nanoparticles 
that were introduced into an ICP-TOF-MS through a microdroplet generator.201  It is 
hoped that the enhanced time resolution demonstrated here may pave the way for 
fundamental studies into the interaction of material with the Element XR. 
 
 
 
 
  
  
  
Figure ‎4.16 Signals observed for single cell LA-ICP-MS of individual gold labelled 
macrophages using the Enterprise cell and the fast data acquisition board.  Signals 
were measured using bin widths of 100 (image A) and 10 µs (image C).  Images B and 
D are magnifications of discrete events following the main peak in images A and C 
respectively, with each horizontal line representing the signal in an individual time bin.  
All data was acquired at 0 mm extension. 
  
A B 
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4.4 Conclusion 
 
In this chapter, a prototype LA-ICP-MS interface was modified to enable the rapid 
analysis of Gd labelled cells at high sensitivity.  There are no universally applied 
criteria to define the performance of laser ablation systems.  However, the FW0.1M is 
perhaps the most significant criterion for cell tracking, since signals below 10% 
maximum are typically lower than the threshold value for identifying a labelled cell.  
Signals for this system were well below 10 ms at FW0.1M, which demonstrates that a 
sampling rate of 100 Hz is now feasible.  This is expected to transform the analysis of 
a typical 1 x 1 mm biopsy, from several hours down to several minutes.  The prototype 
system was also shown to provide a 6-fold increase in absolute sensitivity compared to 
the standard instrumentation.  Assuming minimal label leakage, this will enable the 
analysis of cells after further 1 or 2 cell divisions than previously possible, which could 
potentially extend the therapeutic monitoring period.  The prototype system therefore 
meets the demands of increased speed and sensitivity required by the ONE Study, 
which is critical if LA-ICP-MS is going to be adopted for routine analysis.  Naturally, it 
follows that this level of performance will also benefit wider LA-ICP-MS applications 
than are described in this thesis. 
 
The prototype technology reported here suffered from limitations imposed by financial, 
fabrication and assembly constraints.  It is likely that the system did not precisely meet 
the concept of a perfectly straight and continuous flow path, with an inner injector 
exactly concentric with the outer injector.  Indeed, to fully meet these criteria would 
likely require the manufacture of a combined laser ablation and ICP-MS system, sold 
as one integrated unit.  At the time of writing, such a product is not on the market.  
There is also further scope for computational modelling of the plasma conditions, which 
would allow for increased understanding and optimisation of the system.  For example, 
matching of the inner and outer injector flows could help to reduce turbulence within 
the plasma.  Given the above, the preliminary data suggests that the underlying 
concepts are robust, but the system has further scope for improvement with a fully 
engineered version.  This development task will now be undertaken by Electro 
Scientific Industries, who have filed a patent to protect the invention and intend to 
release a commercial version.202  
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5 Conclusion and Further Work 
 
 
 
This thesis represents the first applications of LA-ICP-MS for single cell tracking of 
therapeutically administered cells.  T cells, Mregs and Tol-DC were labelled with 
commercially available labelling reagents, in order to enable their discrimination from 
native cells.  Uptake rates of up to 108 atoms per cell were achieved when labelling T 
cells with the MRI contrast agent Omniscan, whilst uptakes in the order of 109 atoms of 
Au per cell were observed when labelling Mregs and Tol-DC with 50 nm gold 
nanoparticles.  Cells were examined on an individual basis, with close to 100% 
labelling and detection efficiency observed for all three cell types.  The technique was 
validated using mixed preparations of labelled: non-labelled cells, and enabled 
enumeration of the labelled cells at close to the predicted ratio.  Importantly, the cells 
retained sufficient label to remain detectable for up to 14 days following administration 
to immunodeficient mice. 
 
The combination of laser sampling and mass spectrometric detection provided several 
advantages compared to other cell tracking techniques.  Elemental detection does not 
rely on the stability of administered complexes; thus, labels could be detected at 
periods where detection by MRI or SPECT would be impossible.  Furthermore, the 
exquisite detection capability of sector field ICP-MS allowed detection at levels of 107 
atoms per cell and below, which is an order of magnitude improvement on molecular 
mass spectrometry.124  Although ICP-MS requires ex-vivo samples, the technique is 
fairly versatile in terms of their format.  A nebuliser and spray chamber interface 
enabled the analysis of digested organ samples, which provided a general overview of 
cell trafficking in vivo.  Laser ablation then permitted high resolution imaging of Mregs 
and Tol-DC within tissue sections, as well as individual targeting of T cells that were 
extracted from the peritoneum.  The laser instrumentation employed in this thesis can 
produce 2D images of 4 x 4 µm resolution, which compares favourably to MRI, which 
has a typical voxel size of 100 x 100 x 200 µm.  LA sampling can therefore differentiate 
individual cells from cell clusters, and does not suffer from interfering artifacts, such as 
air pockets, which hinder detection when using alternative techniques.  Incidentally, the 
major weakness of laser ablation, that is the lack of availability of matrix matched 
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calibration standards, does not pose a limitation for this cell tracking application, since 
the analysis is purely qualitative. 
 
The long-term goal of Work Package 2 was to develop technology and methods that 
could be applied to track cell products in the ONE Study human clinical trials.  
Consequently, only labelling agents that were both commercially available and had the 
potential to be licensed for human use were investigated.  Due to the novelty of the LA-
ICP-MS tracking approach, the labels used in this project had naturally been 
developed for other applications.  Considerations taken into account when developing 
these labels were not necessarily aligned with those required for cell tracking by LA-
ICP-MS.  In MRI imaging, stability of the Gd chelates and their cellular localisation are 
prerequisites for image quality enhancement.  Chelates located within endosomes lead 
to a reduction in MRI signal, as they are less able to interact with water molecules than 
those located in the cytoplasm.125, 203  Therefore, ligand modifications that facilitate high 
endosomal uptake, although beneficial for LA-ICP-MS, may be disregarded in the early 
stages of MRI contrast agent development.  If cell tracking by LA-ICP-MS gains 
popularity, then investment into the development of labelling complexes tailored 
exclusively to this technique is highly recommended. 
 
Determining the fate of labels after cell death is vital to achieving reliable detection, 
since free label that has leaked from cells may be taken up by other phagocytes, 
providing a false positive signal.  Co-labelling with two or more labels that are 
metabolised, degraded or excreted by different mechanisms is a suggested solution to 
this problem, since only live cells would carry both labels.  Accordingly, the two 
labelling agents evaluated in this thesis have different primary routes of clearance, with 
Gd-DTPA-BMA excreted renally by glomerular filtration,204 whilst Au nanoparticles (of 
above 8 µm diameter) are most likely removed through the hepatobilliary route.205  A 
dual-labelling approach using these two reagents may be beneficial for future studies.  
An additional validation method could involve post-labelling the samples with metal-
conjugated antibodies, to establish that cells bearing the tracer labels express the 
anticipated marker phenotype.  In Chapter 3, three metal-tagged antibodies, 154Sm-
anti-CD45, 159Tb-anti-CD11c and 174Yb-anti-HLA-DR, were successfully detected in 
individual cells that had been counter-labelled in solution.  However, non-specific 
binding of the antibody labels prevented their successful application in tissue sections.  
The development of additional metal-conjugated antibodies, as well as improved 
histological protocols to block non-specific binding, may improve this analysis. 
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LA-ICP-MS, as demonstrated in this thesis, is an exciting research tool, which has the 
potential to provide new insights into cellular therapy.  However, improvements to the 
core technology are clearly necessary before the technique can be considered for 
routine clinical analysis.  The data presented in Chapters 2 and 3 used a fairly 
standard LA-ICP-MS arrangement, which provided peak widths of around half a 
second and a detection efficiency of around 5 x10-5, during the analysis of Gd labelled 
cells.  Chapter 4 aimed to increase the throughput and absolute sensitivity of the 
analysis, through adaptation of an existing prototype interface 187 for bio-analysis.  This 
interface formed a single diameter low-volume transport conduit from the point of 
ablation to the point introduction of the sample into the plasma, which minimised 
aerosol dispersion.  Peak widths of less than 10 ms (full width at 10% peak maximum) 
were achieved for the analysis of single cells, which means that theoretically the 
analysis rate could be increased from its current rate of 2 cells per second, up to 100 
cells per second, whilst maintaining individual cell resolution.  This places the sampling 
speed of laser ablation within reach of solution based mass cytometry, which is 
reported to analyse 1000 cells per second, whilst LA retains the benefits of 
visualisation and selection of targets that the CyTOF cannot currently provide.  The 
prototype interface was shown to provide a 5-6 fold increase in detection efficiency 
over the standard technology, which may prove critical for long term tracking of cells. 
 
The intellectual property for the Loughborough technology has been purchased by 
Electro Scientific Industries, who have filed a patent to protect the invention,202 and 
intend to incorporate the concepts into a commercial product.  It is clear that this 
system will have wider applications than the studies reported in this thesis.  In fact, 
another user has since coupled the prototype system to the Thermo Neptune and the 
Nu AttoM, for the analysis of sub-micron uranium particles.206   Whilst the current “plug-
and-play” interface is clearly applicable to a wide range of instruments, optimum 
performance could be achieved through the manufacture of an integrated LA and ICP-
MS system, sold as a single instrument.  The type of mass spectrometer best suited to 
this remains unclear.  The work reported in this thesis used a sector-field ICP-MS, 
which delivered sufficient sensitivity for the applications described, but struggles to 
provide multi-parametric analysis due to the sequential mode of detection.  A multi-
collector sector-field instrument could enable simultaneous analysis of a greater 
number of closely spaced isotopes and would provide even higher detection efficiency, 
but these instruments suffer from relatively slow scan speeds, which would limit the 
benefits of the high-speed interface.  Quadrupole mass analysers are perhaps the 
most common choice in current ICP-MS instruments.  These instruments are relatively 
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low cost and, although not simultaneous, they can rapidly scan through the mass 
range.  However, they provide typically 10-fold lower sensitivity than sector-field 
instruments.  Perhaps the most exciting option, in terms of multi-parametric capability, 
are TOF mass spectrometers, which simultaneously sample ions from the plasma and 
can provide ~30,000 spectra per second.  Again, these are intrinsically less sensitive 
than sector-field instruments, with typically 10-50 fold lower sensitivity.  Therefore, at 
present there is no commercially available ICP-MS instrument that satisfies the 
requirements of simultaneous measurement, high detection efficiency, and the 
necessary time resolution to take full advantage of the prototype technology. 
 
It is acknowledged that software development may be also be required to handle the 
large and complex data sets that may be produced by a new system, particularly if the 
technology is to be used by medical technicians for clinical diagnosis.  In the current 
arrangement, a significant proportion of time is spent individually selecting targets for 
ablation, hence automated cell recognition and selection software would be beneficial 
in a commercial instrument, to complement the increased analysis speed.   
 
It can be concluded that the main requirements for cell tracking, namely high labelling 
and detection efficiency, label retention in vivo, and the absence of toxic effects, have 
been successfully demonstrated within the course of this thesis.  If regulatory approval 
can be gained for use of labelled cells in patients, and the speed and sensitivity of the 
prototype LA technology can be incorporated into a commercial instrument, then LA-
ICP-MS has great potential for the tracking of therapeutically administered cells in 
humans. 
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7 Appendix 
 
 
7.1 Appendix 1 – Supplementary FACS data for Chapter 2 
 
 
 
 
Figure ‎7.1 Example FACS plots obtained prior to labelling CD4+ T cells with 
Omniscan.  Human CD4+ cells were isolated to high purity by flow sorting and 
analysed for final CD3+CD4+ T cell purity and CD14 monocyte contamination.  
Monocytes represented approximately 0.1% of the cells subjected to gadolinium 
solution analysis.  Data shown are representative of isolations from three individual cell 
donors.  Figure courtesy of Andrew Bushell. 
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Figure ‎7.2 Example FACS plots from the in vivo mouse studies reported in Chapter 
2.  Human CD4+ T cells were labelled with Omniscan, washed extensively and 
administered intraperitonealy (2x106) to BALB/c immunodeficient mice, together with 
3x106 autologous PBMC.  Peritoneal lavage samples were collected for flow cytometry 
(see above) and LA-ICP-MS (see Chapter 2) analysis. 
Day 6 lavage data: one of three mice shown. Top left panel: leucocyte gate. Top right 
panel: readily detected human CD45+ cells (P2 gate). Bottom left panel: human 
CD3+CD4+ T cells within the gated CD45+ population confirming CD4+ T cell 
reconstitution.  For comparison, the bottom right panel shows another of the three mice 
with no evidence of human cell reconstitution.  Figure courtesy of Andrew Bushell. 
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7.2 Appendix 2 – Supplementary Figures for Chapter 4 
 
 
Figure ‎7.3 Peak profiles from of 5 individual Gd labelled cells that were ablated using 
the Enterprise cell, with the fused silica outlet level with the tip of the injector.  Signals 
are offset by 200 ms in the x direction and 2.5 x 105 cps in the y direction. 
 
 
 
Figure ‎7.4 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with the fused silica outlet level with the tip of the injector. 
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Figure ‎7.5 Peak profiles from of 5 individual Gd labelled cells that were ablated using 
the Enterprise cell, with the fused silica extended 1 mm past the tip of the injector.  
Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y direction to aid 
comparison. 
 
 
 
Figure ‎7.6 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 1 mm past the tip of the injector. 
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Figure ‎7.7 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 2 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.8 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 2 mm past the tip of the injector. 
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Figure ‎7.9 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 3 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.10 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 3 mm past the tip of the injector. 
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Figure ‎7.11 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 4 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.12 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 4 mm past the tip of the injector. 
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Figure ‎7.13 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 6 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.14 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 6 mm past the tip of the injector. 
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Figure ‎7.15 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 8 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.16 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 8 mm past the tip of the injector. 
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Figure ‎7.17 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 10 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.18 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 10 mm past the tip of the injector. 
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Figure ‎7.19 Peak profiles from of five individual Gd labelled cells that were ablated 
using the Enterprise cell, with the fused silica extended 12 mm past the tip of the 
injector.  Signals are offset by 200 ms in the x direction and 2.5 x 105 cps in the y 
direction to aid comparison. 
 
 
Figure ‎7.20 The averaged peak profile obtained for five Gd labelled cells using the 
Enterprise cell, with a fused silica extension of 12 mm past the tip of the injector.  
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7.3 Appendix 3 – Supplementary CAD drawings for Chapter 4 
 
The technical drawings for the components used to construct the Enterprise cell are 
listed below and provided in the following pages. 
 
 Technical drawing  Purpose of component Page 
B
a
s
ic
 c
e
ll 
Optical window holder To lock the optical window securely in place 151 
Top of the cell To maintain pressure inside the cell and 
exclude atmospheric gases. 
152 
Middle of the cell To maintain pressure inside the cell, 
exclude atmospheric gases and to allow 
entry of the carrier gas and exit of the 
ablated material. 
154 
Bar for Sniffer To support the Sniffer parallel to the sample 
and at a fixed distance above its surface. 
157 
Bracket To connect the cell to the UP-213 (via a 3-
axis manual movement stage). 
158 
Bracket To connect the cell to the UP-213 (via a 3-
axis manual movement stage). 
159 
M
a
g
n
e
ti
c
 c
o
u
p
lin
g
 
Sample holder To accommodate 1 mm thick slides of up to 
25 x 25 mm in size. 
161 
Cage for rotary bearing To accommodate a set of magnets (for 
movement of the sample) and to connect 
the rotary bearing to the sample holder (for 
smoothness in movement). 
162 
Base of the cell To maintain pressure inside the cell, 
exclude atmospheric gases and to provide a 
smooth running surface for the rotary 
bearing. 
164 
Lower magnet holder To accommodate a set of magnets, which 
align with those inside the cell to enable 
sample movement. 
166 
Magnet attachment plate To connect the magnet holder to the 2-axis 
movement stage on the UP-213 and hence 
enable computer controlled movement of 
the sample. 
167 
O
-r
in
g
 d
e
s
ig
n
 
Base of the cell To maintain pressure inside the cell and 
exclude atmospheric gases, whilst enabling 
physical coupling to a 2-axis movement 
stage located outside of the cell. 
168 
Sample holder To accommodate 1 mm thick slides of up to 
25 x 25 mm in size, and to provide a gas 
tight seal onto the base of the cell. 
170 
Supporting block To prevent the joining screw from flexing 
during movement. 
171 
Movement plate To connect the sample holder to the 2-axis 
movement stage on the UP-213 and to 
lubricate the o-rings, in order to enable 
computer controlled sample movement with 
low friction. 
172 
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7.4 Appendix 4 – Publications and Conference Attendance 
 
 
7.4.1 Publications 
Two journal articles were produced from the research described in this thesis.  The first 
paper describes tracking of gadolinium labelled T cells, as outlined in Chapter 2, and 
was targeted towards the Analytical Chemistry community.  The paper was classified 
as an editor’s highlight and featured on the front cover of the November 2013 issue of 
Analytical Chemistry.  The second publication was targeted towards an immunological 
audience and focussed on tracking gold nanoparticle labelled Mregs, as covered in 
Chapter 3.  A further publication covering the work on the LA-ICP-MS interface, 
presented in Chapter 4, is currently in preparation and a patent has been filed to cover 
this invention.  The citation information for the published outputs is provided below. 
 
A.J. Managh, S.L. Edwards, A. Bushell, K.J. Wood, E.K. Geissler, J.A. Hutchinson, 
R.W. Hutchinson, H.J. Reid and B.L. Sharp, “Single cell tracking of gadolinium labeled 
CD4+ T cells by laser ablation inductively coupled plasma mass spectrometry”,  
Analytical Chemistry, 2013, 85, 10627-10634. 
 
A.J. Managh, R.W. Hutchinson, P. Riquelme, C. Broichhausen, A. Wege, U. Ritter, N. 
Ahrens, G. Köhl, L. Walter, H.J. Schlitt, H.J. Reid, E.K. Geissler, B.L. Sharp and J.A. 
Hutchinson, “Laser ablation – inductively coupled plasma mass spectrometry: An 
emerging technology for detecting rare cells in tissue sections”, Journal of Immunology, 
2014, 193, 2600-2608. 
 
B.L. Sharp, D.N. Douglas, A.J. Managh, “Laser ablation cell and injector system for a 
compositional analysis system”, Electro Scientific Industries Inc., 2014, US patent, US 
2014/0224775 (A1). 
 
 
7.4.2 Presentations 
The work contained within this thesis has been presented in both oral and poster 
format to audiences from a diverse range scientific backgrounds.  This includes 
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presentations at scientific conferences, presentations at annual meetings of the ONE 
Study consortium, as well as smaller departmental talks.  The highlights are listed 
below: 
 
 
Oral: Work Package 2: Tracking administered cells, ONE Study Annual Meeting 2012, 
Regensburg, Germany, 28/11/12 – 30/11/12. 
 
Oral: Work Package 2: Tracking Administered cells, ONE Study Annual Meeting 2013, 
Regensburg, Germany, 20/11/13 - 22/11/13. 
 
Poster: Single cell tracking by laser ablation ICP-MS, Winter Conference on Plasma 
Spectrochemistry, Amelia Island, Florida, USA,  06/01/14 – 11/01/14. 
 
Oral: Single cell tracking of therapeutic cells by laser ablation ICP-MS, Loughborough 
University Research Network Meeting, Loughborough, UK, 21/05/14. 
 
Oral: Single cell analysis using a fast-washout LA-ICP-MS interface, European 
Workshop on Laser Ablation, London, UK, 08/07/14 – 11/07/14. Awarded the prize for 
the best oral presentation. 
  
 
7.4.3 Training  
A list of the Loughborough University lectures, staff development courses, workshops 
and seminars attended during the course of the PhD is provided below: 
 
Lectures: Atomic and Molecular Spectroscopy 26 & 28/10/10 
Lectures: Mass Spectrometry and Associated Techniques 16, 23 & 30/11/10 
  
Workshop: 9th East Midlands Proteomics Workshop 03/11/10 
Workshop: Health and Life Sciences Conference 14/03/11 
Workshop: 10th East Midlands Proteomics Workshop 02/11/11 
Workshop: New advances in laser ablation (BGS, Keyworth) 20/04/12 
  
Training course: Postgraduate Research Students Induction 02/11/10 
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Training course: Teaching skills: Preparing to teach 29/11/10 
Training course: Teaching skills: Promoting learning 06/12/10 
Training course: Teaching Skills: Supervising practical activities 08/02/11 
Training course: Influencing: how to get out of your own way 18/03/11 
Training course: Getting the most from the skills development 
programme 
03/03/11 
Training course: Getting the most out of supervision 28/03/11 
Training course: Introduction to University laser safety 30/03/11 
Training course: Designing and producing conference posters 07/04/11 
Training course: Excel 2007 – Tables and lookup functions 18/05/11 
Training course: Excel 2007 – Pivot tables and pivot charts 25/05/11 
Training course: Networking skills: attending conferences 02/06/11 
Training course: Speed reading for research students 07/06/11 
Training course: Blood borne viruses and other pathogens 12/01/12 
Training course: Copyright and your thesis 09/05/12 
Training course: Introduction to the design of multi-factor                 
experiments 
30/05/12 
Training course: Working effectively with outside organisations 17/10/12 
Training course: Writing up your PhD thesis 24/04/13 
Training course: VIVA – what happens? 14/05/13 
Training course: Public engagement and research 22/05/13 
Training course: Successful interviews 11/06/13 
Training course: Academic job applications 12/11/13 
Training course: Introduction to the job of lecturer for 
postgraduates and RA’s 
19/11/13 
  
Safety seminar: Good Laboratory Practice (Paul Thomas) 22/02/12 
Safety seminar: Flammable materials (Anish Patel) 14/03/12 
Safety seminar: Fire safety/extinguisher training (Rod Harrison) 16/04/12 
Safety seminar: Liquefied gases, cryogenics (Claire Camp) 18/04/12 
Safety seminar: Corrosive materials (Paul O’Hara) 23/05/12 
Safety seminar: Pressurised gases (Shuo Kang) 06/06/12 
Safety seminar: Electrical hazards (Iain Kirkpatrick) 05/07/12 
Safety seminar: Radioactive materials and ionising radiation 
(Monica Felipe-Sotelo) 
25/10/12 
Safety seminar: Waste disposal (Nolwenn Derrien) 16/01/13 
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Research seminar: From Laboratory to Clinic - Analytical 
Chemistry in Action (Barry Sharp) 
08/02/12 
Research seminar:  Mass spectrometry simplified: ambient 
ionization and miniature mass spectrometers (R. Graham Cooks) 
23/02/12 
Research seminar:  Molecular recognition using functionalised 
nanoparticles (David Russell) 
07/03/12 
Research seminar:  Semi-integration and electrochemistry 
(Keith Oldham) 
27/03/12 
Research seminar:  From the electronics of molecules to 
molecular electronics (Paul Low) 
30/05/12 
Research seminar:  Surface Mobility, Structure Modulation and 
Host-Guest Effects in Supramolecules (Jon Hill) 
07/06/12 
Research seminar:   Dye-sensitised solar cells and 
thermoelectrics (Jorge Garcia-Cañadas) 
21/09/12 
Research seminar:   Recent Advances in Total Synthesis and 
Asymmetric Catalysis (Patrick Guiry) 
24/10/12 
Research seminar:   Novel Diagnostics and Sensors for Fuel 
Cells (Dan Brett) 
23/01/13 
Research seminar:  Solid oxide fuel cells (John Irvine) 06/03/13 
Research seminar:  Managing the UK's Radioactive Waste 
Legacy (Francis Livens) 
13/03/13 
 
 
 
 
 
 
 
Single Cell Tracking of Gadolinium Labeled CD4+ T Cells by Laser
Ablation Inductively Coupled Plasma Mass Spectrometry
Amy J. Managh,† Sheldon L. Edwards,‡ Andrew Bushell,‡ Kathryn J. Wood,‡ Edward K. Geissler,§
James A. Hutchinson,§ Robert W. Hutchinson,⊥ Helen J. Reid,† and Barry L. Sharp*,†
†Centre for Analytical Science, Department of Chemistry, Loughborough University, Loughborough, Leicestershire, LE11 3TU,
United Kingdom
‡Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United
Kingdom
§Division of Experimental Surgery, Department of Surgery, University Hospital Regensburg, Regensburg, Bavaria, 93053, Germany
⊥Electro Scientific Industries, 8 Avro Court, Ermine Business Park, Huntingdon, Cambridgeshire, PE29 6XS, United Kingdom
ABSTRACT: Cellular therapy is emerging as a promising
alternative to conventional immunosuppression in the fields of
hematopoietic stem cell (HSC) transplantation, autoimmune
disease, and solid organ transplantation. Determining the
persistence of cell-based therapies in vivo is crucial to understanding
their regulatory function and requires the combination of an
extremely sensitive detection technique and a stable, long-lifetime
cell labeling agent. This paper reports the first application of laser
ablation inductively coupled plasma mass spectrometry (LA-ICP-
MS) to perform single cell detection of T cell populations relevant
to cellular immunotherapy. Purified human CD4+ T cells were
labeled with commercially available Gd-based magnetic resonance
imaging (MRI) contrast agents, Omniscan and Dotarem, which
enabled passive loading of up to 108 Gd atoms per cell. In mixed preparations of labeled and unlabeled cells, LA-ICP-MS was
capable of enumerating labeled cells at close to the predicted ratio. More importantly, LA-ICP-MS single cell analysis
demonstrated that the cells retained a sufficient label to remain detectable for up to 10 days post-labeling both in vitro and in vivo
in an immunodeficient mouse model.
Cellular therapy with defined populations of regulatoryimmune cells is emerging as a clinically viable strategy to
augment or replace conventional immunosuppression in the
fields of hematopoietic stem cell (HSC) transplantation,
autoimmune disease, and solid organ transplantation where
the major driver is improved therapy and a reduction in drug
toxicities. Much of the optimism surrounding these approaches
is based on data from a large number of diverse animal models
which show unequivocally that cellular therapy can take
advantage of endogenous regulatory mechanisms in the
mammalian immune system.
Phase I/II clinical trials have evaluated naturally occurring
regulatory T cells (nTreg), in the context of graft-versus-host-
disease (GVHD), a life-threatening complication of HSC
transplantation1−3 and in pediatric patients with new-onset
Type 1 diabetes.4 In solid-organ transplantation, an interna-
tional consortium is currently seeking regulatory approval for
the evaluation of several types of regulatory immune cells in
living-donor kidney transplantation. Cell types under inves-
tigation in this study will include nTreg,5−7 Tr1 cells,8,9
dendritic cells,10 and macrophages.11,12
Determining the persistence and tissue distribution of the
administered cells is essential for assessing their immunor-
egulatory effects in vivo, but tracking therapeutic cells presents
two significant challenges. First, in the majority of cases, the
cellular therapy will be derived from the transplant donor in
HSC transplantation or from the recipient in the case of kidney
transplantation. Thus, in most cases, the cells will be autologous
with the immune system of the transplant recipient and
therefore invisible to normal phenotypic methods of detection
such as flow cytometry. Second, at current planned doses, the
administered cells will represent a small fraction of the
recipient’s endogenous regulatory immune cells adding further
to the problem of detection. A solution to these two related
problems would be the development of clinically acceptable
(GMP) cell labeling techniques combined with a sensitive
detection method, capable of detection of single cells and at
very high cell detection efficiency.
Contrast agents (CA) are frequently used in conjunction
with clinical magnetic resonance imaging (MRI) to enhance the
quality of images. These agents typically consist of a
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paramagnetic metal ion, such as Gd3+ or Fe2+/Fe3+, associated
with a strong chelating ligand.13 Gadolinium-based contrast
agents are a particularly attractive option for cell labeling, due
to their low background levels in the human body, and indeed
several studies have reported their use as cellular labels for MRI
tracking studies.14−16 However, while MRI is undoubtedly
valuable for bulk imaging, the technique is currently incapable
of providing the necessary sensitivity and spatial resolution for
single cell monitoring.
Laser ablation inductively coupled plasma mass spectrometry
(LA-ICP-MS) is a sensitive analytical technique, widely used for
mapping the distribution of elements in complex biological
samples.17 Examples include the analysis of copper and zinc in
liver and kidney sections,18,19 the mapping of copper, zinc, iron,
and manganese in sections of brain tissue,20−24 and the
quantification of metal binding proteins in gels following
electrophoretic separation of blood serum.25 Recently, the
technique has been applied to image the distribution of iodine,
silver, and gold in single fibroblast cells, following labeling in
vitro with KI3 and gold and silver nanoparticles, respec-
tively.26,27 Studies have also reported the detection of
gadolinium-based contrast agents in tumor and tissue
samples.28−30 Two of these investigations involved a direct
comparison between LA-ICP-MS and MRI and demonstrated
the enhanced sensitivity and spatial resolution achievable when
using LA-ICP-MS.29,30
Although LA-ICP-MS clearly has remarkable sensitivity,
application of this technique to cellular therapy depends upon
cell labeling techniques that are likely to be approved for
clinical use. In the current study, purified human CD4+ T cells
were labeled with the contrast agents, Omniscan (gadolinium
diethylenetriaminepentaacetic acid bismethylamide, Gd-DTPA-
BMA) or Dotarem (gadolinium 1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetracarboxylic acid, Gd-DOTA), that are both in
routine clinical use in magnetic resonance imaging. We
demonstrate that human CD4+ T cells and highly purified
naturally occurring regulatory T cells can be labeled efficiently
with Gd-chelates and that the cells can then be readily detected
in mixed populations using LA-ICP-MS. Importantly, both in
vitro and in vivo, the cells retain a detectable label for at least 10
days. To the authors’ knowledge, this is the first application of
LA-ICP-MS to track single gadolinium labeled human T cells.
■ EXPERIMENTAL SECTION
Instrumentation and Operating Parameters. Analyses
were performed on a sector-field ICP-MS instrument (Element
2XR, Thermo Scientific, Bremen, Germany). For solution
analyses, the instrument was fitted with a cyclonic spray
chamber (Glass Expansion, Victoria, Australia), a conical glass
concentric nebulizer (Glass Expansion, Victoria, Australia), and
a 0.25 mm I.D. probe (Elemental Scientific, Omaha, USA). For
laser ablation, a UP-213 laser ablation system (Electro Scientific
Industries, Cambridgeshire, UK) was coupled to the sector-field
ICP-MS instrument. The laser system was fitted with a low-
volume, tear-drop shaped cell, which has been described
elsewhere.31 Helium was used as an ablation gas, at a typical
flow rate of 0.6 L/min, with argon introduced through a Y-
piece, at a flow rate of 0.8 L/min, after the ablation cell. The
system was tuned for maximum 238U signal intensity, while
keeping the Th/U ratio to approximately 1, during the ablation
of NIST 611 glass. Typical operating conditions are given in
Table 1.
Cell Culture and Labeling. Human peripheral blood
mononuclear cells (PBMC) were isolated from a leukocyte
cone obtained from a local blood bank. Leukocytes were
enriched by Ficoll density gradient centrifugation, and CD4+
cells were isolated (∼95−98% purity) by MACS positive
selection (Miltenyi Biotec). To isolate defined populations to
>98% purity, cells were labeled with anti-CD4 (Beckman-
Coulter clone SFCI2T4D11), anti-CD25 (BD Biosciences
clone M-A251), and anti-CD127 (BD Biosciences clone hIL-
7R-M21) antibodies and flow-sorted on a BD FACSAria (BD
Biosciences). After isolation, cells were plated at a density of 1
× 106 cells per well in 2 mL of RPMI 1640 medium,
supplemented with 10% human albumin, penicillin, streptomy-
cin, and glutamine, plus 1 × 105 U/mL human recombinant IL-
2 (Proleukin, Novartis). Each well also received a volume of
either Gd-DTPA-BMA (Omniscan, GE Healthcare, UK) or
Gd-DOTA (Dotarem, Guerbet Laboratories, France). The cells
were incubated overnight (∼16 h) at 37 °C in 95% air/5%
CO2. Following the incubation period, the cells were washed
extensively in PBS/2% FCS to remove any unbound label. Cell
viability was determined using a trypan blue assay.
Optimization of the Labeling Dose and Incubation
Time. Labeling optimization experiments for Gd-DOTA and
Gd-DTPA were carried out in parallel using cells from the same
donor. Cell culture and sample preparation were performed in
accordance with the procedure detailed above. Quantification
of label uptake by the cell population was determined using
solution-based ICP-MS. For this, cells were spun down into
pellets and then digested according to the method proposed by
Yamada et al.32 and modified by Kerr.33 Briefly, this involved
addition of 67% HNO3 (100 μL per 1 × 10
6 cells) and heating
at 70 °C for 1 h, followed by addition of 30% H2O2 (100 μL
per 1 × 106 cells) and heating at 70 °C for a further 4 h. The
samples were then evaporated to dryness under a stream of
nitrogen and reconstituted in 2% HNO3. A range of calibration
standards were prepared by dilution of a 10 ppm elemental
standard solution (SPEX Certiprep Ltd., Middlesex, UK).
For the dose optimization study, doses of 5, 10, 20, 50, 100,
and 200 μL of either Omniscan or Dotarem were added to each
well, prior to incubation overnight. This corresponds to 0.19,
0.38, 0.75, 1.86, 3.63, and 6.72 mg Gd/mL and 0.20, 0.39, 0.78,
1.92, 3.74, and 7.15 mg of Gd/mL, for the Omniscan and
Dotarem wells, respectively. A total of three replicates were
performed for each dose. In addition, three control wells
containing cells without contrast agent were prepared.
Table 1. Typical Operating Conditions for ICP-MS and LA-
ICP-MS Analyses
parameters ICP-MS LA-ICP-MS
ICP radio frequency (RF) power, W 1215 1260
cool gas flow rate, L min−1 15.50 15.50
auxiliary gas flow rate, L min−1 0.95 0.95
sample gas flow rate, L min−1 0.90 0.80
sample uptake rate, μL min−1 ∼70
torch x position, mm 3.9 5.2
torch y position, mm 3.0 2.9
torch z position, mm −2.5 −1.9
ablation gas flow, L min−1 He, 0.60
laser spot size, μm 25−30
repetition frequency, Hz 1 (single shot)
laser power setting, % 50
laser fluence, J cm−2 8.97
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Following dose optimization, the incubation time was varied
using the optimum dose. Incubation times of 0, 1, 2, 4, 8, and
16 h were assessed in triplicate. The optimum dose and
incubation time were then carried forward to subsequent
experiments.
Laser Ablation of Single Cells. For laser ablation-ICP-
MS, labeled cells were plated onto slides (Thermo Superfrost,
Thermo Scientific, UK) using a CytoSpin (Shandon Cytospin,
Thermo Scientific, UK). This was to ensure removal of the cell
culture media and provide an even distribution of the cells
across the slide, enabling single cell targeting. In addition to the
slides containing labeled cells, control slides containing non-
labeled CD4+ cells were also prepared. Each slide held
approximately 50 000 cells. Single cell identification was
demonstrated by ablating 25 μm diameter areas at locations
corresponding to cells. This size was chosen to ensure sampling
of the complete cell, while minimizing the chance of overlap
onto neighboring cells. Only single cells were targeted; cells
present in clusters or closer than 25 μm apart were disregarded.
The presence or absence of label was determined from the
157Gd signal.
To simulate biological samples, where labeled cells are
present among a background of non-labeled cells, slides
containing mixed labeled and non-labeled cells were prepared.
For these, the relevant dilutions were made in solution before
fixing the cells onto slides. Ratios of 1:1, 1:10, and 1:100 were
prepared as known samples, and a replicate of each was
provided as a blind sample. Blind samples were randomized and
identified with a nondescriptive character. The expected ratios
of these were not disclosed to the analyst until after the analysis
was completed.
In Vivo and in Vitro Label Retention. In order to
demonstrate cellular retention of the label and assess its
potential for cell tracking studies, a 10 day in vivo mouse study
was conducted. All mouse experiments were conducted in
accordance with the Animals (Scientific Procedures) Act 1986.
Human peripheral blood mononuclear cells (PBMC) were
isolated from leukocyte cones. The CD4+ component was
isolated using the procedure described above, and these cells
were labeled using the optimized labeling procedure. Following
labeling, the Gd-CD4+ cells were washed extensively and
recombined with the non-CD4+ PBMC component. Remixing
with the unlabeled PMBC component was found to be
necessary to ensure viability of the cells in the host. The
recombined cells were then injected intraperitoneally into
BALB/C Rag-/-common-γ chain mice, at a level of 5 million
cells per mouse. At 3, 6, and 10 days post infusion, the spleen
and blood were harvested and a peritoneal lavage was
performed. The extracted cells were plated onto slides for
LA-ICP-MS analysis, using the CytoSpin method described
above. Flow cytometry (BD FACSCanto, BD Biosciences) was
used to determine the extent of human cell reconstitution.
To estimate the degree of signal loss caused by label leakage,
an in vitro label retention study was performed in parallel to the
in vivo mouse experiments, using cells from the same donor.
For this, the cells were washed extensively after labeling and
cultured for a further period in vitro before rewashing and
plating onto slides.
■ RESULTS AND DISCUSSION
Label Uptake and Optimization. Figure 1 shows the
impact of increasing the dose of gadolinium chelate on the
uptake of Gd by human CD4+ cells. Uptake of Gd increased in
a dose-dependent manner. A quadratic fit with a low second
order term fitted the data; however, no plateau was reached in
the dose range examined. Despite the higher uptake at 100 and
200 μL, a dose of 50 μL was chosen as the optimum (this
corresponds to 1.86 and 1.96 mg Gd/mL for Omniscan and
Dotarem, respectively). Volumes higher than 50 μL occupied a
significant portion of the 2 mL culture medium, which could
potentially cause osmotic effects. However, it should be pointed
out that the cell viability was 96% or above for all doses tested.
Gadolinium uptake also increased as a function of incubation
time for both complexes, as shown in Figure 1. The highest
uptake was observed after 16 h, which was used as the standard
incubation time in all subsequent experiments. Longer
incubation times were not tested on the grounds that they
might have a detrimental effect on cell viability. As shown later,
the labeling levels achieved were more than adequate for
achieving ∼100% detection efficiency. A 0 h time point was
included in the study as a measure of the efficiency of the cell
washing process. For this, the Gd complex was added to the
well and the cells were washed immediately, thereby allowing
insufficient time for label internalization. Consequently, any Gd
found in these samples was taken to be from incomplete
removal of the non-internalized complex and thus represents
the background in the assay. The Gd content of the 0 h samples
ranged between 5 and 20 times larger than that in the non-
labeled controls. However, this figure represents only 0.7% and
3% of the final uptake achieved using the optimized labeling
conditions for Gd-DTPA-BMA and Gd-DOTA, respectively.
The cell washing procedure was therefore considered sufficient
to enable quantification of label uptake. The optimization
Figure 1. Relationship between the dose of Gd-DOTA and Gd-
DTPA-BMA (top) and the incubation time (bottom) on the uptake of
Gd atoms by human CD4+ T cells. Uptake was determined using
solution-based ICP-MS. Error bars show the standard error of the
mean (n = 3).
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experiments, shown in Figure 1, indicated that Gd-DTPA-BMA
provides higher net Gd loading than Gd-DOTA, with an
average loading of 1.43 × 108 atoms per cell observed for Gd-
DTPA-BMA compared to only 9.36 × 107 atoms per cell for
Gd-DOTA at the optimized conditions. Therefore, Gd-DTPA-
BMA was used in all subsequent experiments.
It is likely that uptake of the Gd complexes occurred
predominately by pinocytosis, as has been reported for other
cell lines.34,35 Gadolinium internalized via this route is known
to localize to endosomes within the perinuclear region of the
cell,34 where subsequent detachment of Gd3+ from its chelate
may occur.35 Dechelation is expected to be more prevalent for
Omniscan than Dotarem. As shown in Figure 2, the DTPA-
BMA chelate is non-ionic and has an open chain structure,
hence providing less stable binding to Gd3+ than the
macrocylic, ionic DOTA chelate.36 Dechelation is accelerated
in the presence of phosphate or competing cations,37 both of
which are constituents of the cell culture media. Thus, it is
likely that, by the 16 h time point, a portion of the Gd in the
culture media was also present as free rather than complexed
Gd. Free Gd3+ ions may be subject to a different route of
uptake than the complexed form. In 1999, Cheng et al.
conducted a comprehensive study into the uptake of lanthanide
3+ ions by erythrocytes.38 Gd3+ was found to bind initially to
membrane phospholipids, followed by a transfer to membrane
proteins. This process induced conformational changes in the
membrane, which resulted in the formation of pores, facilitating
the entry of Gd3+. It is possible that this mechanism may have
provided an additional route for Gd uptake. Since Gd-DTPA-
BMA is known to be more unstable than Gd-DOTA, this
additional route may account for the differences between Gd
uptake for the two chelates, particularly at the 16 h time point.
The data shown in Figure 1 was obtained using cells isolated
from human PBMC by magnetic negative selection of CD19+ B
cells and CD14+ monocytes followed by CD4 positive
selection. Phenotypic analysis showed that the resultant
populations were between 95% and 98% CD4+ T cells, but
they also contained ∼2−5% monocytes due to low level
monocyte expression of CD4. In view of the fact that these cells
are known to have very active phagocytic and pinocytic
pathways, the possibility that the Gd labeling seen was due to
preferential monocyte uptake could not be ruled out. To
address this question, human CD4+ T cells were purified by
flow sorting to purities exceeding 99%, containing <0.2%
CD14+ monocytes (data not shown). The resultant populations
were then labeled using the optimized Gd-DTPA-BMA
protocol described above. Subsequent analysis showed a
gadolinium uptake of 4.53 × 107 atoms per cell for 99.6%
pure CD4+ T cells, compared with the 1.43 × 108 atoms per
cell seen for the lower purity (∼95−98%) CD4+ T cells.
Most of the initial focus on regulatory immune cellular
therapy has been and will continue to be on naturally occurring
Treg (nTreg).5−7 Although these cells represent only ∼5−10%
of CD4+ T cells in human peripheral blood, the actual
proportion and function varies considerably between individ-
uals. To determine the likely variability in Gd labeling of
functional nTreg, human CD4+CD25+CD127lo T cells were
flow sorted from three different individuals using a sort strategy
known to isolate nTreg with high functional activity both in
vitro and in humanized mouse models.39,40 The resultant
populations (purity 97.9%, 98.5%, and 98.1%, donors 1−3,
respectively) were then labeled with the optimized Gd-DTPA-
BMA protocol and analyzed as described. The labeling of these
nTreg showed remarkable consistency with 5.06 × 107, 5.08 ×
107, and 5.88 × 107 Gd atoms per cell detected from donors 1−
3, respectively.
The above data show unequivocally that populations of non-
phagocytic human T cells being considered for cellular therapy
can be labeled with gadolinium chelates, thus offering a
potential approach for therapeutic T cell tracking. However,
determining the persistence of gadolinium-labeled T cells in
accessible tissues such as the peripheral blood is potentially
compromised by the presence of highly phagocytic cells such as
granulocytes, neutrophils, and monocytes. Positive selection on
the basis of CD4 would allow enrichment of populations likely
to contain administered nTreg but, as described above,
monocytes would present a problem since they might
phagocytose gadolinium from dying circulating T cells, thereby
giving false positives. Although flow sorting to >99% T cell
homogeneity is a valuable research approach, cell losses would
preclude this as a diagnostic strategy. Therefore, laser ablation-
ICP-MS was evaluated for the ability to identify labeled targets
at a single cell level where the ablation of specific, individual
cells could provide a key advantage not available from solution
analysis.
Laser Ablation of Single Cells. Human CD4+ T cells were
purified by positive selection (final purity, 97.2%) and labeled
with Gd-DTPA-BMA as described. Unlabeled cells cultured for
16 h in the presence of IL-2 served as a negative control. Figure
3 shows the 157Gd signal intensities for the ablation of 25
individual labeled cells (A) and 25 individual unlabeled cells
(B) after deposition onto slides by centrifugation. Distinct
signals were observed for the ablation of the labeled cells,
compared to only background noise for their non-labeled
counterparts. The 25 μm spot size and ∼9 J cm−2 fluence used
in these experiments ensured complete ablation of each ∼10
μm cell in less than a second; see Figure 4. Therefore, each
signal observed can be regarded as representative of the total
amount of Gd per individual cell. Figure 5 is a histogram
showing the variation in label uptake observed when ablating
1000 individual labeled cells taken from the same labeled
population as used in Figure 3. For this, the 157Gd signal
intensities were grouped into classes, with the number of
occurrences for each class plotted on the y-axis. Of the 1000
cells ablated, 998 gave clear signals, confirming uptake of Gd by
human CD4+ T cells. In the range of 0−1.5 × 104 counts, the
distribution of signals was approximately Gaussian, with a RSD
of 39%. A small percentage (1.6%) of signals occurred outside
this region. These higher signals are likely to correspond to the
ablation of monocytes. Accordingly, the number of high signals
Figure 2. Structures of the commercially available contrast agents used
for cell labeling.
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observed matches closely with the proportion of contaminating
CD14+ monocytes (2.8%) in the input cell population.
Application of the technique to cell tracking requires
discrimination of labeled cells from a background of non-
labeled cells. In a demonstration experiment, labeled CD4+ T
cells were mixed with non-labeled CD4+ T cells in various
ratios, prior to analysis by LA-ICP-MS. As shown in Table 2,
the percentage labeled as determined by LA-ICP-MS matched
approximately with the prepared ratios, with differences
accounted for by a combination of incomplete mixing and
pipetting errors. As a further test of the technique, blind ratios
of labeled and unlabeled CD4+ T cells were prepared and the
blinding was only revealed after LA-ICP-MS analysis. As shown
in Table 2, ratios observed from the blind experiments
corresponded with the expected ratios, adding further
confirmation to the reliability of the technique.
In Vivo and in Vitro Label Retention. In addition to
detection, a second key characteristic for any label considered
for in vivo cell tracking is label retention. Therefore, Gd-DTPA-
BMA labeled CD4+ T cells were cultured in vitro in
gadolinium-free T cell growth medium containing IL-2 and
samples taken daily for LA-ICP-MS analysis. As shown in Table
3, although the average signal intensities fell with time, reaching
roughly 50% of the day 1 value after 10 days, the label remained
detectable at all time points examined, with 98.8% of cells
retaining sufficient Gd for detection up to 10 days in culture. In
view of the low background signals observed for non-labeled
cells, it seems likely that Gd labeled cells should be detectable
for periods well beyond 10 days.
Although in vitro label retention is encouraging, a more
important question with respect to cellular therapy is whether
cells retain a gadolinium signal in vivo. To address this
question, we took advantage of a well characterized humanized
mouse model in which immunodeficient BALB/c mice lacking
T cells, B cells, and functional NK cells are reconstituted with
defined populations of human immune cells.39 These double
knockout (DKO) mice were reconstituted intraperitoneally
with 2 × 106 Gd-DTPA-BMA labeled CD4+ T cells together
with 3 × 106 autologous PBMC which aid T cell reconstitution
by providing essential T cell growth and survival factors. At 3, 6,
Figure 3. Signal intensities obtained when performing LA-ICP-MS on
(A) 25 single Gd-DTPA-BMA labeled human CD4+ T cells and (B)
25 single non-labeled human CD4+ T cells.
Figure 4. Images showing slide mounted cells before (top) and after
(bottom) the ablation of five single cells. The scale bar is 10 μm.
Figure 5. Histogram showing the distribution of 157Gd signal
intensities for the ablation of 1000 Gd labeled cells. It is speculated
that the human CD4+ cells (97.2% pure in the total cell population)
are present within the first peak, with signals outside this range (1.6%
of the signals observed) corresponding to the ablation of phagocytic
monocytes. The inset shows the expanded view of the distribution
within the first peak.
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and 10 days after reconstitution, the mice were killed for
recovery of the peritoneal lavage, spleen, and blood.
Reconstitution in this model is defined as >1% human
CD45+ cells in the leucocyte gate as determined by flow
cytometry.39 In agreement with previous experience of this
model which showed that reconstitution of spleen and blood
lags behind that of the peritoneal lavage, human cells were not
found in the spleen or blood up to day 10 (not shown).
However, human CD45+ cells were readily detected in the
peritoneal lavage. Example data for one of three mice harvested
6 days after cell administration is shown in Figure 6A. For
comparison, the lower histogram shows an example of non-
reconstitution. As shown in the lower dot plot, region P3
confirms the presence of human CD4+ T cells within the
human CD45+ gate.
Aliquots of each lavage sample were plated without cell
purification onto slides for LA-ICP-MS analysis. Figure 6B
shows an LA-ICP-MS plot from the lavage sample in Figure 6A
showing identification of 5 gadolinium labeled cells. It is
notable that, while cells analyzed after in vitro culture were
relatively uniform in size, those examined from the lavage
samples contained significant numbers of blasting cells possibly
representing T cells mounting a xenogeneic graft-versus-host
response. To accommodate the larger cell diameters, the
ablation spot size was increased from 25 to 30 μm. However,
increasing the spot size made the selection of single cells more
challenging and it is possible that some of the low signals in
Figure 6B were caused by slight overlap of the ablated region
with the edges of neighboring labeled cells. To account for the
low signals, a threshold value was set at 5% of the average signal
intensity of the corresponding in vitro sample. Signals below
this threshold were not included in the % labeled count.
Table 4 summarizes the in vivo Gd retention data for day 3,
day 6, and day 10 following the administration of labeled CD4+
T cells and shows the percentage of labeled cells found in the
mouse lavage samples. In each case, the detection of Gd labeled
cells by LA-ICP-MS correlated with the presence of human
CD4+ T cells in the lavage. Furthermore, at the last time point
examined when only two mice were available (day 10), both
showed clear reconstitution and gadolinium positive cells were
unambiguously detected (Table 4). Thus, both the in vitro and
the in vivo data indicate that, when labeled with Gd-DTPA-
BMA, human CD4+ T cells retain a detectable gadolinium level
for at least 10 days.
Nephrogenic Systemic Fibrosis. The potential use of
gadolinium labeling for tracking immune cellular therapies
would depend on a favorable toxicity profile for the label itself
and while Gd-chelates are widely used in clinical MRI, one
significant complication of in vivo gadolinium administration is
Table 2. Percentage of Gd Labeled Cells Observed When
Performing Single Cell LA-ICP-MS on Slides Containing
Various Ratios of Gd Labeled to Non-labeled Human CD4+
T Cellsa
labeled/non-labeled
ratio
% labeled cells
identified
% labeled cells
expected
known 1:0 99.8 100
1:1 39.6 50
1:10 5.5 9.1
1:100 0.6 1
0:1 0.1 0
blind 1:1 39.1 50
1:10 5.2 9.1
1:100 0.7 1
aLabeled cells were identified on the basis of their 157Gd signal. 1000
cells were ablated per sample.
Table 3. Number of Gd Labeled Human CD4+ Cells
Observed after Various Periods of in Vitro Culture,
Following Labeling with the Gd Chelate Omniscana
day % Gd labeled cells observed average signal/counts
1 100 4118
2 100 3296
3 100 2901
4 99.6 2959
5 100 2744
6 100 2473
7 99.6 2220
10 98.8 2014
aIndividual cells (250 per sample) were analysed by LA-ICP-MS.
Labeled cells were identified on the basis of their 157Gd signal.
Figure 6. Human CD4+ T cells (purity 97.2%) were labeled with Gd-
DTPA-BMA, washed extensively, and administered intraperitoneally
(2 × 106) to BALB/c immunodeficient mice together with 3 × 106
autologous PBMC. Peritoneal lavage samples were collected for flow
cytometry (A) and LA-ICP-MS analysis (B). (A) Day 6 lavage data:
one of three mice shown; upper left panel: leucocyte gate; upper right
panel: readily detected human CD45+ cells (P2 gate); lower left panel:
human CD3+CD4+ T cells within the gated CD45+ population
confirming CD4+ T cell reconstitution. For comparison, lower right
panel shows another of the three mice with no evidence of human cell
reconstitution. (B) Example data from the reconstituted lavage shown
in (A) (day 6, mouse 5 lavage), showing the presence of 6 Gd labeled
cells. Small peaks below the threshold value (red line) were not
included in the % labeled count.
Analytical Chemistry Editors' Highlight
dx.doi.org/10.1021/ac4022715 | Anal. Chem. 2013, 85, 10627−1063410632
nephrogenic systemic fibrosis (NSF). Although rare, this
condition is potentially fatal and is characterized by “extensive
thickening and hardening of the skin”.41 Studies on patients
with impaired renal function have found a link between the
intravenous administration of gadolinium chelates and the
onset of NSF.42,43 Consequently, the administration of
gadolinium contrast agents for MRI imaging is contra-indicated
in patients with renal impairment. Thus, any proposed use of
gadolinium labeling should be treated with caution, particularly
since regulatory approval is currently being sought for cellular
therapy in renal transplant patients.44 However, it is important
to note that, at the anticipated cell doses used in this study (3 ×
106/kg patient body weight), the Gd exposure from the
proposed labeling method is dramatically lower than that
received during a typical MRI scan. When taking into account
the average cell uptake shown in the current study of ∼27 fg
and the anticipated cell dose, the likely Gd exposure from cell
labeling is ∼81 ng/kg. This is over 100,000 times lower than
the 15.2 mg/kg dose employed for MRI imaging. (Omniscan is
typically administered at a level of 0.2 mL per kg patient
weight; the formulation contains 287 mg/mL Gd-DTPA-BMA,
which equates to 76.1 mg/mL Gd.) The risk is further
minimized due to the route of administration, since for cell
labeling, the gadolinium chelates are essentially compartmen-
talized inside the cells rather than being introduced into the
systemic circulation.
■ CONCLUSION
This paper represents the first application of LA-ICP-MS to
perform single cell tracking of therapeutically administered
cells. The technique was demonstrated on an immunodeficient
mouse model, where the Gd-DTPA-BMA label allowed
discrimination of human CD4+ cells for up to 10 days post-
administration. A working dose of 50 μL of Omniscan/2 mL
well (1.86 mg Gd/ml) was used for cell labeling, which was
based on sufficiency for cell tracking. However, since Gd cell
content decreases with each cell division, it may be beneficial to
increase this dose when performing longer term tracking
experiments. Doses of up to 200 μL of Omniscan (6.72 mg
Gd/ml) were utilized during the solution study without
noticeable impact on cell viability. Assessment of the effect of
Gd-DTPA-BMA on the regulatory function of T cells will be
the subject of a future study.
The LA-ICP-MS detection method has several advantages
over other cell tracking techniques. First, elemental detection
does not rely on stable binding of Gd3+ to the chelate; thus, the
label can be detected at periods where its enhancement on MRI
relaxation would be lost. Second, the use of laser ablation allows
single cell targeting, removing interferences from other artifacts,
and also has the potential to track cells in tissue biopsies. Third,
the superior detection capability of sector field ICP-MS allows
detection at levels of 107 atoms per cell and below, compared to
the value of 108 atoms per cell recently reported for molecular
mass spectrometry.35 With improved instrumentation, which
will be described in another paper, and the use of higher
efficiency mass spectrometers, it should be possible to improve
this detection limit by 2−3 orders of magnitude. A further
advantage of the technique is that, if combined with
fluorescently labeled antibody staining, it would be possible
to target ablation to specific and defined cell subsets in a sample
of peripheral blood or tissue biopsy and provide semi-
quantitative data. If applied to the tracking of Gd-labeled
CD4+CD25+ nTreg in vivo, it would thus be possible to define
the proportion of cell therapy nTreg within the total CD4+ T
cell compartment. If immune cellular therapy is to progress
beyond the current phase I/II trials, such quantification will
probably prove to be essential.
LA-ICP-MS, as demonstrated here, is an exciting research
tool, which has the potential to provide new insights into
cellular therapy, and will be a key enabling technique for the
development of the field of single cell metallomics. However,
improvements to increase throughput are necessary before the
technique can be considered for routine analysis in the clinical
setting. Current LA-ICP-MS instrumentation has a data rate of
approximately 1−5 pixels per second, limited by the LA cell−
mass spectrometer interface. Developments to improve the
efficiency of this region, and hence increase the speed of data
acquisition, will be reported in a subsequent paper.
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Laser Ablation–Inductively Coupled Plasma Mass
Spectrometry: An Emerging Technology for Detecting
Rare Cells in Tissue Sections
Amy J. Managh,* Robert W. Hutchinson,† Paloma Riquelme,‡ Christiane Broichhausen,‡
Anja K. Wege,x Uwe Ritter,{ Norbert Ahrens,‖ Gudrun E. Koehl,‡ Lisa Walter,‡
Christian Florian,‡ Hans J. Schlitt,‡ Helen J. Reid,* Edward K. Geissler,‡
Barry L. Sharp,* and James A. Hutchinson‡
Administering immunoregulatory cells to patients as medicinal agents is a potentially revolutionary approach to the treatment of
immunologically mediated diseases. Presently, there are no satisfactory, clinically applicable methods of tracking human cells in
patients with adequate spatial resolution and target cell specificity over a sufficient period of time. Laser ablation–inductively
coupled plasma mass spectrometry (LA-ICP-MS) represents a potential solution to the problem of detecting very rare cells in
tissues. In this article, this exquisitely sensitive technique is applied to the tracking of gold-labeled human regulatory macrophages
(Mregs) in immunodeficient mice. Optimal conditions for labeling Mregs with 50-nm gold particles were investigated by exposing
Mregs in culture to variable concentrations of label: Mregs incubated with 3.5 3 109 particles/ml for 1 h incorporated an average
of 3.39 3 108 Au atoms/cell without loss of cell viability. Analysis of single, gold-labeled Mregs by LA-ICP-MS registered an
average of 1.9 3 105 counts/cell. Under these conditions, 100% labeling efficiency was achieved, and label was retained by Mregs
for ‡36 h. Gold-labeled Mregs adhered to glass surfaces; after 24 h of culture, it was possible to colabel these cells with human-
specific 154Sm-tagged anti–HLA-DR or 174Yb-tagged anti-CD45 mAbs. Following injection into immunodeficient mice, signals
from gold-labeled human Mregs could be detected in mouse lung, liver, and spleen for at least 7 d by solution-based inductively
coupled plasma mass spectrometry and LA-ICP-MS. These promising results indicate that LA-ICP-MS tissue imaging has great
potential as an analytical technique in immunology. The Journal of Immunology, 2014, 193: 000–000.
A
dministration of regulatory or suppressor cell populations
to nontolerant recipients as a means of establishing
tolerance is a well-known technique in experimental
immunology, but its clinical application is only now being seriously
investigated (1). In principle, a broad spectrum of immunological
conditions might be amenable to treatment with cell-based im-
munoregulatory therapies, including T cell–mediated autoimmune
diseases (2, 3), chronic inflammatory conditions (4), graft-versus-
host disease (5), and solid organ transplant rejection (6). In such
conditions, cell-based immunoregulatory therapies might reduce
or obviate the need for conventional immunosuppressive therapy,
sparing patients its attendant complications. Moreover, because
tolerance achieved through peripheral regulation (as opposed to
purely deletional mechanisms or immunological ignorance) is
dominant and self-sustaining, there exists the staggering possi-
bility that cell-based immunotherapy might offer curative treat-
ments for diseases that would otherwise require long-term general
immunosuppressive therapy (7).
Several immunoregulatory cell types are now reaching the point
of preclinical development that would allow them to be investigated
as immunosuppressive agents in early-phase clinical trials (8–11).
One particularly promising candidate cell type for use as an ad-
junct immunosuppressive agent in transplantation is the regulatory
macrophage (Mreg) (12). The Mreg reflects a unique state of
macrophage differentiation, distinguished from macrophages in
other activation states by its mode of derivation, robust phenotype,
and potent T cell suppressor function (13). Mregs potently sup-
press mitogen-stimulated T cell proliferation in vitro, which can
be attributed to IFN-g–induced IDO activity, as well as contact-
dependent deletion of activated T cells. In addition, Mregs drive
the development of activated induced regulatory T cells that, in
turn, suppress the proliferation of effector T cells and inhibit the
maturation of monocyte-derived dendritic cells in response to
TNF-a (14). Therefore, it is thought that when Mregs are ad-
ministered to an allogeneic recipient they can initiate a feed-
forward loop of immunological regulation, potentially leading to
the long-term acceptance of a foreign transplant (15).
To use any therapeutic agent safely and effectively, clinicians
must be able to predict its effectiveness and safety in individual
patients (16). An important determinant of the biological effect
and safety of any therapeutic cell product is its pharmacokinetics
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(i.e., its distribution, survival, and fate in the recipient). Typically,
pharmacokinetic studies in humans are performed as part of the
early clinical pharmaceutical development process; however, in
the case of Mregs, and cell-based medicinal products in general,
adequate methods for reliably detecting infused cells in tissues
over days or weeks after transfer are not available (17). In a pre-
vious study, we used single-photon emission computed tomogra-
phy to track 111In oxine-labeled allogeneic human Mregs in one
patient: Mregs given by central venous infusion were first con-
centrated in the pulmonary vasculature but by 3 h postinfusion had
migrated to the liver, spleen, and hematopoietically active bone
marrow via the blood (13). Although this radiological tracing
study provided valuable information, it tells us very little about the
precise distribution of Mregs within tissues, and, owing to the
short half-life of [111In], the survival and fate of Mregs after 30 h
postinfusion could not be characterized.
Cell tracking in patients presents a number of substantial
obstacles (18). To identify cells after administration to a recipient,
it is necessary that they are specifically and durably labeled. A
variety of cell labeling reagents and corresponding detection
technologies exist, notably radioisotopic labeling (19), stable
isotope labeling (e.g., deuterium), nuclear magnetic resonance
labels (20), nanoparticles (21), and luminescent dyes (22); how-
ever, to some degree, each of these approaches is limited by de-
tection sensitivity, signal nonspecificity, and the impermanence or
toxicity of labels. Thus, there is an unfulfilled need for a cell la-
beling and cell detection technology capable of reliably quanti-
fying very low-frequency cells (perhaps as few as 1 in 107 cells) in
tissues with a very low false-positive detection rate. Most im-
portantly, none of the existing cell-tracking techniques are capable
of reliable single-cell detection at a suitable level of resolution to
identify single cells and their microanatomical context. Judged by
these performance requirements, existing technologies are not
suitably sensitive or specific, so alternative approaches must be
considered.
Laser ablation–inductively coupled plasma mass spectrometry
(LA-ICP-MS) is an analytical technique that is predominantly
used in earth and material sciences, but it is also beginning to be
applied to analysis of biological samples (23). In principle, LA-
ICP-MS entails vaporizing small parts of a sample using a focused
pulse of laser energy. The elemental composition of this vaporized
material is analyzed by mass spectrometry, which provides ex-
quisitely sensitive detection. By taking contiguous samples across
a specimen, a map of the distribution of elements within a com-
plex sample can be constructed. This strategy has been used to
visualize endogenous elements in biological tissues (24), and
elemental tagging prior to LA-ICP-MS enables specific tissue
features, such as amyloid deposits in brain tissue (25), to be
distinguished. Applications of this remarkable technique to the
problem of tracking rare cells would overcome many of the lim-
itations associated with other methodologies: A “microscope” that
used LA-ICP-MS to map tissue components labeled with rare
earth metals would be incredibly sensitive and specific, because
most rare earth metals are completely absent from tissues. Hence,
the objective of the work presented in this article was to develop
an LA-ICP-MS method for identifying labeled human Mregs in
tissues specimens.
Materials and Methods
Experiments in animals
Animal experiments were performed in accordance with permission Nr. 54-
2532.1-10/12 granted by the Regierung von Oberbayern. NSG (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mice were bred in-house. Animals were kept in
individually ventilated cages and fed a conventional diet.
Generation and gold labeling of human Mregs
Human Mregs were generated as previously described (26). Briefly, CD14+
monocytes were isolated from Ficoll-prepared PBMCs by positive selec-
tion using anti-CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). Monocytes were plated in six-well Cell+ plates (Sarstedt,
N€umbrecht, Germany) at 106 cells/well in RPMI 1640 (Lonza, Cologne,
Germany) containing 10% heat-inactivated human AB serum (Lonza),
2 mM GlutaMAX (Invitrogen, Karlsruhe, Germany), 100 U/ml penicillin
(Lonza), 100 mg/ml streptomycin (Lonza), and recombinant human
M-CSF (R&D Systems, Wiesbaden-Nordenstadt, Germany) at 25 ng/ml
carried on 0.1% human albumin (CSL-Behring, Hattersheim-am-Main,
Germany). On day 6 of culture, cells were stimulated for 18 h with 25
ng/ml recombinant human IFN-g (Chemicon, Billerica, MA). To label
Mregs with 50-nm gold nanoparticles (Sigma, Munich, Germany), human
Mregs were harvested, washed twice in Dulbecco’s PBS (DPBS), and
resuspended at 106 cells/ml in prewarmed X-Vivo 10 (Lonza) containing
3.5 3 109 gold nanoparticles/ml. The cell suspension was incubated at
37˚C for 1 h in a closed 15-ml tube with end-over-end rotation. Thereafter,
the cells were washed three times in DPBS before further processing.
Flow cytometry
Cell surface staining was performed at 4˚C in DPBS/1% BSA/0.02% NaN3/
10% FcR-block (Miltenyi Biotec), as described elsewhere (13). Dead cells
were excluded with 7-aminoactinomycin D (BD Biosciences, Heidelberg,
Germany). Data were collected using a FACSCanto II cytometer (BD
Biosciences), and the proportion of live Mregs, gated by physical char-
acteristics, was analyzed using FlowJo v7.6.5 software. To assess the
T cell–suppressive capacity of Mregs, allogeneic PHA-stimulated CFSE-
labeled CD3+ T cells and Mregs were set in direct 1:1 coculture for 5 d.
Subsequently, T cell proliferation was quantified by flow cytometry, as
previously described (26).
Culture of gold-labeled Mregs in chamber slides
Mregs were resuspended in Mreg-generation medium (as above) before
replating into chamber slides (BD Falcon, Heidelberg, Germany) at a
density of 106 viable Mregs/ml. Cells replated in chamber slides were
allowed to adhere over 24 h. For counterstaining, adherent Mregs were
washed three times in ice-cold DPBS, air dried, and stained with Diff-Quik
Giemsa reagents (Medion Diagnostics, Munich, Germany).
Administration of gold-labeled human Mregs to NSG mice and
tissue preparation
Immediately prior to injection, the concentration of gold-labeled Mregs
was adjusted to 5 3 106 viable cells/ml in DPBS, without Ca2+ or Mg2+,
supplemented with 60 IU/ml heparin. Cell suspensions were injected
through a 27-gauge needle into the tail vein of recipient NSG mice over
30–180 s. For solution-based ICP-MS and LA-ICP-MS analyses, organs
were harvested at 24 h or 7 d postinfusion by postmortem dissection.
Tissues for analysis by LA-ICP-MS were fixed in paraformaldehyde and
embedded in paraffin wax, and 6-mm sections were cut. Sections were
mounted on SuperFrost glass microscope slides (Thermo Fisher Scientific,
Schwerte, Germany) and stored in a dry environment at 37˚C for several
days prior to further processing. Sections were dewaxed with Roti-Histol
(Carl Roth, Karlsruhe, Germany) and progressively rehydrated in increas-
ingly dilute ethanol. Following conventional immunohistochemical techni-
ques, tissues were blocked with 5% normal mouse serum in TBS for 1 h.
Tissues were stained overnight at 4˚C using primary metal-tagged MaxPar
Abs (Fluidigm Sciences, Sunnyvale, CA) diluted in TBS + 5% normal
mouse serum, according to the manufacturer’s recommendations. Specifi-
cally, tissues were stained with 154Sm-tagged anti-CD45 (clone HI30) or
174Yb-tagged anti–HLA-DR (clone L243). Sections were counterstained
with H&E before progressive dehydration in alcohol and air drying.
Solution-based ICP-MS
Analyses were performed on a sector-field ICP-MS instrument (Element
2XR; Thermo Scientific, Bremen, Germany). The instrument was fitted with
a cyclonic spray chamber, a conical glass concentric nebulizer (both from
Glass Expansion, West Melbourne, VIC, Australia), and a 0.25-mm inner
diameter probe (Elemental Scientific, Omaha, NE). Prior to analysis, the
samples were digested in small volumes of concentrated acid using the
procedure reported previously by our group (23). Following evaporation of
the acid, a 5% aqua regia solution was used to reconstitute the samples.
Gold is known to have a high affinity for the surfaces of the sample in-
troduction system (27). Therefore, to minimize memory effects, solutions
of 5% aqua regia and 10 mM cysteine were aspirated between samples.
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LA-ICP-MS
Analyses were performed on a laser ablation system (UP-213, Nd:YAG, l
213 nm; ElectroScientific Industries) coupled to a sector-field ICP-MS
instrument (Element 2XR; Thermo Scientific) in external trigger mode.
The laser ablation system was fitted with a low-volume, teardrop-shaped
ablation cell, which was described elsewhere (28). Helium was used as
the ablation gas, at a typical flow rate of 0.6 l/min, with an argon make-
up flow introduced, at a flow rate of 0.8 l/min, after the ablation cell.
Single-cell identification was demonstrated by ablating 55-mm-diameter
areas at locations corresponding to individual cells. Only single cells
were targeted; cells present in clusters or ,55 mm apart were discounted.
The presence of label was determined from the time-resolved 197Au
signal-intensity profile. Imaging of the cells and tissue sections was ac-
complished by performing adjacent line scans over sections of the slide,
while measuring 197Au, 154Sm, or 174Yb in time-resolved mode. Images were
constructed using Iolite version 2.15 (Melbourne Isotope Group, Melbourne,
VIC, Australia), a freeware data deconvolution package that runs on the
IGOR-Pro 6.22A platform (WaveMetrics, Lake Oswego, OR). The software
converts each raw data point into a color-coded pixel; thus, the color profile
of the resulting image depicts the distribution of the respective elements
across the sampled region.
Results
Labeling of human Mregs for detection by LA-ICP-MS
From an analytical chemistry perspective, most d-block and f-block
elements can be equally easily quantified by LA-ICP-MS. Metal
labels can be incorporated into living cells by various biological
processes, including phagocytosis, pinocytosis, receptor-mediated
endocytosis, or cell surface labeling. Retention of a metal label may
be passive or active, and it may or may not require reaction of the
metal with cellular constituents. The choice of metal label, its
chemical form, and the mechanisms by which it is taken up and
retained by living cells determine its properties as a tracer label.
From a biological perspective, the qualities that we expect of
a useful living cell label for in vivo tracking studies are durability,
biological inertness, and specificity; hence, absence of label from
normal tissues. Omniscan, a gadolinium-based nuclear magnetic
resonance contrast agent, was shown to be a suitable reagent for
labeling human regulatory T cells, which presumably acquired
label by fluid-phase pinocytosis (23).
In the current study, 50-nm gold particles were selected as a label
because Mregs are known to be highly phagocytic (15). Optimal
conditions for labeling were determined by incubating Mregs with
gold particles at a range of concentrations for various periods prior
to measuring cellular gold content by solution-based ICP-MS
(Table I). Label uptake was time and concentration dependent
and did not reach saturation within the range of tested conditions;
nevertheless, gold incorporation after 1 h of incubation with 3.5 3
109 particles/ml was .500-fold the lower limit of detection. To
ascertain whether gold labeling had any effect on Mreg viability,
cell surface phenotype, or in vitro function, gold-labeled and un-
labeled Mregs were analyzed by flow cytometry and suppression
assays (Fig. 1). After labeling, no differences in dead cell
frequency, marker phenotype, or suppressor activity were ob-
served. Accordingly, gold nanoparticles at concentrations of
3.5 3 109 particles/ml are suitable for labeling human Mregs with-
out obvious toxic effects.
Laser ablation of single Mregs
To assess the uptake of gold label by individual cells, gold-labeled
Mregs were washed extensively after labeling and replated in
chamber slides. The majority of replated Mregs readhered to the
vessel surface within 1 h and acquired typical Mreg morphology
(Fig. 2A). After 1 h, the adherent cells were washed extensively
and Giemsa stained prior to analysis by LA-ICP-MS. Single
Mregs were ablated with single shots of a 55-mm-diameter laser.
This beam size ensured complete ablation of an individual cell,
while reducing the chance of inadvertently ablating neighboring
cells. LA-ICP-MS of the labeled cells yielded an average signal
intensity of 1.9 3 105 counts/cell (77% relative SD). Each signal
was clearly distinguishable from the low background signal ∼0–
10 counts (Fig. 2B). No signals above background were observed
for the ablation of nonlabeled cells or from control areas of the
slide containing no cells (Fig. 2C). This demonstrated that labeled
cells can be rapidly and reliably distinguished from their non-
labeled counterparts, a point that was subsequently confirmed
during the analysis of mixed populations of labeled/nonlabeled
cells (Table II). To prove that gold nanoparticles are retained by
living Mregs, labeled cells were cultured for 36 h in chamber
slides before LA-ICP-MS analysis. Clear signals, with an average
signal intensity of 1.6 3 105 counts/cell (69% relative SD), were
obtained for this analysis (Fig. 2D). Therefore, it is concluded that
living, adherent Mregs can be labeled with 100% labeling effi-
ciency and retain gold nanoparticles for $36 h after labeling.
The above experiments sampled entire cells to demonstrate
100% cell labeling and detection capability. For tissue imaging, it is
clearly beneficial to decrease the diameter of the laser spot to less
than the size of the cell and, hence, increase the resolution of the
image. To demonstrate that the cells internalize sufficient label for
high-resolution imaging, 8-mm-wide line scans were performed
across a cluster of labeled cells (Fig. 3). The count rates remained
sufficient to enable detection of the cells, whereas the 8-mm spot
size was sufficient to discriminate between the signals from in-
dividual cells.
Gold-labeled Mregs can be dual labeled with 154Sm-tagged or
174Yb-tagged Abs
When gold-labeledMregs are administered to a recipient, release of
gold nanoparticles and subsequent reuptake by recipient phag-
ocytes could lead to misidentification of those recipient cells as
Mregs. One solution to this problem is to establish that cells bearing
the tracer label express the anticipated marker phenotype by im-
munohistochemical “postlabeling” using metal-conjugated Abs.
Table I. Optimizing conditions for labeling human Mregs with 50-nm gold particles
Gold Concentration
(particles/ml)
Incubation Time
10 s 1 h 2 h
0 Not detected Not detected Not detected
3.50 3 107 Not detected 1.79E+06 1.75E+06
1.75 3 108 Not detected 1.06E+07 9.52E+06
3.50 3 108 1.54E+06 3.09E+07 3.76E+07
1.75 3 109 1.05E+07 1.71E+08 3.64E+08
3.50 3 109 1.51E+07 3.39E+08 4.36E+08
Human Mregs were incubated with various concentrations of gold nanoparticles, and their gold uptake was determined
by ICP-MS. Data are the average number of gold atoms internalized/cell for each labeling condition.
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Therefore, we examined the technical feasibility of codetecting
Mregs labeled with gold and 174Yb-tagged anti–HLA-DR (Fig. 4A)
or 154Sm-tagged anti-CD45 (Fig. 4B) Abs. Mregs were labeled with
gold nanoparticles prior to overnight culture in chamber slides.
Unfixed, adherent Mregs were counterlabeled by incubation with
metal-conjugated Abs. After extensive washing, the dual-labeled
Mregs were analyzed by LA-ICP-MS. Coextensive signals were
obtained for gold labeling and the postlabels, proving that this
method could, in principle, be used to detect dual labeling of cells
in tissues.
FIGURE 1. Labeling human Mregs with 50-nm gold nanoparticles did not affect their viability, phenotype, or suppressor function. Human Mregs were
incubated for 1 h in the presence or absence of 3.5 3 109 gold nanoparticles/ml. Subsequently, the phenotype and viability of unlabeled and gold-labeled
Mregs were assessed by flow cytometry. Data are representative of n = 3 independent allogeneic pairs. No difference was observed in the viability of gold-
labeled Mregs compared with unlabeled Mregs. Likewise, no differences were observed between gold-labeled and unlabeled Mregs in the expression of
CD11b, HLA-DR, CD14, or CD16. Both gold-labeled and unlabeled Mregs expressed similar levels of IDO, which is indispensible for the T cell–sup-
pressive function of human Mregs. Accordingly, gold labeling of Mregs did not affect their capacity to suppress polyclonal proliferation of CFSE-labeled,
PHA-stimulated allogeneic CD4+ T cells in direct 1:1 cocultures.
FIGURE 2. One hundred percent labeling efficiency was achieved when Mregs were incubated with 3.5 3 109 gold nanoparticles/ml for 1 h. (A) After
labeling with gold nanoparticles, Mregs were able to readhere to a plastic tissue culture surface. Cells were visualized using a Giemsa counterstain. (B) Single
gold-labeled Mregs were ablated with single shots of a 55-mm-diameter laser, yielding an average signal intensity of 1.9 3 105 counts/cell (77% relative SD).
(C) No signals above background were observed when unlabeled Mregs were ablated. (D) Labeled Mregs retained gold for $36 h after labeling.
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Tracking of human Mregs in NSG mice
The eventual anatomical distribution of Mregs after i.v. infusion
reflects their passive and active migration and engraftment into
different tissues, as well as their death and elimination. To track the
survival and tissue distribution of Mregs in vivo, gold-labeled
human Mregs were injected into NSG mice. The presence of la-
bel in brain, heart, kidney, liver, spleen, small intestine, large in-
testine, skeletal muscle, and tail skin was assessed on days 1 and 7
postinjection by solution-based ICP-MS (Table III). At both time
points, gold label was principally detected in lung, liver, and
spleen (although above-background signal was also detected in
kidney, heart, brain, and intestine), which is consistent with pre-
vious results from flow cytometry experiments that showed tran-
sient engraftment of Mregs in these tissues (28).
To investigate whether LA-ICP-MS permits detection of in-
dividual gold-labeled cells in tissues, recipient tissues were
harvested at day 1 or 7 postinjection of gold-labeled Mregs. These
tissues were fixed with paraformaldehyde and embedded in
paraffin. Six-micron sections of lung, liver, and spleen were
conventionally counterstained with H&E prior to analysis by
LA-ICP-MS. Sampled areas were 320 3 245 mm in size, with
two sampled areas selected per tissue section. As predicted by
solution-based ICP-MS, label was detected in all three tissues at
1 and 7 d postinjection (Fig. 5). Within the relatively small areas
of tissue examined, no particular pattern of signal distribution
was perceived.
Discussion
Faced with the problem of detecting very rare cells in tissues, the
aim of this work was to demonstrate that LA-ICP-MS can be used
to identify metal-labeled cells in tissue samples with high sensi-
tivity and specificity. In principle, this objective has been realized;
Table II. Specificity of 197Au labeling of human Mregs
Ratio of Labeled/Nonlabeled
Cells
Culture Time after
Labeling (h)
No. of Cells
Ablated
No. of Labeled
Cells Detected
1:0 1 100 100
0:1 1 100 0
1:1 1 100 45
1:0 36 100 100
0:1 36 100 0
1:1 36 100 43
Various proportions of gold-labeled Mregs were plated in chamber slides and allowed to adhere for 1 or 36 h. The
relative numbers of labeled and unlabeled Mregs were assessed by LA-ICP-MS. Labeled and unlabeled Mregs were clearly
discriminable. There was no significant transfer of gold label from labeled to unlabeled Mregs over the 36-h incubation
period.
FIGURE 3. An 8-mm laser spot–size is sufficient to
allow detection of gold-labeled Mregs. Eight-micro-
meter– line scans were made across a group of gold-la-
beled, Giemsa-counterstained Mregs. Count rates were
adequate to detect labeled cells, whereas the spot size
was small enough to allow spatial resolution of adjacent
cells. The upper panel shows optical images and the
lower panel shows the distribution of gold label.
The Journal of Immunology 5
in practice, the technology is not ready to be commonly used in
immunological research. Nevertheless, the results presented in this
article indicate the enormous future potential of LA-ICP-MS in
imaging biological specimens at a level of resolution suitable for
identifying individual cells. Although this study focused on the
narrow application of this approach to detecting gold-labeled
Mregs, clearly LA-ICP-MS tissue imaging could be useful for
a much broader range of applications. Therefore, we must ask
ourselves how the current system might be improved to better serve
the needs of biologists.
The resolution of images generated by LA-ICP-MS is dictated
primarily by laser parameters (e.g., laser spot diameter, line
spacing, repetition frequency, and scanning speed). Finer reso-
lution is necessarily better when imaging histological specimens.
In the current study, a beam width of 8 mm and scan speed of 8
mm/s were used for the analysis of tissue sections, which pro-
vided sufficient resolution to identify single cells. In principle,
the resolution of images could be increased to #1 mm. However,
the choice of laser parameters must take into account additional
factors, such as the instrument sensitivity and the required
analysis speed.
Presently, the speed of analyzing specimens is slow: to image an
area of 1 mm2 using an 8-mm spot diameter and 8-mm/s scan speed
takes ∼4.5 h. The speed of analysis is largely limited by the
washout time of the laser ablation chamber, which determines
the duration of the signal from each laser pulse. Commercially
available systems typically provide washout times in the order of
a few seconds; however, with custom modifications, many users
have reduced this time, in some cases to ,100 ms. With improved
instrumentation, washout times might be reduced to ∼10 ms,
which would drastically improve both the sensitivity and the speed
of analysis.
Using our current LA-ICP-MS system, it was possible to detect
two labels on cultured cells; however, for many applications it
FIGURE 4. Gold-labeled Mregs can be dual labeled with 174Yb-tagged or 154Sm-tagged Abs. Gold-labeled Mregs were cultured overnight in chamber
slides prior to postlabeling with either 174Yb-conjugated anti–HLA-DR (A) or 154Sm-conjugated anti-CD45 (B) mAbs. After extensive washing, the dual-
labeled Mregs were counterstained with Giemsa and subjected to LA-ICP-MS analysis.
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would be useful to measure many more parameters. In principle, this
could be achieved by combining the existing LA-ICP-MS with
conventional fluorescence microscopy or by developing the system
to detect multiple metal labels. The principal restriction on analyzing
a greater number of metal labels is the rate at which sector field mass
spectrometers detect each element, which they must do sequentially.
Therefore, the capability of the current system to detect multiple
metal labels could be improved by using a simultaneously detecting
mass spectrometer, such as a time-of-flight mass spectrometer.
In this study, we applied LA-ICP-MS to the real-world biological
problem of identifying rare cells in tissues. In doing so, we
demonstrated the potential usefulness and power of this method
in biological research. The technology presented in this article
allowed detection of gold-labeled cells in tissues with very high
specificity and sensitivity, as well as revealing their microana-
tomical relationship to recipient tissue structures. The specificity of
LA-ICP-MS tissue imaging reflects the large signal-to-background
ratio afforded by using rare earth metals or biologically inert
nanoparticles as labels. The sensitivity of LA-ICP-MS tissue im-
aging (i.e., the ability to reliably detect very rare cells) is a re-
flection of the incredible sensitivity of mass spectrometry as an
analytical technique. Unsurprisingly, there is now great interest in
exploiting mass spectrometry as a specific and sensitive detection
method in various biological applications, most notably in flow
cytometry (30). A commercially available device known as the
CyTOF is being adopted by many groups interested in clinical
immune monitoring, with to astonishing results (31, 32). The cou-
pling of laser ablation with ICP-MS–based detection presented in
this article takes this technology to a new level by combining de-
tection of specific Ags with spatial resolution, allowing accurate,
sensitive, and specific mapping of Ag distribution within tissues.
Concurrent detection of signals fromMregs prelabeled with gold
and postlabeled with metal-tagged Abs would imply the presence
of intact human Mregs in mouse tissues. Dual labeling and LA-
ICP-MS detection of gold-labeled Mregs grown on chamber slides
with either 174Yb-tagged anti–HLA-DR or 154Sm-tagged anti-CD45
was successful. Unfortunately, when sections of spleen from mice
that had received gold-labeled Mregs were counterstained with the
174Yb-conjugated anti–HLA-DR Ab before being analyzed at low
resolution by LA-ICP-MS, very high and spatially diverse back-
ground signals for 174Yb were detected (Supplemental Fig. 1).
Therefore, no correlation in the distribution of 174Yb and 197Au
signals could be established. We are unable to explain this
nonspecific staining in mouse tissues. One possibility is that our
metal-tagged mAbs are unsuitable for use on tissue sections,
possibly owing to the destruction of Ags during tissue fixation.
Also, we cannot discount the possibility that MaxPar reagents
have a greater propensity for nonspecific binding to tissues than do
Abs with alternative labels. Because of the very high sensitivity of
LA-ICP-MS, postlabeling with rare earth metal–labeled Abs
might require development of more suitable metal-conjugated
Abs, possibly labeled using different chemistries, as well as bet-
ter histological techniques to block nonspecific binding of Abs.
Importantly, our inability to identify colabeled Mregs does not
detract from the potential usefulness of LA-ICP-MS in detecting
colabeled cells in tissues; rather, it speaks to the current limi-
tations of our metal-labeled Abs and histological techniques,
which are ultimately soluble issues.
Albeit a niche application of LA-ICP-MS tissue imaging,
characterizing the distribution, survival, and fate of therapeutic
cells in patients will be critical to their future development as
pharmaceutical agents (29, 33). LA-ICP-MS offers an unrivaled
combination of sensitivity, specificity, and spatial resolution,
which makes it an especially suitable method for cell tracking.
Moreover, using LA-ICP-MS as a detection method makes avail-
able a variety of nonradioisotopic tracers, which may be safer and
more convenient than currently available labels in the manufacture
and application of cell-based therapies. Another exciting possibility
of LA-ICP-MS cell tracking is that colabeling cells with two or
more metal-containing compounds that are metabolized, degraded,
or excreted by different mechanisms might make discrimination of
live and dead cells possible, because only live cells would carry
both labels. This article is proof-of-concept that gold-labeled Mreg
can be detected in tissues for at least 7 d after infusion. Serious
consideration is being given to the feasibility and clinical safety of
labeling Mreg with gold nanoparticles for infusion into patients;
indeed, clinical translation of cell tracking by LA-ICP-MS is a key
objective of The ONE Study initiative (www.onestudy.org).
We conclude that, although LA-ICP-MS tissue imaging is a
nascent technology, it has the potential to be a very powerful
analytical technique in biology. If the present limitations of res-
olution and number of labels can be overcome, then LA-ICP-MS–
based tissue imaging has a bright future.
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Table III. Presence of 197Au-labeled human Mregs in tissues of recipient mice on days 1 and 7 postinjection
by solution-based ICP-MS
Tissue
Day 1 Day 7
Au-Labeled Mregs Unlabeled Mregs Au-Labeled Mregs Unlabeled Mregs
Lung 251.40 6 13 0.15a 122.47 6 9 0.09a
Spleen 147.85 6 12 0.04a 181.25 6 11 0.07a
Liver 120.46 6 26 0.02a 132.15 6 29 0.02a
Kidney 8.23 6 12 0.23a 2.56 6 3 0.12a
Heart 3.27 6 56 0.23a 1.09 6 124 0.12a
Skeletal muscle 0.48a 0.12a 0.49 6 97 0.21a
Brain 1.46 6 22 0.04a 0.06a 0.07a
Tail skin 35.70 6 134 2.10a 0.47 6 24 nt
Large intestine 0.67a 0.06a 0.63 6 44 0.45a
Small intestine 1.90 6 58 0.43a 0.86 6 47 0.50a
Data are pg Au/mg tissue 6 % RSD; n = 3/group.
aBelow the limit of detection.
nt, not tested; RSD, relative SD.
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(57) ABSTRACT 
A laser ablation system includes a sample chamber 102 con-
figured to accommodate a target 104 within an interior 106 
thereof, a sample generator 108 configured to remove a por-
tion of the target 104 (which may be subsequently captured as 
a sample) aud an analysis systemll 0 configured to analyze a 
composition of the sample. A sample capture cell in the 
chamber proximate to the target has a capture cavity config-
ured to receive target material, a first inlet configured to 
transmit a flow of a carrier gas from a first location adjacent to 
an exterior of the capture cell into a region of the capture 
cavity; and au outlet configured to receive carrier gas from 
another region of the capture cavity. The sample chamber 102 
includes an injection nozzle 120 configured to introduce, into 
the interior 106, a fluid such as a carrier gas. 
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LASER ABLATION CELL AND INJECTOR 
SYSTEM FOR A COMPOSITIONAL 
ANALYSIS SYSTEM 
RELATED APPLICATIONS 
[0001] This application claims benefit of U.S. Provisional 
Patent Application No. 61/764,976, filed on 14 Feb. 2013, 
which application is incorporated by reference as if fully set 
forth herein. This application also claims priority to PCT/ 
US14/16085 filed on 12 Feb. 2014, which application is 
incorporated by reference as if fhlly set forth herein. 
BACKGROUND 
[0002] Embodiments of the present invention exemplarily 
described herein relate generally to apparatuses and methods 
for handling target material ejected or otherwise generated 
from a laser ablation site of a target (e.g., the form of particles 
and/or vapor). More particularly, embodiments of the present 
invention relate to apparatuses and methods for efficiently 
capturing target materiaL for efficiently transporting a sample 
containing the target material and for efficiently injecting a 
sample containing the target material into a sample prepara-
tion system. Embodiments of the present invention exemplar-
ily described herein also relate generally to an apparatus for 
handling a target within a sample chamber. More particularly, 
embodiments of the present invention relate to apparatuses 
and methods for adjusting the position of a target holder with 
reduced lag and motion hysteresis. 
[0003] Laser ablation Inductively Coupled Plasma Mass 
Spectrometry (LA-ICP-MS) or Laser ablation Inductively 
Coupled Plasma Optical Emission Spectrometry (LA-ICP-
OES) teclmiques can be used to analyze the composition of a 
target (e.g., a solid or liquid target material). Often, a sample 
of the target is provided to an analysis system in the form of 
an aerosol (i.e., a suspension of solid and possibly liquid 
particles and/or vapor in a carrier gas, such as helium gas). 
The sample is typically produced by arranging the target 
within a laser ablation chamber, introducing a flow of a carrier 
gas within the chamber, and ablating a portion of the target 
with one or more laser pulses to generate a phune containing 
particles and/or vapor ejected or otherwise generated from the 
target (hereinafter referred to as "target material"), suspended 
within the carrier gas. Entrained within the flowing carrier 
gas, the target material is transported to an analysis system via 
a transport conduit to an ICP torch where it is ionized. A 
plasma containing the ionized particles and/or vapor is then 
analyzed by an analysis system such as an MS or OES system. 
[0004] Conventional techniques such as LA-ICP-MS and 
LA-ICP-OES, however, are undesirably slow to carry out 
high-resolution compositional analysis (i.e., "imaging") of a 
target within a reasonable time frame. For example, current 
techniques undesirably take up to about 278 hours to image an 
area of 100 1111112 at a pixel resolution of 10 11m. In addition, 
currentteclmiques such as LA-ICP-MS andLA-ICP-OES are 
also not sensitive enough for high-resolution imaging or 
analysis of micron-sized and sub-micron side particles (e.g., 
nanoparticles ). Example embodiments disclosed herein 
address these and other problems associated with conven-
tional compositional analysis techniques. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0005] FIG.1 schematically illustrates one embodiment of 
an apparatus for handling a target and for handling target 
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material ejected from or otherwise generated from the target, 
and includes a cross-sectional view of a sample chamber, a 
sample capture cell and a target holder. 
[0006] FIG. 2 is a cross-sectional view, taken along line 
II-II shown in FIG. 2A, schematically illustrating the sample 
capture cell shown in FIG. 1 according to one embodiment. 
[0007] FIG. 2A is a plan view schematically illustrating a 
first inlet, a second inlet, a capture cavity and an outlet of the 
sample capture cell when viewed in the direction indicated 
along line IIA-IIA in FIG. 2. 
[0008] FIG. 2B is a plan view illustrating the first inlet, 
second inlet, capture cavity and outlet of the sample capture 
cell when viewed in the direction indicated along line liB-liB 
in FIG. 2. 
[0009] FIG. 3 is a cross-sectional view schematically illus-
trating laser light directed through the second inlet and cap-
ture cavity of the sample cell onto a target at a laser ablation 
site, and a resultant plume containing target material ejected 
from the target at the laser ablation site into the capture cavity 
of the sample cell. 
[0010] FIG. 4 is a perspective, cross-sectional view sche-
matically illustrating characteristics of the flow of carrier gas 
within the interior of the sample chamber into the capture 
cavity of the sample capture cell shown in FIG. 2. 
[0011] FIG. 5 is an enlarged, top plan view schematically 
illustrating the characteristics of the flow of carrier gas shown 
in FIG. 4 into the capture cavity of the sample capture cell 
shown in FIG. 2. 
[0012] FIG. 6 is an enlarged perspective, cross-sectional 
view of the schematic shown in FIG. 4, schematically illus-
trating characteristics of the flow of carrier gas through an 
opening of the capture cavity and into the outlet of the sample 
capture cell shown in FIG. 2, from a region between the 
sample capture cell and the target. 
[0013] FIG. 7 is an enlarged side, cross-sectional view of 
the schematic shown in FIG. 4, schematically illustrating 
characteristics of the flow of carrier gas through the second 
inlet and into the outlet of the sample capture cell shown in 
FIG. 2. 
[0014] FIG. 8 is a cross-sectional view schematically illus-
trating the sample capture cell shown in FIG. 1 incorporating 
an auxiliary inlet, according to another embodiment. 
[0015] FIG. 9 is a cross-sectional view schematically illus-
trating one embodiment of an injector coupled to a sample 
preparation system, and a portion of an analysis system. 
[0016] FIG. 10 is a partial cross-sectional view schemati-
cally illustrating one embodiment of a desolvation unit 
coupled between a droplet generator and an injector such as 
the injector shown in FIG. 9. 
DETAILED DESCRIPTION OF THE 
ILLUSTRATED EMBODIMENTS 
[0017] Example embodiments are described below with 
reference to the accompanying drawings. Many different 
forms and embodiments are possible without deviating from 
the spirit and teachings of the invention and so the disclosure 
should not be construed as limited to the example embodi-
ments set forth herein. Rather, these example embodiments 
are provided so that this disclosure will be thorough and 
complete, and will convey the scope of the invention to those 
skilled in the art. In the drawings, the sizes and relative sizes 
of components may be exaggerated for clarity. The temlinol-
ogy used herein is for the purpose of describing particular 
example embodiments only and is not intended to be limiting. 
US 2014/0224775 AI 
It is to be understood that various orientational tenns such as 
"front" and "back" and "rear", "left" and "right", "top" and 
"bottom", "upper" and lower" and the like are used herein 
only for convenience, and not with the intention of limiting 
what is described to any absolute or fixed orientation relative 
to any environment in which any described structures may be 
used. As used herein, the singular fom1s "a," "an" and "the" 
are intended to include the plural forms as well, unless the 
context clearly indicates otherwise. It will be further under-
stood that the tenns "comprises" and! or "comprising," when 
used in this specification, specifY the presence of stated fea-
tures, integers. steps, operations, elements. ancl!or compo-
nents, but do not preclude the presence or addition of one or 
more other features, integers, steps, operations, elements, 
components, ancl!or groups thereof. Unless otherwise speci-
fied, a range of values, when recited, includes both the upper 
and lower limits of the range, as well as any sub-ranges 
therebetween. 
[0018] FIG. 1 schematically illustrates one embodiment of 
an apparatus for handling a target and for handling target 
material ejected from or otherwise generated from the target, 
and includes a cross-sectional view of a sample chamber, a 
sample capture cell and a target holder. 
[0019] Referring to FIG.1, an apparatus, such as apparatus 
100, for handling a target and for handling target material 
ejected from or otherwise generated from the target may 
include a sample chamber 102 configured to accommodate a 
target 104 within an interior 106 thereof, a sample generator 
108 configured to remove a portion of the target 104 (which 
may be subsequently captured as a san1ple) and an analysis 
system 110 configured to analyze a composition of the 
sample. Examples of materials that can be provided as a target 
104 include, for example, archaeological materials, biologi-
cal assay substrates and other biological materials, ceramics, 
geological materials, pharmaceutical agents (e.g., pills), met-
als, polymers, petrochemical materials, liquids, semiconduc-
tors, etc. The apparatus 100 may optionally include a sample 
preparation system 112 configured to excite (e.g., ionize, 
atomize, illuminate, heat, or the like or a combination thereof) 
one or more components of the sample before the sample is 
analyzed by the analysis system110. As will be described in 
greater detail below, the sample preparation system 112 may 
include a plasma torch (e.g., an ICP torch), or the like. Fur-
ther, the analysis system 110 may be provided as an MS 
system, an OES system, or the like. 
[0020] The sample chamber 102 may include a frame 114 
having an optical port 116 extending therethrough to permit 
optical connnunication between the san1ple generator 108 
and the interior 106 of the sample chamber 102. Optionally, a 
transmission window 118 may be coupled to the frame 114 
and to span the optical port 116. The transmission window 
118 is typically formed of a material (e.g., quartz) that is at 
least substantially transparent to laser light generated by the 
sample generator 108. The transmission window 118 may 
also be sealed to the frame 114 to prevent dust, debris or other 
unwanted gases or other sources of contamination from enter-
ing into the interior 106 through the optical port 116. In one 
embodiment the transmission window 118 is be sealed to the 
frame 114 also to prevent particles ejected from the target 
104, vapor generated from the target 104, etc., (the particles, 
vapor, etc., being collectively referred to herein as "target 
material", which is removed from the target 104), carrier gas 
or other fluids present within the interior 106, from exiting the 
sample chamber 102 through the optical port 116. Although 
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the frame is illustrated as a single, integrally-formed piece, it 
will be appreciated that the frame 114 may be formed of 
multiple components that are coupled together, as is known in 
the art. 
[0021] The sample chamber 102 may further include one or 
more injection nozzles 120 each configured to introduce, into 
the interior 106, a fluid such as a carrier gas (e.g., helium, 
argon, nitrogen, or the like or a combination thereof) at a flow 
rate in a range from 20 mL/min to 1000 mL/min (e.g., in a 
range from 100 mL/min to 150 mL/min, or 125 mL/min, or 
thereabout). For example, each injection nozzle 120 may be 
inserted through a fluid port in the frame 114 and include an 
inlet configured to be fluidly coupled to a fluid source (e.g., a 
pressurized fluid source) outside the sample chamber 102 and 
an outlet exposed within the interior 106 the sample chamber 
102. Seals (not shown) may be provided between frame and 
the injection nozzles 120 to fluidly isolate the interior 106 of 
the san1ple chamber 102 with the envirmnnent outside the 
sample chamber 102. Upon introducing a carrier gas into the 
interior 106, a flow of the carrier gas (also referred to herein 
as a "carrier gas flow") is generated within the interior 106. It 
will be appreciated that the velocity and direction of the 
carrier gas flow at different locations within the interior 106 
can vary depending upon: the shape and size of the interior 
106 of the sample chamber 102, the configuration of the one 
or more injection nozzles 120, the flow rate with which carrier 
gas is introduced into the interior 106 by any particular injec-
tion nozzle 120, or the like or a combination thereof. In one 
embodiment, the pressure within the interior 106 can be 
maintained (e.g., to a pressure less than or equal to 11 psi) by 
controlling the flow rate with which carrier gas is introduced 
into the interior 106. 
[0022] The apparatus 100 may further include a target posi-
tioning system configured to adjust the position of the target 
104 relative to the optical path 122. In one embodiment, the 
positioning system includes a target holder 124 configured to 
support the target 104, a carriage 126 configured carry the 
target holder 124, a base 130 configured to support the car-
riage 126 within the interior 106 and a positioning stage 128 
configured to move the carriage 126. Although the target 
holder 124 and the carriage 126 are illustrated as separate, 
separatable components, it will be appreciated that the target 
holder 124 and the carriage 126 may be integrally formed. 
Optionally, a height-adjustment mechanism (not shown) such 
as a micrometer can be provided to adjust a position of the 
target holder 124 along a vertical direction (e.g., along the 
optical path 122) to ensure that the target 104 is arranged at a 
suitable or beneficial position within the interior 106. 
[0023] The positioning stage 128 may be configured to 
linearly translate the carriage 126 along at least one direction 
(e.g., an X -direction, a Y-direction orthogonal to the X -direc-
tion, or the like or a combination thereof) relative to the 
optical path 122, or may be configured to rotate the carriage 
126 relative to the optical path 122, or the like or a combina-
tion thereof. In one embodiment, the positioning stage 128 
and the frame 114may both rest on a conunon support surface 
such as a table (not shown).A portionofthe frame 114may be 
spaced apart from the support surface to define a stage-re-
ceiving space therebetween. and the positioning stage 128 
may be disposed in the stage-receiving space. 
[0024] The base 130 may include a first side 132 exposed 
within the interior 106 and a second side 134 opposite the first 
side 132. The base 130 may be coupled to the frame 114 so as 
to fluidly isolate the interior 106 of the sample chamber 102 
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with the environment outside the sample chamber 102. Thus, 
as exemplarily illustrated, the carriage 126 and the position-
ing stage 128 are disposed at opposite sides of the base 130. 
To facilitate movement and beneficial positioning of the tar-
get 104 within the interior 106, the carriage 126 is magneti-
cally coupled to the positioning stage 128 through the base 
130. For example, carriage 126 may include one or more 
magnets (not shown) arranged therein and the positioning 
stage 128 may include an end effector 136 having one or more 
magnets attached thereto. An orientation of the magnets 
within the carriage 126 and the end effector 136 may be 
selected to generate an attractive magnetic field extending 
between the end effector 136 and the carriage 126, through 
the base 130. It will be appreciated that the base 130 may be 
constructed in any suitable or beneficial manner to transmit a 
magnetic field of sufficient strength between the end effector 
136 and the carriage 126. For example, the base 130 may be 
formed from a material such as a metal, a glass, a ceran1ic, a 
glass-ceramic, or the like. In one embodiment, the base 130 
may include a material formed of fluorphlogopite mica in a 
matrix of borosilicate glass. 
[0025] To facilitate movement of the carriage 126 across 
the first side 132 of the base 130, the first side 132 may have 
a relatively smooth surface (e.g., with a surface roughness, 
Ra, of about 0.4 fllll to about 0.8 f.Ull). In one embodiment, the 
positioning system may further include one or more bearings 
coupled to the carriage 126 and configured to contact the first 
side 132 of the base 130. Although the apparatus 100 is 
illustrated as including the target positioning system, it will 
be appreciated that the target positioning system may be 
omitted, modified or substituted for any other suitable or 
beneficial mechanism for adjusting the position of the target 
104 relative to the optical path 122. 
[0026] Constructed according to the various embodiments 
exemplarily described above, the target positioning system 
ensures repeatable lateral angular and positioning of the tar-
get 104 within the interior 106, with low movement lag and 
motion hysteresis. 
[0027] The sample generator 108 is configured to direct 
laser light along an optical path 122, through the optical port 
116 and into the interior 106 of the sample chamber 102 to 
impinge upon the target 104. The laser light may be directed 
along the optical path 122 as one or more laser pulses gener-
ated by one or more lasers. One or more characteristics of the 
laser pulses may be selected or otherwise controlled to 
impinge a region of the target 104 to ablate a portion of the 
target 104. Characteristics that may be selected or otherwise 
controlled may, for example, include wavelength (e.g., in a 
range from about 157mn to about 11 ~un, such as 193nm, 213 
mn, 266 nm, or the like), pulse duration (e.g., in a range from 
about 100 femtoseconds to about 25 nanoseconds), spot size 
(e.g., in a range from about I 11m to about 9 mm, or the like), 
pulse energy, average power, peak power, temporal profile, 
etc. The sample generator 108 may also include laser optics 
(e.g., one or more lenses, beam expanders, collimators, aper-
tures, mirrors, etc.) configured to modify laser light generated 
by one or more of the lasers. As used herein, a region of the 
target 104 that is impinged by a laser pulse is referred to as a 
"laser ablation site". Upon being ablated. target material is 
removed from a region of the target 104 located within or 
adjacent to the laser ablation site to form a plume containing 
the target material. 
[0028] To facilitate handling of the target material (e.g., so 
that the composition of the target material can be analyzed at 
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the analysis system 110) the apparatus 100 may include a 
sample capture cell138 configured to capture the target mate-
rial when it is arranged operably proximate to the target 104. 
Target material captured by the sample capture cell138 is also 
herein referred to as a "sample" or a "target sample". The 
apparatus 100 may further include a transport conduit 140 
configured to transport the sample to the sample preparation 
system112. In the illustrated embodiment, the apparatus may 
include a cell support 142 coupled to the sample chamber 102 
(e.g., at the frame 114) to fix the sample capture cell 138 
within the interior 106. 
[0029] In one embodiment, the aforementioned optional 
height-adjustment mechanism may be used to adjust the 
height of the target holder 124 (and, thus, the target 104) 
relative to the sample capture cell 138 to ensure that the 
sample capture cell 138 is operably proximate to the target 
104. In another embodiment, a height adjustment mechanism 
such as a micrometer may be optionally provided to adjust a 
position of the sample capture cell138 relative to the target 
104 (e.g., along the optical path 122) to ensure that the sample 
capture cell138 is arranged at a suitable or beneficial position 
within the interior 106. Thus, in addition to (or instead of) 
adjusting a position of the target 104 relative to the san1ple 
capture cell138, the position of the sample capture cell138 
relative to the target 104 may be adjusted to ensure that the 
sample capture cell 138 is operably proximate to the target 
104. In one embodiment the sample capture cell138 is oper-
ably proximate to the target 104 when the san1ple capture cell 
138 is spaced apart from the target 104 by a gap distance, d 
(see, e.g., FIG. 2) in a range from 0.01 nlll1 to 1 nlll1 (e.g., in 
a range from 0.05 mm to 0.2 mm, or in a range from O.llllll1 
to 0.2mm). It will be appreciated, however, that depending on 
factors such as the carrier gas flow velocity within a region of 
the interior 106 between the sample capture cell138 and the 
target 104, the gap distance can be less than O.Ql lllll1 or 
greater than 1 lllll1, and may even contact the target 104. 
[0030] FIG. 2 is a cross-sectional view, taken along line 
II-II shown in FIG. 2A, schematically illustrating the san1ple 
capture cell shown in FIG. 1 according to one embodiment. 
FIG. 2A is a plan view schematically illustrating a first inlet, 
a second inlet, a capture cavity and an outlet of the sample 
capture cell when viewed in the direction indicated along line 
IIA-IIA in FIG. 2. FIG. 2B is a plan view illustrating the first 
inlet, second inlet, capture cavity and outlet of the sample 
capture cell when viewed in the direction indicated along line 
IIB-IIB in FIG. 2. FIG. 3 is a cross-sectional view schemati-
cally illustrating laser light directed through the second inlet 
and capture cavity of the sample cell onto a target at a laser 
ablation site, and a resultant plume containing the target 
material from the laser ablation site into the capture cavity of 
the sample cell. FIG. 4 is a perspective, cross-sectional view 
schematically illustrating characteristics of the flow of carrier 
gas within the interior of the sample chamber into the capture 
cavity of the sample capture cell shown in FIG. 2. FIG. 5 is an 
enlarged, top plan view schematically illustrating the charac-
teristics of the flow of carrier gas shown in FIG. 4 into the 
capture cavity of the sample capture cell shown in FIG. 2. 
FIG. 6 is an enlarged perspective, cross-sectional view of the 
schematic shown in FIG. 4, schematically illustrating char-
acteristics of the flow of carrier gas through an opening of the 
capture cavity and into the outlet of the sample capture cell 
shown in FIG. 2, from a region between the sample capture 
cell and the target. FIG. 7 is an enlarged side, cross-sectional 
view of the schematic shown in FIG. 4, schematically illus-
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trating characteristics of the flow of carrier gas through the 
second inlet and into the outlet of the sample capture cell 
shown in FIG. 2. 
[0031] Referring to FIGS. 2, 2A and 2B, the san1ple capture 
cell138 may generally be characterized as having an upper 
surface 200 (e.g., configured to generally face toward the 
sample generator 108) and a lower surface 202 (e.g., config-
ured to generally face toward the target 104), a front end 
region and a back end region opposite the front end region. 
Generally, the sample capture cell138 is arranged within the 
interior 106 such that the front end region is disposed 
upstream of the back end region, relative to the predominant 
direction of the carrier gas flow at the location in the interior 
106 where the sample capture cell138 is arranged. In one 
embodiment, a surface of the sample capture cel1138 defining 
the front end region is configured so as to be convexly-curved. 
For example, and as best shown in FIG. 2B, the surface of the 
sample capture cell138 defining the front end region is cir-
cularly curved, centered on an axis of a second inlet 204 
(discussed in greater detail below) with a radius in a range 
froml.2mm to 1.5 mm, or thereabout). It will be appreciated, 
however, that depending on factors such as the predominant 
direction of the carrier gas flow at the location in the interior 
106 where the sample capture cel1138 is arranged, the loca-
tion of the second inlet 204 within the sample capture cell 
138, and other dimensions of the sample capture cell138, the 
geometric configuration of the surface defining the front end 
region of the sample capture cell138 may be varied in any 
manner that may be suitable or beneficial. It will further be 
appreciated that the location of the sample capture cell138 
within the interior 106 can be selected based upon factors 
such as the geometry of the interior 106, and the number and 
location of injection nozzles 120 generating the carrier gas 
flow within the interior 106. For example, if the interior 106 
has a cylindrical geometry, and if only one injection nozzle 
120 is used to introduce carrier gas into the interior 106 along 
the diameter of the cylindrical interior 106 at the aforemen-
tioned flow rate, then the sample capture cell 138 can be 
located at or near the center of the interior 106. 
[0032] According to one embodiment, the sample capture 
cel1138 may further include a capture cavity 206, a first inlet 
208 in fluid collllllunication with the capture cavity 206, an 
outlet 210 in fluid communication with the capture cavity 
206, and a guide wall 212 exposed within the capture cavity 
206. In a further embodiment, the sample capture cell may 
further include the aforementioned second inlet 204 in fluid 
commllllication with the capture cavity 206. In one embodi-
ment, the sample capture cell138 can be provided as a mono-
lithic body formed of any suitable material such as a glass, a 
ceramic, a polymer, a metal, or the like or a combination 
thereof. Moreover, two or more or all of the capture cavity 
206, the first inlet 208, the second inlet 204, the outlet 210, 
and the guide wall 212, may be integrally formed within the 
body by conventional techniques (e.g., by machining, grind-
ing, cutting, drilling, 3-D printing, etc.). In another embodi-
ment, however, two or more or all of the capture cavity 206, 
the first inlet 208, the second inlet 204, the outlet 210, and the 
guide wall 212, may be separately formed from different 
components, which are subsequently coupled together. 
[0033] The capture cavity 206 extends from an opening 214 
formed in the lower surface 202 of the sample capture cell138 
and is configured to receive, through the opening 214, the 
plume containing the target material ejected or otherwise 
generated from the laser ablation site on the target 104 when 
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the sample capture cell138 is arranged operably proximate to 
the target 104. In an embodiment in which the sample capture 
cell138 is spaced apart from the target 104, carrier gas adja-
cent to the target 104 can be also be transmitted into the 
capture cavity 206 through the opening 214. In the illustrated 
embodiment, the guide wall 212 defines the extent (e.g., 
lateral, vertical, etc.) of the capture cavity 206 within the 
san1ple capture cell138. In one embodiment, the volume of 
the capture cavity 206 can be in a range from 0.001 cm3 to I 
cm3 (e.g., 0.005 cm3 , or thereabout). It will be appreciated, 
however, that depending on factors such as the carrier gas 
flow velocity within the region of the interior 106 where the 
sample capture cell 138 is located, the size of the plume of 
target material, etc., the volume of the capture cavity 206 can 
be less than 0.001 cm3 or greater than 1 cm3 . 
[0034] As bestshowninFIGS. 2 and2A, a transition region 
of the guide wall212 extending from the lower surface 202 
into the interior of the sample capture cell138 is rounded or 
chamfered. By providing a rounded or chan1fered transition 
region, the turbulence of a surface flow 216 of carrier gas 
entering into the capture cavity 206 from the a region near the 
surface of the target 104 through the opening 214 can be 
controlled to be suitably or beneficially small. In one embodi-
ment, the round or chan1fer of the transition region may have 
a radius of 0.1 nun, or thereabout. It will be appreciated, 
however, that depending on factors such as the carrier gas 
flow velocity within a region of the interior 106 between the 
sample capture cell138 and the target 104 and the aforemen-
tioned gap distance, the radius of the transition region can be 
significantly more or less than 0.1 nun. A more detailed 
rendering of the flow of carrier gas into the capture cavity 206 
via the opening 214 is exemplarily and schematically illus-
trated in FIGS. 4 and 6. In some embodiments, the sample 
capture cell138 can be configured such that the surface flow 
216 is sufficient to lift target material from the surface of the 
target 104 into the capture cavity 206 through the opening 214 
(where, thereafter, it can be transferred into the outlet 210) 
when the sample capture cell138 is operably proximate to the 
target 104. 
[0035] The first inlet 208 extends from the capture cavity 
206 to a surface of the sample capture cell138 defining the 
front end region. Accordingly, the first inlet 208 is configured 
to transmit a primary flow 218 of the carrier gas ±rom a first 
location adjacent to the front end region of the sample capture 
cell138 into a first region 220 of the capture cavity 206, which 
is adjacent to the first inlet 208. A more detailed rendering of 
the flow of carrier gas through the first inlet 208 into the first 
region 220 of the capture cavity 206 is exemplarily and sche-
matically illustrated in FIGS. 4 and 5. In the illustrated 
embodiment, the first inlet 208 extends vertically ±rom the 
lower surface 202 toward the upper surface 200 to a height, hl 
(see, e.g., FIG. 2A), of 1 nun (or thereabout), and extends 
horizontally between the lower surface 202 and upper surface 
200 across a width, w (see, e.g., FIG. 2A), of 2.2 nun (or 
thereabout). It will be appreciated, however, that depending 
on factors such as the carrier gas flow velocity within a region 
of the interior 106 at the first location, the size and shape of 
any portion of the first inlet 208 (e.g., from the surface of the 
sample capture cell138 defining the front end region to the 
capture cavity 206) may be modified in any suitable or ben-
eficialmamler. Constructed as exemplarily described above, 
the first inlet 208 is configured to transmit the primary flow 
218 into the first region 220 of the capture cavity 206 along a 
first direction that is generally (or at least substantially) par-
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aile! to a surface of the target 104. Although, in the illustrated 
embodiment, the first inlet 208 extends from the lower surface 
202 toward the upper surface 200, it will be appreciated that, 
in other embodiments, the first inlet 208 may be spaced apart 
from the lower surface 202. Although, in the illustrated 
embodiment, dimensions (e.g., height and width dimensions) 
of the first inlet 208 are illustrated as being the same as those 
of the capture cavity 206 at the first region 220, it will be 
appreciated that, in other embodiments, dimensions (e.g., 
height and width dimensions) of the first inlet 208 may be 
different from those of the capture cavity 206 at the first 
region 220. 
[0036] The second inlet 204 extends from the capture cav-
ity 206 to the upper surface 200 of the sample capture cell 
138. Accordingly, the second inlet 204 is configured to trans-
mit a secondary flow 222 of the carrier gas from a second 
location, adjacent to the upper surface 200 of the sample 
capture cell 138, into a second region 224 of the capture 
cavity 206. A more detailed rendering of the flow of carrier 
gas through the second inlet 204 into the second region 224 of 
the capture cavity 206 is exemplarily and schematically illus-
trated in FIG. 7. In the illustrated embodiment, the second 
inlet is a configured as a circular tube having a diameter in a 
range from 0.5 mm to 0.85 mm (or thereabout), aligned with 
and extending along the optical path 122 from the capture 
cavity 206 to the upper sudace 200 so as to a height, h2 (see, 
e.g., FIG. 2A), of2mm (or thereabout). It will be appreciated, 
however, that depending on factors such as the carrier gas 
flow velocity within the interior 106 at the second location, 
the size and shape of any portion of the second inlet 204 (e.g., 
from the upper surface 200 of the sample capture cell to the 
capture cavity 206) may be modified in any suitable or ben-
eficialmanner. 
[0037] As best shown in FIGS. 2 and2A, a transition region 
of a wall extending from the upper surface 200 into the second 
inlet 204 is rounded or chamfered. By providing a rounded or 
chamfered transition region, the turbulence of the flow of 
carrier gas entering into the second inlet 204 can be controlled 
to be suitably or beneficially small. In one embodiment, the 
round or chamfer of the transition region may have a radius of 
0.25 mm, or thereabout. Thus, the second inlet 204 may have 
a relatively large first diameter at the upper surface 200 and a 
relatively small second diameter at a location below the tran-
sition region (e.g., 0.85 mm, or thereabout). It will be appre-
ciated, however, that depending on factors such as the carrier 
gas flow velocity within a region of the interior 106 over the 
upper surface 200 of the sample capture cell138, the radius of 
the transition region can be significantly more or less than 
0.25mm. 
[0038] Constmcted as exemplarily described above, the 
second inlet 204 is configured to transmit the flow of the 
carrier gas into the second region 224 of the capture cavity 
206 along a second direction that is generally (or at least 
substantially) perpendicular to a surface of the target 104. In 
another embodiment, however, the second inlet 204 may be 
configured to transmit the flow of the carrier gas into the 
second region 224 of the capture cavity 206 along a second 
direction that is substantially oblique to a surface of the target 
104. Further, and as best shown in FIG. 3, the secondinlet204 
is configured such that the sample generator 108 is in optical 
communication with a region of the target 104 (e.g., along the 
optical path 122) through the second inlet 204 and the capture 
cavity 206. Accordingly, laser light 300 may be directed from 
the sample generator 108 along the optical path 122, through 
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the second inlet 204 and the capture cavity 206 to impinge 
upon the target 104 at a laser ablation site. When the directed 
laser light 300 impinges the target 104 at the laser ablation 
site, a plume 302 containing the target material ejected or 
otherwise generated from the target 104. 
[0039] Depending on factors such as the material of the 
target 104, characteristics of the directed laser light 300, the 
velocity of the carrier gas flow, etc., vertical expansion of the 
plume may occur very rapidly. For example, the phnne may 
extend to a height, h3 (see, e.g., FIG. 3) above the target 104 
of about 2 nnn within less than 0.5 ms (e.g., about 2ms) after 
the directed laser light 300 impinges the target 104 at the laser 
ablation site. By transmitting a flow of the carrier gas through 
the second inlet into the third region via along the second 
direction, the vertical expansion of the plume may be pre-
vented or otherwise minimally re-entrained, thereby reducing 
or minimizing the volume that the plume of target material 
would otherwise occupy within the capture cavity 206. By 
reducing or minimizing the volume that the plume of target 
material occupies within the capture cavity 206, target mate-
rial within the can be efficiently captured and transferred into 
the outlet 210, as will be described in greater detail below. 
[0040] The outlet 210 extends from a surface of the sample 
capture cell138 defining the back end region to a region ofthe 
guide wall 212 exposed within the capture cavity 206. 
Accordingly, the outlet 210 is configured to receive carrier 
gas from a third region 226 of the capture cavity 206 so that 
the received carrier gas can be transmitted to a location out-
side the sample capture cell138 (e.g., via the transport con-
duit 140). In the illustrated embodiment, the outlet 210 
includes a first bore 228 having an inlet arranged at the third 
region 226 of the capture cavity 206, and a second bore 230 
axially aligned with the first bore 228 and extending from the 
first bore 228 to the surface of the sample capture cell 138 
defining the back end region. The first bore 228 and the 
second bore 230 are generally configured to acconnnodate a 
portion of the transport conduit 140. In the illustrated embodi-
ment, the first bore 228 has a circular cross-section with a first 
diameter and the second bore 230 has a circular cross-section 
with a second diameter larger than the first diameter to addi-
tionally accommodate an outlet conduit seal 232. The first 
diameter may be equal to or slightly larger than the outer 
diameter of the transport conduit 140 (e.g., so that the trans-
port conduit 140 may be inserted into the first bore 228), or 
may be less than or equal to the inner diameter ofthe transport 
conduit 140. In one embodiment, the first bore 228 may have 
a first diameter in a range from 0.5 nnn (or thereabout). 
[0041] As best shown in FIGS. 2 and2B, a transition region 
of a wall extending from the guidewall212 into the outlet 210 
is rounded or chamfered. By providing a rounded or cham-
fered transition region, the turbulence of the flow of carrier 
gas entering into the outlet 210 can be controlled to be suit-
ably or beneficially small. In one embodiment, the round or 
chamfer of the transition region may have a radius ofO.l nnn, 
or thereabout. Thus, the outlet 210 may have a relatively large 
diameter at the inlet of the first bore 228 (i.e., at the guide wall 
212) (e.g., 0.82 mm, or thereabout) and a relatively small 
diameter at a location within an intermediate region of the 
first bore 228 (e.g., corresponding to the aforementioned first 
diameter of the first bore 228). It will be appreciated, how-
ever, that depending on factors such as the carrier gas flow 
velocity within the third region 226 of the capture cavity 206, 
the radius of the transition region can be significantly more or 
less than 0.1 111111. 
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[0042] The guidewall212 is configured to deflect, vector or 
otherwise direct one or more flows of the carrier gas intro-
duced into the capture cavity 206 (e.g., via one or more of the 
opening 214, the first inlet 208 and the second inlet 204) such 
that at least a portion of the plume of target material received 
within the capture cavity 206 through the opening 214 are 
entrained by the directed flow of carrier gas, thereby so as to 
be transferrable into the outlet 210 (see, e.g., FIG. 5). For 
purposes of discussion herein, target material transferred into 
the outlet 210 is "captured" by the sample capture cell138 
and, therefore, may also be referred to as a "sample" of the 
target 104 or as a "target sample". In one embodiment, the 
guidewall212 is configured to direct the one or more flows of 
the carrier gas such that the flow of carrier gas into the plume 
302 or into the outlet 210 is laminar or quasi-laminar. In 
another embodiment, however, the guide wall212 is config-
ured to direct the one or more flows of the carrier gas such that 
the flow of carrier gas into the plume 302 or into the outlet 210 
is turbulent. Similarly, one or more of the aforementioned 
features ofthe sample capture cell138 (e.g., the lower surface 
202, the guide wall 212, the opening 214, the first inlet 208, 
the second inlet 204, or the like) may be configured such the 
flow of carrier gas over the surface of the target 104 and 
outside the capture cavity 206 is laminar, quasi-laminar, tur-
bulent or a combination thereof. 
[0043] As best shown in FIG. 2, the guide wall 212 is 
configured such that the inlet of the first bore 228 is recessed 
relative to a surface defining the front end region of the 
sample capture cell138 by a distance of 2.5 mm (or there-
about). It will be appreciated, however, that depending on 
factors such as the carrier gas flow velocity within the capture 
cavity 206 and the location and orientation of the second inlet 
204 within the sample capture cell138, the distance by which 
the inlet of the first bore 228 is recessed relative to a surface 
defining the ±rout end region of the sample capture cell138 
can be significantly more or less than2.5 nm1. As best shown 
in FIG. 2B, the guide wall212 is configured so as to be curved 
in a region adjacent to the inlet of the first bore 228 (e.g., 
circularly curved, centered on an axis of the second inlet 204 
with a radius in a range from 0.9 mm to 1.1 mm, or there-
about). It will be appreciated, however, that depending on 
factors such as the carrier gas flow velocity and direction 
within the capture cavity 206 and the location and orientation 
ofthe second inlet 204 within the sample capture cell138, the 
geometric configuration may be varied in any mmmer that 
may be suitable or beneficial. 
[0044] If the sample capture cell 138 is coupled to the 
transport conduit, the sample transferred into the outlet 210 
cm1 be transported to a location outside the sample capture 
cell138 (e.g., via the transport conduit 140). To couple the 
transport conduit 140 to the sample capture cell138, an end of 
the transport conduit 140 (also referred to as a "first end" or a 
"sample receiving end") is inserted into the second bore 230 
and through the outlet conduit seal 232. Optionally, and 
depending upon the diameter of the first bore 228, the trans-
port conduit 140 may be further inserted into the first bore 
228. In one embodiment, the transport conduit 140 is inserted 
into the first bore 228 such that the sample receiving end is 
recessed within the first bore 228. For example, the sample 
receiving end can recessed within the first bore 228 to be 
spaced apart from the inlet of the first bore 228 by a distm1ce 
in a range from 1 mm to 3 mm (or thereabout). In other 
embodiments, however, the trm1sport conduit 140 is inserted 
into the first bore 228 such that the sample receiving end is 
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recessed flush with, or extends beyond, the inlet of the first 
bore 228. Upon coupling the transport conduit 140 to the 
sample capture cell138 in the mam1er described above, the 
carrier gas received at the outlet can also be received within 
the transport conduit 140 and transported to a location outside 
the sample chamber 102 (e.g., to the sample preparation 
system112). 
[0045] In addition to the sample receiving end, the transport 
conduit 140 may further include a second end (also referred to 
herein as a sample injection end) that is opposite the sample 
receiving end. Generally, the transport conduit 140 is at least 
substantially straight from the sample receiving end to the 
sample injection end, with a length (defined from the sample 
receiving end to the sample injection end) in a range from 20 
mm to 2m (e.g., in a range from 50 mm to 500 mm, or in a 
range from 100 rnm to 600 mm, or in a range from 200 nnn to 
500 nnn, or in a range from 200 mm to 450 nnn, or thereabout) 
and an illller diameter in a range from 50 11m to 1 nnn (e.g., in 
a range from 50 lllll to 500 !liD, or 250 !liD, or thereabout). It 
will be appreciated, however, that depending on factors such 
as the pressure within the interior 106, the illller diameter of 
the transport conduit 140, the configuration of the sample 
chamber 102 and the sample preparation system 112, the 
length of the transport conduit 140 may be less than 20 mm or 
greater than 2 m. Similarly, depending on factors such as the 
pressure within the interior 106 atld the length of the transport 
conduit 140, the illller dimneter of the transport conduit 140 
may be less than 50 lllll or greater than 1 mm. The illller 
diameter of the transport conduit 140 at the sample receiving 
end may be same or different (i.e., larger or smaller) than the 
illller diameter of the transport conduit 140 at the sample 
injection end. Further, the illller dian1eter of the transport 
conduit 140 may be at least substantially constant along the 
length thereof, or may vary. In one embodiment, the transport 
conduit 140 is provided as a single, substantially rigid tube 
having no valves between the sample receiving end and 
sm11ple injection end. Exemplary materials ±rom which the 
transport conduit 140 can be formed include one or more 
materials selected from the group consisting of a glass, a 
polymer, a ceramic and a metal. In one embodiment, however, 
the transport conduit 140 is formed offused glass. In another 
embodiment, the transport conduit 140 is formed of a poly-
mer material such as a fluoropolymer (e.g., perfluoroalkoxy, 
polytetrafluoroethylene, or the like or a combination thereof), 
polyethylene terephthalate, or the like or a combination 
thereof. In yet another embodiment, the transport conduit 140 
is fom1ed of a ceramic material such as alumina, sapphire, or 
the like or a combination thereof. In still another embodiment, 
the transport conduit 140 is formed of a metal material such as 
stainless steel, copper, platinum, or the like or a combination 
thereof. 
[0046] Constructed as exemplarily described above, the 
transport conduit 140 can efficiently transport a sample from 
the sample capture cell138 to the sm11ple preparation system 
112. Efficient capture and transfer of a sample from a laser 
ablation site to the transport conduit 140, coupled with effi-
cient transport ofthe sample from the sample capture cell138 
to the sample preparation system 112, can enable the analysis 
system 110 to generate signals (e.g., corresponding to the 
composition of target sample) that have relatively short peak 
widths (e.g., in a rm1ge from about 10 ms to about 20 ms (e.g., 
12 ms, or thereabout), measured relative to a baseline where 
98% of the total signal is observed within 10 ms) and corre-
spondingly fast wash-out times. Generating signals having 
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such relatively short peak widths and fast wash-out times, can 
help to facilitate high-speed and high sensitivity composi-
tional analysis of the target 104. Similarly, depending on 
factors such as the pressure within the interior 106 and the 
length of the transport conduit 140, the imler diameter of the 
transport conduit 140, the peak width may be beneficially 
increased to I s or thereabout. 
[0047] FIG. 8 is a cross-sectional view schematically illus-
trating the sample capture cell shown in FIG.1 incorporating 
an auxiliary inlet, according to another embodiment. 
[0048] Referring to FIG. 8, the aforementioned sample cap-
ture cell may further include an auxiliary inlet, such as aux-
iliary inlet 800, extending from the capture cavity 206 to the 
upper surface 200 of the sample capture cell 138. Accord-
ingly, the auxiliary inlet 800 is configured to transmit an 
auxiliary flow 802 of the carrier gas from a third location, 
adjacent to the upper surface 200 of the sample capture cell 
138, into a fourth region 804 of the capture cavity 206. Upon 
being introduced into the fourth region 804, the auxiliary flow 
802 may mix with the directed flow(s) of carrier gas present 
within the capture cavity 206 and, thereafter, transferred into 
the outlet 210. In the illustrated embodiment, the fourth 
region 804 is closer to the first region 220 than the third region 
226. In other embodiments, however, the fourth region 804 
may be closer to the thirdregion226 than the first region 220, 
or may be equidistant between the first region 220 and the 
third region 226. 
[0049] In the illustrated embodiment, the auxiliary inlet is 
configured as a circular tube having a diameter equal to or 
different from (e.g., larger than or smaller than) the diameter 
of the second inlet. It will be appreciated, however, that 
depending on factors such as the carrier gas flow velocity 
within the interior 106 at the second location, the size and 
shape of any portion of the auxiliary inlet 800 (e.g., from the 
upper surface 200 of the sample capture cell to the capture 
cavity 206) may be modified in any suitable or beneficial 
mamler. Although not illustrated, the auxiliary inlet may 
include a wall having a transition region extending from the 
upper surface 200 into the auxiliary inlet 800 aud configured 
in the mam1er discussed above with respect to the second inlet 
204. Constructed as exemplarily described above, the auxil-
iary inlet 800 is configured to transmit the auxiliary flow 802 
into the fourth region 804 of the capture cavity 206 along a 
third direction that is for example, different from the afore-
mentioned first direction and second direction. In one 
embodiment, the third direction may be substantially oblique, 
at least substantially parallel or at least substantially perpen-
dicular to the surface of the target 104 when the sample 
capture cell138 is operably proximate to the target 104. 
[0050] Although the auxiliary inlet 800 is illustrated as 
being integrally formed within the body of the sample capture 
cell138, it will be appreciated that the auxiliary inlet 800 may 
be separately formed from a different component, which is 
subsequently coupled to the body of the sample capture cell 
138. Further, although the auxiliary inlet 800 is illustrated as 
transmitting the auxiliary flow 802 of carrier gas into the 
fourth region 804 of the capture cavity 206, the auxiliary inlet 
800 may be positioned, oriented or otherwise configured to 
transmit the auxiliary flow 802 of carrier gas into the first 
region 220, the third region 226, or the second region 224 
(e.g., the auxiliary inlet 800 may extend to the second inlet 
204). In the illustrated embodiment, the auxiliary inlet 800 is 
configured to transmit the auxiliary flow 802 of carrier gas 
into the capture cavity 206 along a third direction that extends 
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toward the outlet 210 and the target 104. In other embodi-
ments, however, the third direction may extend toward the 
outlet 210 and away from the target 104, toward the first inlet 
208 and the target 104, toward the first inlet 208 and away 
from the target 104. or the like or a combination thereof. 
[0051] Although the auxiliary inlet 800 is described above 
as being configured to transmit the auxiliary flow 802 of 
carrier gas from the third location adjacent to the upper sur-
face 200 of the sample capture cell138 into the capture cavity 
206, it will be appreciated that the auxiliary inlet 800 may be 
configured to transmit a flow of the carrier gas from auy 
location adjacent to auy surface of the sample capture cell 
138. Moreover, although the auxiliary inlet 800 is described 
above as being configured to transmit a flow of carrier gas into 
the capture cavity 206, it will be appreciated that the sample 
capture cell 138 may be configured such that the auxiliary 
inlet 800 can be coupled to an extemal auxiliary fluid source 
(e.g., containing a fluid such as helium gas, argon gas, nitro-
gen gas, water vapor, atomized or nebulized fluids, atomized 
or nebulized solvents, discrete droplets containing micropar-
ticles, nanoparticles, or biological samples such as cells, or 
the like, or a combination thereof). In such a configuration, 
the auxiliary inlet 800 may transmit a fluid that is different 
from the carrier gas into the capture cavity 206, or may 
transmit an auxiliary flow of the carrier gas into the capture 
cavity 206, the auxiliary flow having a different characteristic 
(e.g., a different temperature, a different flow rate, etc.) from 
the carrier gas flow generated by the one or more injection 
nozzles 120. It will be appreciated that any fluid introduced 
into the capture cavity 206 by the auxiliary inlet 800 may mix 
with the directed flow(s) of carrier gas present within the 
capture cavity 206 and, thereafter, transferred into the outlet 
210. In one embodiment, when coupled to an auxiliary fluid 
source, the auxiliary inlet 800 may transmit one or more fluids 
such as nitrogen gas or water vapor to facilitate sample count-
ing, laser ablation standardization, calibration, or the like or a 
combination thereof. 
[0052] FIG. 9 is a cross-sectional view schematically illus-
trating one embodiment of an injector coupled to a sample 
preparation system, and a portion of au analysis system. 
[0053] In the embodiment exemplarily illustrated in FIG. 9, 
the sample preparation system 112 may be provided as au ICP 
torch 900 including au outer tube 902 (also referred to herein 
as a "confinement tube 902") enclosing a space 904 where a 
plasma can be generated, au imler tube 906 (also referred to 
herein as a "plasma gas tube 906") arranged within the con-
finement tube 902, coaxial with an injection axis 910 of the 
confinement tube 902, and a coil908 configured to ionize gas 
within the space 904 to generate a plasma 912 (e.g., occupy-
ing the darkly-shaded region within the space 904) when 
energized by an RF source (not shown). Although the sample 
preparation system 112 is illustrated as including a coil 908, 
it will be appreciated that the sample preparation system 112 
may alternatively or additionally include ionization mecha-
nisms of other configurations. For example, a set (e.g., a pair) 
of flat plates may be disposed outside the confinement tube 
902 to ionize the plasma gas within the space 904 to generate 
the plasma. 
[0054] In the illustrated embodiment, the confinement tube 
902 and the plasma gas tube 906 are spaced apart from each 
other to define an amlular outer gas transmission conduit 914 
(also referred to as a "coolant gas transmission conduit") that 
may be coupled to a gas source (e.g., a reservoir of pressur-
ized gas, not shown) to receive an outer flow 916 (also 
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referred to as a "coolant flow") of gas (e.g., argon gas) and 
transmit the received outer flow 916 of gas into the space 904 
(e.g., at a flow rate in a range from 10 Llmin to 15 Llmin, or 
thereabout). Gas introduced into the space 904 via the outer 
flow 916 can be ionized to form the aforementioned plasma 
912. Generally, plasma 912 generated has a power of about 
1.5 kW or less. In one embodiment, however, the plasma 912 
generated can have a power higher than 1.5 kW (e.g., suffi-
cient to melt the confinement tube 902). In such an embodi-
ment, the gas introduced into the space 904 via the outer flow 
916 can also be used to cool the confinement tube 902, pre-
venting the confinement tube 902 from melting. 
[0055] Optionally, the plasma gas tube 906 may be coupled 
to an auxiliary gas source (e.g., a reservoir of pressurized gas, 
not shown) to receive an intermediate flow 918 (also referred 
to as an "auxiliary flow") of gas (e.g., argon gas) and transmit 
the received intermediate flow 918 of gas into the space 904 
(e.g. at a flow rate in a range from 1 Llmin to 2 L/min). Gas 
introduced into the space 904 via the intem1ediate flow 918 
can be used to adjust the position the base of the plasma 912 
along the injection axis 910 relative to the confinement tube 
902. 
[0056] A portion of the plasma 912 generated within the 
space 904 is then transferred into the analysis system 110 
(e.g., an MS system) by passing sequentially through an 
interface (e.g., an interface including a sampling cone 920 
and a skinuuer cone 922) of the analysis system 110. 
Although the analysis system 110 is illustrated as having an 
interface with the sampling cone 920 and the skimmer cone 
922, it will be appreciated that the interface may be differently 
configured in any manner suitable or beneficialma11t1er. If the 
aforementioned target material generated within the sample 
chamber 102 is introduced in the plasma generated within the 
space 904, then the target material may transferred into the 
analysis system110 for compositional analysis. 
[0057] To facilitate introduction of the sample through the 
transport conduit 140 into a sample preparation system such 
as san1ple preparation system 112, the apparatus 100 may 
include an injector, such as injector 924. The injector 924may 
be detachably coupled to, or otherwise arranged operably 
proximate to, the sample preparation system112 by any suit-
able or beneficial mechanism. In the illustrated embodiment, 
the injector 924 may include an outer conduit 926 having a 
fluid injection end 928, and the aforementioned transport 
conduit 140. 
[0058] Generally, the outer conduit 926 is arranged within 
the plasma gas tube 906, coaxial with the injection axis 910 
and is configured to be coupled to a fluid source (e.g., one or 
more reservoirs of pressurized gas, not shown) to receive an 
outer injector flow 930 of a fluid (e.g., argon gas). Fluid within 
the outer injector flow 930 is injectable into the space 904 
through a fluid injection end 928 of the outer conduit 926. 
Generally, the i11t1er diameter of the outer conduit 926 at the 
fluid injection end 928 is in a range from 1.5 11llll to 3 nuu 
(e.g., 2 11t1n, or thereabout). Upon injecting the fluid into the 
space 904 from the fluid injection end 928, a central cha11t1el 
932 (e.g., occupying the lightly-shaded region within the 
space 904) can be formed within or "punched through" the 
plasma 912. Further, fluid injected into the space 904 through 
the fluid injection end 928 tends to generate a first zone 934 
relatively close to the fluid injection end 928, which is char-
acterized by a relatively high turbulence of fluid (e.g., includ-
ing fluid from the outer injector flow 930 and possibly gas 
from the intermediate flow 918). Turbulence quickly 
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decreases along the injection axis 910 with increasing dis-
tance from the fluid injection end 928 into the plasma 912. 
Accordingly, a second zone relatively distant from the fluid 
injection end 928 along the injection axis 910 and located 
within the central chatmel 932, can be characterized by a 
relatively low turbulence of fluid (e.g., including fluid from 
the outer injector flow 930 and possibly gas from the inter-
mediate flow 918). 
[0059] Generally, the trat1sport conduit 140 configured to 
direct a carrier flow 936 containing the aforementioned target 
sample, along with any other fluids that carry the sample 
through the transport conduit 140 (e.g., the aforementioned 
carrier gas, any fluid introduced into the capture cavity 206 by 
the auxiliary inlet 800, or the like or a combination thereof) 
through the aforementioned sample injection end (indicated 
at 938). When directed through transport conduit 140 and past 
the sample injection end 938, the carrier flow 936 (and. thus. 
the sample contained therein) is injectable into the space 904 
(e.g., along the injection axis 910), where it can be ionized 
and subsequently transferred to the analysis system110. 
[0060] In one embodiment, the transport conduit 140 may 
be arranged within the outer conduit 926, coaxial with the 
injection axis 910, such that the sample injection end 938 is 
locatable within the outer conduit 926, locatable outside the 
outer conduit 926, or a combination thereof. For example, the 
transport conduit 140 may be arranged within the outer con-
duit 926 such that the sample injection end 938 is located 
within the outer conduit 926, and is spaced away from the 
fluid injection end 928 by a distance in a rat1ge from 0 nuu to 
20 mm. In at1other example, trat1sport conduit 140 may be 
arranged within the outer conduit 926 such that the sample 
injection end 938 is located outside the outer conduit 926, and 
is spaced away from the fluid injection end 928 by a distance 
in a range from greater than 0 mm to 15 mm (e.g., by a 
distance in a range from 6 mm to 12 mm, or by a distance in 
a range from 8 nuu to 12 mm, or by a distance in a range from 
10 nuu to 12ml, or by a distance of 12 nuu, or thereabout). 
Depending on factors such as the configuration of the outer 
conduit 926, the flow rate of the outer injector flow 930 
exiting the outer conduit 926, and the configuration of the 
sample preparation system112, it will be appreciated that the 
sample injection end 938 may be located within the outer 
conduit 926 and spaced away from the fluid injection end 928 
by a distance greater than 20 mm (or may be located outside 
the outer conduit 926 and spaced away from the fluid injec-
tion end 928 by a distance greater than 15 nuu). The position 
of the transport conduit 140 may be fixed relative to the outer 
conduit 926, or may be adjustable. 
[0061] In one embodiment, the relative position of the 
sample injection end 938 may be selected or otherwise 
adjusted to be positioned at a location (e.g., within the space 
904) characterized by a fluid turbulence which is less that 
associated with the aforementioned first zone 934. For 
example, the sample injection end 938 may be positioned to 
be disposed within the aforementioned second zone. When 
the carrier flow 936 is injected from the sample injection end 
938 when located within the second zone. lateral diffhsion of 
the ionized target sample within the central chal1llel932 ofthe 
plasma 912 can be reduced significantly compared to the 
central chatmel 932 (e.g., as indicated by the relatively 
focused beam 940 of the ionized target sample). As a result, 
the beatn 940 can be kept at least substantially on-axis relative 
to the interface of the analysis system 110 to enhance the 
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sampling efficiency obtainable by the analysis system 110 
and the sensitivity of the analysis system 110. 
[0062] In one embodiment, the injector 924 may include a 
centering member 94 2 configured to maintain the radial posi-
tion of the transport conduit 140 within the outer conduit 926. 
As exemplarily illustrated, the centering member 942 may be 
disposed within the outer conduit 926 and include a central 
bore 944 though which the transport conduit 140 can be 
inserted and a plurality of peripheral bores 946 disposed 
radially and circumferentially about the central bore 944 to 
permit transmission of the outer injector flow 930 from the 
aforementioned fluid source to the fluid injection end 928. In 
one embodiment, the injector 924 may further include a con-
duit guide 948 configured to help guide insertion of the trans-
port conduit 140 into the centering member 942 from a loca-
tion outside the injector 924. 
[0063] Constructed as exemplarily described above, the 
outer conduit 926 of the injector 924 may have the same 
primary function as a conventional ICP torch injector, in that 
it provides a fluid flow (e.g., Ar, or admixtures thereof with 
helium gas or nitrogen gas), that establishes the central chan-
nel of the plasma 912 into which the sample is introduced. In 
the injector 924 described above, the transport conduit 140 
need not be coupled to the san1ple capture cell 138 as 
described above. In other such embodiments, the transport 
conduit 140 may alternatively or additionally be used to intro-
duce a standard (e.g., to enable optimization of instrumental 
parameters, to enable calibration, etc.) into the analysis sys-
tem 110 via a sample preparation system such as the sample 
preparation system 112, or the like. Such a standard could be 
introduced as an aerosol or dried aerosol (e.g. from a nebu-
liser, or as discrete droplets from a droplet generator, or as a 
gas or vapor generated by chemical or thennal means, etc.). 
The standard could even be an aerosol from a sample chamber 
other than the sample chamber 102. In other such embodi-
ments. the transport conduit 140 may alternatively or addi-
tionally be used to introduce additional gases into the sample 
preparation system 112 (e.g. helium gas, nitrogen gas, water 
vapor derived for example from thermal vaporization or a 
nebulizer or droplet generator, etc.). 
[0064] In one embodiment, the sample chamber 102 may 
be substituted or used in conjunction with a discrete droplet 
generator (e.g., derived from piezoelectric or thermal ink jet 
technologies, although any source of discrete droplets 
capable of delivering particles of less than 25 fllll, or there-
about, to the sample preparation system 112 would work). In 
some applications, a continuous source of droplets, such as 
from a nebulizer, or continuous flow of vapor (e.g., water 
vapor). In such embodiments, the droplet generators may be 
coupled to a desolvation stage to carry out prior evaporation 
(which may be complete or partial) of the droplets. Droplet/ 
desolvation technologies are well known and widely pub-
lished. 
[0065] In one embodiment, the droplet generator and 
accompanying desolvation unit may include two modes of 
operation. In a first mode of operation, the droplet generator 
and accompanying desolvation unit may replace the sample 
chamber 102 as the sample source. in which case a sample 
may be introduced directly into the transport conduit 140 of 
the injector 924 as a sequence of discrete droplets having 
diameters in the low or sub-micron range (after desolvation). 
These droplets may contain variously, for example, liquid 
san1ples, liquid droplets containing biological samples such 
as single cells, or micro or nano-particles. In a second mode of 
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operation, the droplet generator and accompanying desolva-
tion unit may nm simultaneously and in synchronicity with 
the sample generator 108 and sample chamber 102 so that the 
liquid droplets can be introduced into the transport conduit 
simultaneously with the aerosol containing the target mate-
rial, or sequentially in single or multiple events alternated 
with the aerosol containing the target material. This second 
mode of operation provides a mechanism for calibration (e.g., 
if the droplets contain standards), a mechanism for control of 
plasma conditions (e.g., if the droplets contain a solvent), or 
a mechanism for a quasi-continuous signal output that can be 
used for optimisation of instnunental parameters. 
[0066] FIG. 10 is a partial cross-sectional view schemati-
cally illustrating one embodiment of a desolvation unit 
coupled between a droplet generator and an injector such as 
the injector shown in FIG. 9. 
[0067] Referring to FIG. 10, the desolvation unit may 
include an adaptor 4 configured to receive a flow of droplets 
and/or vapor (e.g., as indicated at 1) and one or more desol-
vator gas flows (e.g., as indicated at 2) where the received 
droplet(s), vapor(s) and other gas flows can be mixed and 
thereafter be transported (e.g., vertically downwardly under 
the influence of gravity/and or the desolvating gas flow) 
through a tube 5 (e.g., a stainless steel tube) into a first inlet of 
an adaptor coupling 6, which may further include a second 
inlet configured to receive a flow of a make-up fluid (e.g., as 
indicated at 3). Within the adaptor coupling 6, the mixed 
droplet(s), vapor(s) and other gas flows are entrained by the 
flow of make-up fluid, transported through a tapered reducer 
7 and into the transport conduit 140 and, thereafter, into the 
aforementioned injector 924. It will be appreciated that the 
taper provided by the tapered reducer 7 can be made suffi-
ciently gradual to avoid introducing undesirable turbulence 
and particle loss. 
[0068] Constructed as described above, the illustrated 
droplet generator and associated desolvation unit replace the 
sample chamber 102 and sample capture cell138 discussed 
above. In another embodiment, however, the illustrated drop-
let generator and associated desolvation unit may be placed 
in-line with the sample chamber 102 and/or sample capture 
cell138. In such an embodiment, an opening may be formed 
in the transport conduit 140 at a location between the sample 
receiving end (which is disposed within the sample chamber 
102, coupled to the sample capture cell138) and the sample 
injecting end 938 (which is disposed within the injector 924 ), 
and the adaptor coupling 6 may be coupled to the transport 
conduit 140 to place the tube 5 in fluid coll1llltmication with 
the interior of the transport conduit 140. 
[0069] The foregoing is illustrative of example embodi-
ments of the invention and is not to be construed as limiting 
thereof. Although a few example embodiments have been 
described, those skilled in the art will readily appreciate that 
many modifications are possible without materially departing 
from the novel teachings and advantages of the invention. 
Accordingly, all such modifications are intended to be 
included within the scope of the invention as defined in the 
following claims. 
What is claimed is: 
1. An apparatus, comprising: 
an i1~jector configured to be arranged operably proximate 
to a plasma torch configured to generate a plasma within 
a confinement tube thereof, the injector including: 
an outer conduit having a fluid injection end, wherein the 
outer conduit is configured to transport an outer injec-
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tor flow of a fluid to the fluid injection end such that 
the fluid is injectable into the confinement tube from 
the fluid injection end; and 
a transport conduit disposed within the outer conduit at 
the fluid injection end and having an sample injection 
end, wherein the transport conduit is configured such 
that a carrier flow containing material is injectable 
through the sample injection end. 
2. The apparatus of claim 1, wherein: 
the outer conduit is configured to generate, within the 
confinement tube, a first zone containing a fluid flow 
having a relatively high turbulence and a second zone 
containing a fluid flow having a relatively low turbu-
lence, wherein the first zone is closer to the fluid injec-
tion end than the second zone; and 
the transport conduit has a sample injection end located 
within the second zone, wherein the transport conduit is 
configured such that the carrier flow containing material 
is injectable into the second zone from the sample injec-
tion end. 
3. The apparatus of claim 2, wherein the outer conduit 
extends from the fluid injection end along an injection axis 
and the transport conduit extends from the sample injection 
end along the injection axis. 
4. The apparatus of claim 2, wherein the outer conduit and 
the transport conduit are coaxial. 
5. The apparatus of claim 2, wherein sample injection end 
extends beyond the fluid injection end by a distance in a range 
greater than 1 mm. 
6. The apparatus of claim 2, wherein sample injection end 
extends beyond the fluid injection end by a distance in a range 
less than 15 mm. 
7. The apparatus of claim 1, wherein the sample injection 
end is located within the outer conduit. 
8. The apparatus claim 1, wherein the sample injection end 
is located outside the outer conduit. 
9. The apparatus of claim 1, wherein a position of the 
transport conduit relative to the outer conduit is fixed. 
10. The apparatus of claim 1, wherein a position of the 
transport conduit relative to the outer conduit is adjustable. 
11. The apparatus of claim 1, wherein the transport conduit 
further includes an sample receiving end opposite the sample 
injection end and configured to receive the target material. 
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12. The apparatus of claim 1, wherein the transport conduit 
is configured to transport at least a portion of the material 
received at the sample receiving end to the sample i1~jection 
end. 
13. The apparatus of claim 12, wherein the transport con-
duit is configured to transport at least a portion of the material 
received at the sample receiving end to the sample injection 
end, and the transport conduit is configured such that at least 
substantially all of the material is transportable from the 
sample receiving end to the sample injection end. 
14. The apparatus of that claim 1, further comprising the 
plasma torch. 
15. The apparatus of claim 1, further comprising the 
plasma torch, wherein the plasma torch comprises an induc-
tively coupled plasma (ICP) torch having the confinement 
tube. 
16. The apparatus of claim 15, wherein the ICP torch 
includes an induction coil disposed outside the confinement 
tube and configured to ionize the fluid and the aerosol. 
17. The apparatus of claim 15, wherein the ICP torch 
includes a set of flat induction plates disposed outside the 
confinement tube and configured to ionize the fluid and the 
aerosol. 
18. The apparatus of claim 1, further comprising a sample 
chamber having an interior configured to accommodate a 
target from which the material is removed. 
19. The apparatus of claim 18, wherein the sample receiv-
ing end of the transport conduit is disposed within the sample 
chamber. 
20. The apparatus of claim 1, further comprising a sample 
capture cell coupled to the sample receiving end of the trans-
port conduit and configured to be arranged operably proxi-
mate to the target, wherein the san1ple capture cell is config-
ured capture the material and transfer the captured material to 
the transport conduit. 
21. The apparatus of claim 20, wherein the sample capture 
cell is arranged within the interior of the sample chamber. 
22. The apparatus of claim 1, further comprising a droplet 
generator in fluid communication with an interior of the trans-
port conduit, the droplet generator is configured to deliver 
particles into the interior of the transport conduit. 
23. The apparatus of claim 22, further comprising a desol-
vation unit coupled between the droplet generator and the 
transport conduit. 
* * * * * 
